cancer incidence report saudi arabia 1999 - 2000 · cancer incidence report saudi arabia 1999 -...
Post on 27-Jun-2020
1 Views
Preview:
TRANSCRIPT
Kingdom of Saudi ArabiaMinistry of Health
National Cancer Registry
Cancer Incidence ReportSaudi Arabia1999 - 2000
Published by the Main Office, National Cancer Registry, under the Depository Number atKing Fahad National Library, 3840/22, date: 6/9/1422H, ISSN: 1658-0559, Riyadh May, 2004.
Report prepared by: Haya S. Al-Eid, BDS, DFE, CTR
Suad O. Arteh, MA
Reviewed by: Shouki Bazarbashi, MDEdward B. De Vol, PhD
Susan Young, CTR, CCHRA(C)
ACKNOWLEDGEMENT
The Board of Directors of the National Cancer Registry would like to acknowledge the manypeople who have facilitated the publication of this report. It is impossible to name every individualbut those who have helped us in any way should feel proud of the project and this report.
We take this opportunity to thank H.E. Professor Osama Shobokshi, the former Minister of Heath,for his support of the NCR. His inspiration and assistance encouraged the Board of Directors tocontinue in their endeavor. We also thank H.E. Dr. Qassim al Gasabi former Executive Deputyfor the Ministry of Health, for his commitment and supervision.
We are grateful for the continuing support of Dr. Anwar Al Jabarti, the Executive and Council forthe Management at King Faisal Specialist Hospital & Research Center, in extending technical andadministrative facilities to help maintain the NCR.
We would also like to thank former members of the Board of Directors and administrative staff fortheir involvement and contributions to the continued development of the NCR:
Dr. Peter Tallos, National Guard Hospitals, RiyadhDr. Osama Koreich, Armed Forces Hospitals, RiyadhDr. Salah Al Ghamdi, King Khalid University, AbhaDr. Assem Al Radi, King Abdulaziz Hospital & Oncology Center, JeddahDr. Abdulrahman Al Diab, Security Forces Hospital, RiyadhBrenda J. Lange, CTR, Administrative Director
We wish to extend our thanks and appreciation to the laboratories, pathology and medical recorddepartments in healthcare facilities throughout the Kingdom who have assisted the registry staff inthe data collection process.
Finally, we would like to thank Ms. Jinky B. Gomez for her assistance in formatting the final reportand the registry team, in both the Regional and Main Offices, whose skill and dedication havemade possible the data capture and analysis resulting in this report.
FOREWARD
The 1999-2000 Cancer Incidence Report is the fourth publication of the National Cancer Registry.The information in this report is a very important part of the infrastructure which is required in theefforts to reduce the burden of cancer. The registry data will assist researchers studying cancer andauthorities involved in the planning of cancer services (epidemiological research, identification ofrisk factors for use in cancer control, development of screening and prevention programs, planningfor diagnostic and treatment services.)
The registry continues to be committed to quality data focusing on improving case-ascertainment,patient and tumor linkage and editing processes through training and quality control procedures.Throughout the data collection and analysis process, every effort is made to ensure both patientand facility confidentiality.
Some changes from the previous reports have been made in the presentation of the data althoughwe have tried to maintain consistency to enable easy comparison of data over the years. Since it isour goal to present this report in a manner that will be easily understood by all, we welcome and,indeed, encourage feedback from readers for consideration in the preparation of future reports.
Dr. Shouki BazarbashiChairmanNational Cancer Registry
INTRODUCTION
This is the fourth report to be published in an effort designed to provide information on cancerincidence in Saudi Arabia. The first of its kind was the 1994 Summary Report, the second and thethird were the 1994-1996 and 1997-1998 Incidence Reports respectively, and this one coverscancer Incidence Report for the years 1999-2000. It is the objective of the National CancerRegistry of Saudi Arabia to present the data on a period of two-three years now and in a moreextended period of time in later years. Data on an extended period of time has advantages ofpresenting more stable incidence rates and time-trends studies.
The structure of this report can be outlined as follows:
Part I Materials and Methods
This part of the report contains information about the background of the National Cancer Registryand methods used in collecting and analyzing the data. We present the basics of coding andclassification of tumor topography, morphology and extent of disease at the time of diagnosis. Alsowe explain the software program we used to analyze the data.
Part II Overview
Part II contains figures and tables that show overall cancer incidence in Saudi Arabia for the years1999-2000. We present these figures and tables mainly by sex and in certain areas we have itanalyzed by different age groups. There are pie and bar charts representing the age distribution ofcancer incidence for the years 1994-2000 among Saudis by sex and age groups. We presentseparate incidence and morphology tables for the most common types of cancers among adultsand children. In addition, a bar chart depits the 10 most common types of cancer, by sex, in eachof the 13 administrative regions of Saudi Arabia.
Part III Incidence of Selected-Sites
In this part the incidences of selected cancer types among Saudis are outlined in order of relativefrequency. A standardized layout presents data for all patients and both sexes where applicable.For each selected site we list the number and the percentage of all newly diagnosed cases for theyears 1999 and 2000, the Age-Standardized Incidence Rate (ASR) per 100,000 population foreach sex, and the specific cancer rank for both sexes. In addition, we provide (whenever available)international statistics for the specified cancer including the ranking of the cancer worldwide, estimatednumber of cases for 1999-2000, and areas of the world that have the highest ranking.
Part IV Cancer Incidence among non-Saudis
In this part we have the incidence cases of cancer among non-Saudis. We present the most commontypes of cancer among them and the age-specific incidence rates. The age distribution of non-Saudis is over-represented in the 25-54 age-group as a result of the nature of the expatriatepopulation. For this reason we have opted to do the analysis separately.
Part V Tables of Incidences
Part V contains the following detailed tables for all newly diagnosed cancer types among Saudisand non-Saudis for 1999-2000.
For the years 1999 and 2000 we have separate tables for male and female
· age-distribution of cancer cases among Saudis
· age-standardized incidence rate for cancer cases among Saudis by age group (per 100,000 population)
For the years 1999 and 2000 we have for each region
· age-standardized incidence rate and relative frequencies for all cancer cases among Saudis by site and sex
For the years 1999 and 2000 we have separate tables for male and female
· age-distribution of cancer cases among non-Saudis
· crude incidence rates for cancer cases among non-Saudis by age group (per 100,000 population)
Part VI Appendices
Reporting hospitals list
· Includes hospital names in each administrative region. The objective is to receive feedback from hospitals in order to minimize under-reporting.· Addresss of the National Cancer Registry offices· Cancer Registration Form· The Data Request Form
TABLES OF CONTENTS
ACKNOWLEDGEMENT ................................................................................................................................. 3FOREWARD ................................................................................................................................................... 4INTRODUCTION ............................................................................................................................................ 5
PART IBackground on Saudi Arabia .................................................................................................................. 13NATIONAL CANCER REGISTRY .......................................................................................................... 15Definitions of Statistical Terms ............................................................................................................... 19
PART IICancer in Saudi Arabia 1994-2000 ........................................................................................................... 22Reported Cancer Incidence Cases in Saudi Arabia, 1999-2000 ................................................................ 25Distribution of Cancer Cases in Saudi Arabia by Nationality and Sex .................................................... 25Ten Most Common Types of Cancer Among Saudis, 1999-2000 (All Ages) ........................................... 27Adult Cancers in Saudi Arabia, 1999-2000 (above 14 years) ................................................................... 29Childhood Cancers in Saudi Arabia 1999-2000 (14 years and under) ...................................................... 32Cancer in the 13 Administrative Regions of the Kingdom ...................................................................... 35International comparison of age-standardized incidence rates ............................................................... 40
PART IIICancer Incidence for Specific Sites 1999-2000 ........................................................................................ 42Female Breast (C50) ................................................................................................................................ 43Non-Hodgkins Lymphoma (C82-C85;C96) .............................................................................................. 46Leukaemia (C91-C95) ............................................................................................................................... 49Colo-rectal (C18-C21) .............................................................................................................................. 51Liver (ICD-10 C22) .................................................................................................................................. 54Thyroid (C73) .......................................................................................................................................... 57Brain, nervous system (C70-C72) ............................................................................................................ 60Lung (C33-C34) ....................................................................................................................................... 63Hodgkin’s Disease (C81) ......................................................................................................................... 66Urinary Bladder (C67) ............................................................................................................................. 69Skin (Non-Melanoma) (C44) ................................................................................................................... 72Prostate Cancer (ICD-10 C61) ................................................................................................................. 74Ovary (C56) ............................................................................................................................................. 77Cervix Uteri (C53) .................................................................................................................................... 80
PART IVCancer among the non- Saudi Population 1999-2000 .............................................................................. 84
PART VTABLES OF INCIDENCE ........................................................................................................................ 87
PART VIAPPENDIX A .........................................................................................................................................117APPENDIX B .........................................................................................................................................118APPENDIX C .........................................................................................................................................119APPENDIX D .........................................................................................................................................120APPENDIX E .........................................................................................................................................121APPENDIX F .........................................................................................................................................122
FIGURES
PART IFigure 1-1 Administrative Regions of Saudi Arabia ................................................................................ 13Figure 1-2 Population Pyramid of Saudis by Sex and Age Groups, 2000 ................................................. 14Figure 1-3 Population Pyramid of non-Saudis by Sex and Age Groups, 2000 ......................................... 14Figure 1-4 Organizational Chart of the National Cancer Registry of Saudi Arabia .................................. 16
PART IIFig. 2-1 Percentage Distribution of Cancer Incidence among Saudis by Age Group and Sex, 1994-2000 22Fig. 2-2 A Most Frequent Types of Cancer by Age and Sex among Saudis, 1994-2000 .......................... 22Fig. 2-3 Ten Most Common Cancers for Saudis by Sex, 1999-2000 ......................................................... 27Fig. 2-4 Average Age-Specific Incidence Rates (AIR) for All Cancers among Saudis, 1999-2000 ........... 28Fig. 2-5Age Standardized Rate ( ASR) Regional Distribution of All Sites of Cancer among Saudis,1999-2000 ................................................................................................................................................ 28Fig. 2-6 Ten Most Common Types of Cancer among Adult Saudis by Sex, 1999-2000 ............................ 30Fig. 2-7 Ten Most Common Types of Cancer among Saudi Children by Sex, 1999-2000 ......................... 33Fig. 2-8-1 Riyadh Region, 1999-2000 (Percentage Distribution) .............................................................. 35Fig. 2-8-2 Najran Region, 1999-2000 (Percentage Distribution) ............................................................... 35Fig. 2-8-3 Eastern Region, 1999-2000 (Percentage Distribution) ............................................................. 36Fig. 2-8-4 Makkah Region, 1999-2000 (Percentage Distribution) ............................................................. 36Fig. 2-8-5 Northern Region, 1999-2000 (Percentage Distribution) ........................................................... 36Fig. 2-8-6 Qassim Region, 1999-2000 (Percentage Distribution) .............................................................. 37Fig. 2-8-7 Jazan Region, 1999-2000 (Percentage Distribution) ................................................................. 37Fig. 2-8-8 Hail Region, 1999-2000 (Percentage Distribution) ................................................................... 37Fig. 2-8-9 Madinah Region, 1999-2000 (Percentage Distribution) ........................................................... 38Fig. 2-8-10 Baha Region, 1999-2000 (Percentage Distribution) ................................................................ 38Fig. 2-8-11 Tabuk Region, 1999-2000 (Percentage Distribution) .............................................................. 38Fig. 2-8-12 Asir Region, 1999-2000 (Percentage Distribution) ................................................................. 39Fig. 2-8-13 Jouf Region, 1999-2000 (Percentage distribution) ................................................................. 39Fig. 2-9 Shows the 2000 ASR Estimation in Selected Countries among the Females and Male .............. 40
PART IIIFig. 3-1 Average Age-Specific Incidence Rate (AIR) for Female Breast Cancer in Saudi Arabia,1999-2000 ................................................................................................................................................ 43Fig. 3-2 ASR Regional Distribution of Female Breast Cancer in Saudi Arabia, 1999-2000 ....................... 44Fig. 3-3 Stage Distribution of Female Breast Cancer in Saudi Arabia, 1999-2000 .................................... 45Fig. 3-4 Average Age-Specific Incidence Rates (AIR) for NHL in Saudi Arabia, 1999-2000 .................... 46Fig. 3-5 ASR Regional Distribution of NHL in Saudi Arabia, 1999-2000 .................................................. 47Fig. 3-6 Stage Distribution of NHL in Saudi Arabia, 1999-2000 ............................................................... 48Fig. 3-7 Average Age-Specific Incidence Rate (AIR) for Leukaemia in Saudi Arabia, 1999-2000 ............. 49Fig. 3-8 ASR Regional Distribution of Leukaemia in Saudi Arabia, 1999-2000 ........................................ 50Fig. 3-9 Average Age Specific Incidence rate (AIR) for Colo-rectal Cancer in Saudi Arabia, 1999-2000 . 51Fig. 3-10 ASR Regional Distribution of Colo-rectal Cancer in Saudi Arabia, 1999-2000 .......................... 52Fig. 3-11 Stage Distribution of Colo-rectal Cancer, 1999-2000 ................................................................. 53Fig. 3-12 Average Age-Specific Incidence Rate (AIR) for Liver Cancer in Saudi Arabia, 1999-2000 ....... 54Fig. 3-13 ASR Regional Distribution of Liver Cancer in Saudi Arabia, 1999-2000 ................................... 55Fig. 3-14 Stage Distribution of Liver Cancer in Saudi Arabia, 1999-2000 ................................................. 56Fig. 3-15 Average Age-Specific Incidence Rate (AIR) for Thyroid Cancer in Saudi Arabia, 1999-2000 ... 57Fig. 3-16 ASR Regional Distribution of Thyroid Cancer in Saudi Arabia, 1999-2000 ............................... 58Fig. 3-17 Stage Distribution of Thyroid Cancer in Saudi Arabia, 1999-2000 ............................................ 59Fig. 3-18 Average Age-Specific Incidence Rate (AIR) for Brain, CNS Cancer in Saudi Arabia, 1999-200060
Fig. 3-19 ASR Regional Distribution of Brain, CNS Cancer in Saudi Arabia, 1999-2000 .......................... 61Fig. 3-20 Stage Distribution of Brain, CNS Cancer in Saudi Arabia, 1999-2000 ....................................... 62Fig. 3-21 Average Age-Specific Incidence Rate (AIR) for Lung Cancer in Saudi Arabia, 1999-2000 ....... 63Fig. 3-22 ASR Regional Distribution of Lung Cancer in Saudi Arabia, 1999-2000 ................................... 64Fig. 3-23 Stage Distribution of Lung Cancer in Saudi Arabia, 1999-2000 ................................................ 65Fig. 3-24 Average Age-Specific Incidence Rate (AIR) for Hodgkin’s Disease in Saudi Arabia,1999-2000 ................................................................................................................................................ 66Fig. 3-25 ASR Regional Distribution of Hodgkin’s Disease in Saudi Arabia, 1999-2000 ......................... 67Fig. 3-26 Stage Distribution of Hodgkin’s Disease in Saudi Arabia, 1999-2000 ....................................... 68Fig. 3-27 Average Age-Specific Incidence Rate (AIR) for Urinary Bladder Cancer in Saudi Arabia,1999-2000 ................................................................................................................................................ 69Fig. 3-28 ASR Regional Distribution of Urinary Bladder Cancer in Saudi Arabia, 1999-2000 .................. 70Fig. 3-29 Stage Distribution of Urinary Bladder Cancer in Saudi Arabia, 1999-2000 ............................... 71Fig. 3-30 Average Age-Specific Incidence Rates (AIR) for Skin Cancer in Saudi Arabia, 1999-2000 ....... 72Fig. 3-31 ASR Regional Distribution of Skin Cancer in Saudi Arabia, 1999-2000 ..................................... 73Fig. 3-32 Stage Distribution of Skin Cancer in Saudi Arabia, 1999-200 .................................................... 73Fig. 3-33 Average Age-Specific Incidence Rate (AIR) for Prostate Cancer in Saudi Arabia, 1999-2000 .. 74Fig. 3-34 ASR Regional Distribution of Prostate Cancer in Saudi Arabia, 1999-2000 .............................. 75Fig. 3-35 Stage Distribution of Prostate Cancer in Saudi Arabia, 1999-2000 ........................................... 76Fig. 3-36 Average Age-Specific Incidence Rate (AIR) for Ovary Cancer in Saudi Arabia, 1999-2000 ...... 77Fig. 3-37 ASR Regional Distribution of Ovary Cancer in Saudi Arabia, 1999-2000 .................................. 78Fig. 3-38 Stage Distribution of Ovary Cancer in Saudi Arabia, 1999-2000 ............................................... 79Fig. 3-39 Average Age-Specific Incidence Rate (AIR) for Cervix Uteri Cancer in Saudi Arabia,1999-2000 ................................................................................................................................................ 80Fig. 3-40 ASR Regional Distribution of Cervix Uteri Cancer in Saudi Arabia, 1999-2000 ......................... 81Fig. 3-41 Stage Distribution of Cervix Uteri Cancer in Saudi Arabia, 1999-2000 ...................................... 82
PART IVFig. 4-1 Ten Most Common Cancers among non-Saudis by Sex, 1999-2000 ........................................... 85Fig. 4-2 Average Age-Specific Incidence Rate (AIR) for All Cancers among non-Saudis in Saudi Arabia,1999-2000 ................................................................................................................................................ 85
TABLES
PART IITable 2-1 Distribution of Cancer Cases in Saudi Arabia by Nationality and Sex, 1999-2000 ................... 25Table 2-2 Number of New Cases by Primary Site and Sex among Saudis, 1999-2000 .............................. 26Table 2-3 Distribution of Adult’s Cancers Cases in Saudi Arabia by Nationality and Sex, 1999-2000 ..... 29Table 2-4 Number and Proportion of Morphological Types for the Most .............................................. 30Table 2-5 Distribution of Childhood Cancer Cases in Saudi Arabia by Nationality and Sex, 1999-2000 . 32Table 2-6 Number and Proportion of the Most Common Types of Childhood Cancer among Saudis,1999-2000 ................................................................................................................................................ 34
PART IIITable 3-1 Histology of Female Breast Cancer in Saudi Arabia, 1999-2000 ............................................... 44Table 3-2 Comparison of ASR for Breast Cancer among Saudi Females with 2000 ASR Estimation inSelected Countries .................................................................................................................................. 45Table 3-3 Histology of NHL, 1999-2000 ................................................................................................... 47Table 3-4 Comparison of ASR for NHL among Saudis with 2000 ASR Estimation in Selected Countries 48Table 3-5 Histology of Leukemia, 1999-2000 .......................................................................................................50Table 3-6 Comparison of ASR for Leukemia among Saudis with 2000 ASR Estimation inSelected Countries .................................................................................................................................. 50Table 3-7 Histology of Colo-rectal Cancer, 1999-2000 ............................................................................. 52Table 3-8 Comparison of ASR for Colo-rectal among Saudis with 2000 ASR Estimation inSelected Countries .................................................................................................................................. 53Table 3-9 Histology of Liver Cancer, 1999-2000 ...................................................................................... 55Table 3-10 Comparison of ASR for Liver Cancer among Saudis with 2000 ASR Estimation inSelected Countries .................................................................................................................................. 56Table 3-11 Histology of Thyroid Cancer, 1999-2000 ................................................................................ 58Table 3-12 Comparison of ASR for Thyroid Cancer among Saudis with 2000 ASR Estimation inSelected Countries .................................................................................................................................. 59Table 3-13 Histology of Brain, CNS Cancer, 1999-2000 ........................................................................... 61Table 3-14 Comparison of ASR for Brain, CNS Cancer among Saudis with 2000 ASR Estimation inSelected Countries .................................................................................................................................. 62Table 3-15 Histology of Lung Cancer, 1999-2000 .................................................................................... 64Table 3-16 Comparison of ASR for Lung Cancer among Saudis with 2000 ASR Estimation inSelected Countries .................................................................................................................................. 65Table 3-17 Histology of Hodgkin’s Disease, 1999-2000 .......................................................................... 67Table 3-18 Comparison of ASR for Hodgkin’s Disease among Saudis with 2000 ASR Estimation inSelected Countries .................................................................................................................................. 68Table 3-19 Histology of Urinary Bladder Cancer, 1999-2000 ................................................................... 70Table 3-20 Comparison of ASR for Urinary Bladder Cancer among Saudis with 2000 ASR Estimation inSelected Countries .................................................................................................................................. 71Table 3-21 Histology of Skin Cancer (Non-Melanoma), 1999-2000 ......................................................... 73Table 3-22 Histology of Prostate Cancer, 1999-2000 ............................................................................... 75Table 3-23 Comparison of ASR for Prostate Cancer among Saudis with 2000 ASR Estimation inSelected Countries .................................................................................................................................. 76Table 3-24 Histology of Ovary Cancer, 1999-2000 ................................................................................... 78Table 3-25 Comparison of ASR for Ovary Cancer among Saudis with 2000 ASR Estimation in Selected 79Table 3-26 Histology of Cervix Uteri, 1999-2000 ..................................................................................... 81Table 3-27 Comparison of ASR for Cervix Uteri Cancer among Saudis with 2000 ASR Estimation inSelected Countries .................................................................................................................................. 82
PART VTable 5-1-1 Age Distribution of Cancer Cases among Saudi Males, 1999 ............................................... 87Table 5-1-2 Age Distribution of Cancer Cases among Saudi Females, 1999 ............................................ 88Table 5-1-3 Incidence Rates for Cancer Cases among Saudi Males by Age Group (per 100,000), 1999 .. 89Table 5-1-4 Incidence Rates for Cancer Cases among Saudi Females by Age Group (per 100,000), 1999 90Table 5-1-5 Age Distribution of Cancer Cases among Saudi Males, 2000 ............................................... 91Table 5-1-6 Age Distribution of Cancer Cases among Saudi Females, 2000 ............................................ 92Table 5-1-7 Incidence Rates for Cancer Cases among Saudi Males by Age Group (per 100,000), 2000 .. 93Table 5-1-8 Incidence Rates for Cancer Cases among Saudi Females by Age Group (per 100,000), 2000 94Table 5-2-1 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Riyadh Region, 1999-2000 .................................................................................................. 95Table 5-2-2 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Najran Region, 1999-2000 ................................................................................................... 96Table 5-2-3 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Eastern Region, 1999-2000 ................................................................................................. 97Table 5-2-4 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Makkah Region, 1999-2000 ................................................................................................ 98Table 5-2-5 Age Standarized Rates and Relative Frequencies for All Cases among Saudis by Site and Sex,Northern Region, 1999-2000 .................................................................................................................... 99Table 5-2-6 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Qassim Region, 1999-2000 ................................................................................................100Table 5-2-7 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Jazan Region, 1999-2000 ...................................................................................................101Table 5-2-8 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Hail Region, 1999-2000 ......................................................................................................102Table 5-2-9 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Madinah Region, 1999-2000 ..............................................................................................103Table 5-2-10 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Baha Region, 1999-2000 ....................................................................................................104Table 5-2-11 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Tabuk Region, 1999-2000 ..................................................................................................105Table 5-2-12 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Asir Region, 1999-2000 ......................................................................................................106Table 5-2-13 Age Standarized Rates and Relative Frequencies for All Cancer Cases among Saudis bySite and Sex, Jouf Region, 1999-2000 .....................................................................................................107Table 5-3-1 Age Distribution of Cancer Cases among non-Saudi Males, 1999 ......................................108Table 5-3-2 Age Distribution of Cancer Cases among non-Saudi Females, 1999 ...................................109Table 5-3-3 Incidence Rates for Cancer Cases among non-Saudi Males by Age Group (per 100,000),1999 ........................................................................................................................................................110Table 5-3-4 Incidence Rates for Cancer Cases among non-Saudi Females by Age Group (per 100,000),1999 ........................................................................................................................................................111Table 5-3-5 Age Distribution of Cancer Cases among non-Saudi Males, 2000 ......................................112Table 5-3-6 Age Distribution of Cancer Cases among non-Saudi Females, 2000 ...................................113Table 5-3-7 Incidence Rates for Cancer Cases among non-Saudi Males by Age Group (per 100,000),2000 ........................................................................................................................................................114Table 5-3-8 Incidence Rates for Cancer Cases among non-Saudi Females by Age Group (per 100,000),2000 ........................................................................................................................................................115
PART IMATERIALS AND METHODS
12
Background on Saudi ArabiaSaudi Arabia is a vast country extending over four-fifths of the Arabian Peninsula. It stretches fromthe Arabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700* squarekilometers in area. It is divided into 13 administrative regions (Figure 1-1).
Figure 1-1 Administrative Regions of Saudi Arabia
The estimated Saudi National population for year 2000 was 15,588,805**. Of these 7,800,051were males and 7,788,754 were females. The estimated non-Saudi population in 2000 was5,258,079; of these 3,514,915 were males and 1,743,164 females.Figures 1-2 and 1-3 shows the Saudi and non-Saudi population pyramids by sex and age-group.
* Source: Demographic and Health Indicators for Countries of the East Meditranian, WHO, Regional Office for the EM, 1999
·** Source: Central Department for Statistics (CDS). Ministry of Planning.
13
14
Figure 1-3 Population Pyramid of non-Saudis by Sex and Age Groups, 2000
8,172
7,028
12,349
28,635
60,071
114,785
213,433
368,732
546,810
650,627
506,077
204,807
119,998
192,901
240,758
239,732
5,824
8,359
6,032
10,791
17,743
29,730
53,761
108,576
204,782
230,971
157,989
115,298
120,382
194,556
249,066
229,304
3,514,915 1,743,164Male Female
0 5 10 15 20
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
0 5 10 15 20
National Cancer Registry
The National Cancer Registry of Saudi Arabia is a population-based registry developed in 1992.It was established under the jurisdiction of the Ministry of Health (MOH) by the Order of HisExcellency the Minister of Health. The NCR commenced reporting cancer cases from 01 January1994.
Objectives:
The primary goal of the NCR is to define the population-based incidence of cancer in SaudiArabia. Programs for early detection and cancer screening, as well as cancer research projectsare planned for future consideration.
Organizational Structure:
A Board of Directors was appointed to include representatives from the MOH, King FaisalSpecialist Hospital and Research Center (KFSH&RC), and the Medical Services Departments ofthe Ministry of Defense and Aviation, Ministry of Interior, the National Guard, King Saud University,King Faisal University, King Abdul-aziz University and King Khalid University.
The Board is charged with the responsibility of overseeing the NCR’s establishment, definingdemographic and cancer-related data to be collected, approving research requests, and reportingfindings, as well as disseminating information collected while ensuring the confidentiality of all datareported to the NCR.
The NCR Main Office, including administrative and technical staff, is located on the premises ofthe KFSH&RC in Riyadh. Additionally, five regional branches and three hospital-based officeswere set up to ensure comprehensive data collection from all over the Kingdom Figure 1-4.
Central Region: King Khalid University Hospital in Riyadh, covering Riyadh, Qassim, andHail Health Regions.Eastern Region: King Fahad Hospital of the University, Khobar, covering Dammam, AlAhsa, and Hafr Al-Batin Health Regions.Western Region: King Abdulaziz Hospital and Cancer Center, Jeddah, covering Jeddah,Makkah, Taif and Qunfudah Health Regions.Southern Region: King Khalid University, Abha, covering Asir, Baha, Najran, Jazan andBisha Health Regions.Madinah/Northern: King Fahad Hospital, Madinah, covering Madinah, Tabuk, Jouf andNorthern Health Regions.Offices at the Medical Services Division or Oncology Department of the followingestablishments:
Ministry of Defense and Aviation, Armed Forces Hospital, RiyadhNational Guard, King Fahad Hospital, Riyadh covering KFNGH & KKNGH.Ministry of Interior, Security Forces Hospital, Riyadh.
15
Ministry of HealthSaudi Arabia
National Cancer RegistryMain Office
Each of these branches and offices are under the supervision of a member of the Board ofDirectors who is responsible for the daily management of that office and for ensuring the accuracyof information reported to the NCR. In addition to tumor registrars and secretarial staff, eachoffice is provided with the necessary computer facilities, printers, and other office equipment.
Functions of the NCR Main office include:♦ compilation of data collected from all the regions and offices♦ merging of all cases to ensure that each case is counted only once♦ verification of diagnosis♦ conducting quality control review of all abstracts submitted♦ preparation of regular reports for dissemination of information to the medical
community, government establishment, international organizations and the media.♦ training of staff.
Figure 1-4 Organizational Chart of the National Cancer Registry of Saudi Arabia
16
National GuardHospitals(Riyadh &Jeddah)
SecurityForces(Riyadh)
Armed ForcesHospitals(Riyadh &Jeddah)
Madinah Region
(Madinah, Tabuk,Jouf & Northern
Region)
WesternRegion(Jeddah,
Makkah, Taif &Gunfudah)
EasternRegion
(Dammam,Ahsa & H. Al
Batin)
CentralRegion(Riyadh,
Qassim & Hail)
King FaisalSpecialistHospital &Research
Centre(Riyadh)
SouthernRegion
(Asir, Baha,Jazan, Najran
& Bisha)
Format
The format of the current report is similar to the previous reports; however the first part has beenextended by adding a section for childhood and adult cancer and morphology of the most commontypes of childhood and adult cancer. We also report the ten most common cancers for each regionand present a comparative bar chart in which we compare age standardized rate (ASR) of cancerincidence among Saudis with other countries.
Data management
A ministerial decree has categorized cancer as a mandatory notifiable disease. This ensures theopportunity for comprehensive data collection. The NCR strives for full access to cancer datafrom all MOH, governmental and private hospitals, as well as clinics and laboratories throughoutthe Kingdom. Cancer data are abstracted from patients’ medical records based on clinical and/orhistopathological diagnosis, by NCR-trained cancer registrars.
The data abstract (see appendix E) includes the patient’s personal identification (name, ID Number,sex, age), demographic information (address, telephone number, nationality), and tumor details(diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primarysite (topography) and histology (morphology) of the malignancies are identified and coded accordingto the International Classification of Diseases for Oncology, 2nd Edition (ICD-O-2), publishedby the World Health Organization (WHO), 1990.
Every effort is made to accurately code patient and tumor information, to ensure that all data canbe reviewed, matched, and merged, as appropriate, so that each malignancy is counted only oncefor statistical analysis. The computer software program used for data entry and incidence tablesoutput is CanReg 3.21, developed by the International Agency for Research on Cancer, (IARC)Lyon, France.
The second part of the report includes the overall cancer incidence in Saudi Arabia and the relevantepidemiological and clinic-pathological details for the 14 most common cancers among Saudinationals for the years of 1999 and 2000. A standardized layout is used to present data for allpatients and both sexes where applicable.
For each cancer site the first paragraph includes the number and the percentage of all newlydiagnosed cases for the years 1999 and 2000, the age-standardized incidence rate for each sex(ASR) (per 100,000 population), and the specific cancer rank in comparison to all cancers forboth sexes.
The second paragraph contains useful international statistics for the specified cancer. It includesthe ranking of the cancer worldwide, the estimated number of cases for 1999-2000, and the highincidence areas of the world. The relevant source of this information is World Health Organization.GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. InternationalAgency for research on Cancer (IARC), Lyon, 2001.
17
The relevant data incorporate details for all patients presented over the years 1999 and 2000. Foreach cancer there are four figures- a line chart, a bar chart, a pie chart and a table outlined asfollows:
1. Arithmetic line graphs represent the change in average age-specific incidence rate (AIR)for all age groups at five-year intervals. The graphs are plotted by sex, where applicable.
2. Bar charts show regional distribution of ASR for particular cancer across theadministrative regions and are given separately for males and females.
3. Tables list the percentages of the most common histology subtypes for each cancer.
4. Pie charts show the distribution of the clinical stages of each cancer such as in-situ, localized,regional, distant metastasis and unknown.
5. Tables show comparison of age-standardized incidence rate (ASR) for each cancer typein Saudi Arabia with 2000 ASR estimation in selected countries
In reviewing the data and its collection and analysis, two qualifying statements can be made:a. The number of patients presenting with malignant disease from the Riyadh region exceeds
the anticipated number per population. The reason for this is that Riyadh has many referralcenters providing patients from outside the region with cancer-related care. Many of thesepatients fail to provide their permanent address, and instead, provide a temporary Riyadhaddress. It is anticipated that this situation will be resolved as soon as computerization ofidentification documents is completed.
b. As previously noted, the software used in analyzing this report, CanReg-3 Ver.3.21,did not enroll in-situ cases in the incidence tables. These cases were added to thetotal cancer cases in the overview.
Notification
The data used for this report was extracted in January 2003. Additional cases diagnosed in 1999and 2000 may be added later in subsequent incidence reports, which means an increase of thetotal cases for those two year, which has not been included in the analysis.
18
Definitions of Statistical TermsICD-10The World Health Organization’s International Classification of Diseases, tenth edition.
ICD-02The World Health Organization’s International Classification of Diseases for Oncology, 2nd Edition.
MetastasisIt is the distant spread of cancer from its original site to other organs of the body, includinglymph nodes, skeletal and or visceral organs.
Incidence RateIt is defined as the rate at which new event occur in a population. It is calculated as thenumber of new cases of disease arising in a population over a defined time period, dividedby the population at risk of developing that disease.
Crude Incidence RateThe crude incidence rate for a cancer site is the total number of cases registered as a proportionof the total population. It denotes the approximate number of cases occurring in each 100,000individuals. All rates are thus, expressed as per 100,000 population.Cancer rates vary greatly with age and the crude rate is strongly influenced by the demographicstructure of the population. Hence, if the population structure changes over time the cruderate over that period may be artificially altered. It is not appropriate to compare crude ratesacross geographical areas of cancer registries with different population age structures.Therefore, in order to assess time trends in registration data or compare incidence acrossgeographical areas or between registries it is necessary to first standardize the rates withrespect to age.
PrevalenceThis reflects the total number of patients with a disease in a specified population at a specifiedtime, including both new and old cases.
Relative FrequencyThis statistic is defined as the number of specific cancer cases registered relative to the totalnumber of all cancer. It is expressed as a percentage.
RankThis measure reflects the importance of a specific cancer site relative to other sites, in termsof the number of registrations. Ranking illustrates the most and least frequent cancer sites ina population according to their frequency.
Average Age-Specific Incidence Rate (AIR)The number of cancer cases occurring during a specific period in a population of a specificage and sex group, divided by the number of mid-year population of that age and sex group.
19
Age Class Age ClassPopulation Population0 - 45 - 9
10 - 1415 - 1920 - 2425 - 2930 - 3435 - 3940 - 44
12,00010,0009,0008,0008,0006,0006,0006,0006,000
45 - 4950 - 5455 - 5960 - 6465 - 6970 - 7475 - 7980 - 8485 +Total 100,000
6,0005,0004,0004,0003,0002,0001,000500500
Age-Standardized Rate (ASR)The Age-standardized rate is a summary measure of a rate that a population would have if ithad a standard age structure. Standardization is necessary when comparing several populationsthat differ with respect to age structure. The most frequently used standard population is theWorld Standard Population (see below). The calculated incidence is known as the WorldStandardized Incidence Rate. The rate is expressed per 100,000 populations.
The World Standard Population
20
The World Standard Population (Doll et al., 1966)
PART IIOVERVIEW OF CANCER
21
Cancer in Saudi Arabia 1994-2000The total number of cancer cases reported among Saudis during the years 1994-2000 were39209. Fifty two percent (20,532) of the cases were reported among men and 48% (18677)among women. In Saudi Arabia, taking into consideration the population structure and the factthat cancer is primarily a disease of the old, the pattern of cancer has some unique characteristics.During this period, 49% of the cases in men and 33% of the cases in women were found in theabove-59 age-group. This age-group accounts for only 5.2% of the Saudi population. This signifiesthat a large proportion of cancer cases in women occur in younger age-group. If we look at theage-group between 30-44 year, we will find that 22% of the cases in women and 12% of the casesin men were found in this group. It can be safely said that Saudi women are affected in early agesmore than men and this can be attributed to breast and thyroid cancer (figure 2-1).
10.78.3
11.5
20.3
32.2
17.0
9.310.8
22.125.3
23.8
8.8
0
5
10
15
20
25
30
35
1 2 3 4 5 6
Age Groups
MaleFemale
0-14 15-29 30-44 45-59 60-74 75 +
Fig. 2-1 Percentage Distribution of Cancer Incidence among Saudis by Age Group and Sex, 1994-2000
Fig. 2-2-A Most Frequent Types of Cancer by Age and Sex among Saudis, 1994-2000
%
22
01020304050 0 10 20 30 40 50
9.4
4.4
3.2
2.9
2.7
2.0
1.8
1.6
1.6
1.3
16.7
5.1
4.7
4.5
3.5
3.2
2.8
2.7
2.3
2.2
2.2
19.3
Breast
Thyroid
Leukaemia
Non-Hodgkin Lymphoma
Colo-rectal
Ovary
Liver
Brain, Nervous System
Cervix Uteri
Skin
Other Sites
Female (18677)*Male (20532)
Liver
Non-Hodgkin Lymphoma
Leukaemia
Lung
Colo-rectal
Prostate
Urinary Bladder
Brain, Nervous System
Stomach
Hodgkin’s Disease
Other Sites
All Ages
* One case of unknown age shows only in total as it could not be added to any age group.
Thyroid
Leukaemia
Hodgkin’s Disease
Non-Hodgkin Lymphoma
Ovary
Bone
Brain, Nervous System
Connective Tissue
Nasopharynx
Other Sites
Female (2014)Male (1712)
Leukaemia
Hodgkin’s Disease
Non-Hodgkin Lymphoma
Bone
Brain, Nervous System
Thyroid
Connective Tissue
Testis
Nasopharynx
Colo-rectal
Other Sites
15 - 29 Years
Breast
Thyroid
Colo-rectal
Cervix Uteri
Leukaemia
Non-Hodgkin Lymphoma
Ovary
Nasopharynx
Brain, Nervous System
Kidney
Other Sites
Female (4128)Male (2370)
Non-Hodgkin’s Lymphoma
Leukaemia
Colo-rectal
Nasopharynx
Thyroid
Hodgkin’s Disease
Brain, Nervous System
Urinary Bladder
Lung
Skin
Other Sites
30 - 44 Years
Fig. 2-2-B Most Frequent Types of Cancer by Age and Sex among Saudis, 1994-2000
23
01020304050 0 10 20 30 40 50
12.3
6.1
5.7
5.3
3.6
3.1
2.6
2.5
1.9
1.4
9.5
8.3
8.2
5.4
4.5
3.6
2.1
2
2
1.7
1.5
6.6
Breast
01020304050 0 10 20 30 40 50
21.5
10.4
3.1
3.0
2.9
2.8
2.4
1.3
1.2
1.2
13.8
4.0
3.3
3.1
2.6
2.3
2.0
2.0
1.7
1.6
1.3
12.5
Leukaemia
Brain, Nervous System
Hodgkin’s Disease
Non-Hodgkin Lymphoma
Kidney
Connective Tissue
Bone
Eye
Ovary
Thyroid
Other Sites
Leukaemia
Brain, Nervous System
Hodgkin’s Disease
Non-Hodgkin Lymphoma
Connective Tissue
Bone
Eye
Kidney
Liver
Testes
Other Sites
0 - 14 Years
01020304050 0 10 20 30 40 50
14.2
7.2
3.4
3.1
2.6
2.5
2.5
2.1
1.0
0.7
4.7
18.3
8.6
5.9
5.5
3.4
2.8
2.5
2.4
0.9
0.8
4.8
Female (1737)Male (2201)
24Fig. 2-2-C Most Frequent Types of Cancer by Age and Sex among Saudis, 1994-2000*
6.1
3.3
2.8
2.5
1.9
1.8
1.7
1.7
1.5
1.4
15.4
8.6
5.9
4.8
4.6
3.9
3.9
3.3
2.6
1.9
1.9
18.1
Breast
Colo-rectal
Non-Hodgkin Lymphoma
Liver
Thyroid
Skin
Ovary
Oesophagus
Stomach
Corpus Uteri
Other Sites
Female (4441)Male (6602)
Liver
Lung
Prostate
Non-Hodgkin Lymphoma
Urinary Bladder
Colo-rectal
Stomach
Skin
Oesophagus
Leukaemia
Other Sites
60 - 74 Years
3.0
2.1
2.4
2.0
1.9
1.8
1.7
1.4
1.2
1.1
13.1
8.8
7.9
5.0
4.8
4.7
4.5
4.1
4.0
3.6
2.1
18.6
Breast
Non-Hodgkin Lymphoma
Colo-rectal
Skin
Liver
Stomach
Oesophagus
Lung
Ovary
Cervix Uteri
Other Sites
Female (1638)Male (3483)
Prostate
Liver
Urinary Bladder
Lung
Non-Hodgkin Lymphoma
Stomach
Skin
Colo-rectal
Oesophagus
Leukaemia
Other Sites
75+ Years
01020304050 0 10 20 30 40 50
01020304050 0 10 20 30 40 50
01020304050 0 10 20 30 40 50
Breast
Colo-rectal
Thyroid
Non-Hodgkin Lymphoma
Liver
Ovary
Cervix Uteri
Corpus Uteri
Leukaemia
Stomach
Other Sites
Female (4718)Male (4164)
Liver
Non-Hodgkin Lymphoma
Colo-rectal
Lung
Urinary Bladder
Nasopharynx
Leukaemia
Stomach
Skin
Brain, Nervous System
Other Sites
45 - 59 Years14.0
3.6
3.6
3.1
2.6
2.4
2.2
1.7
1.5
1.5
17.1
5.6
4.4
4.1
3.9
2.8
2.4
2.1
2.0
1.7
1.6
16.2
Reported Cancer Incidence Cases in Saudi Arabia, 1999-2000Between January 1999 and December 2000, the total number of cancer cases reported to theNCR was 14,856. Overall, cancer was more predominant in men than in women. Cancers affected7,616 (51.3%) males and 7,240 (48.7%) females, with a male to female ratio of 105:100. Eleventhousand three hundred eighty three (11,383) cases were reported among Saudis, 3,242 amongnon-Saudis and 231 are of unknown nationality. Histological and/or cytological diagnosis ofmalignancy was confirmed in 94.3% of the cases. One-sixth percent of the cases were confirmedclinically, 3.2% radiologically, and 0.6% were diagnosed by other methods. The method of diagnosiswas unknown for 0.3% of the cases.
Distribution of Cancer Cases in Saudi Arabia by Nationality and SexOut of 14,856 cancer cases reported, there were 231 cases of “unknown nationality” reported tothe NCR for 1999 and 2000. Since these cases can be included in neither the Saudi category norin the non-Saudis category, they were excluded from the overall analysis. There were also 68 in-situ cases reported during 1999 and 2000 (Table 2-1). The current software program, CanReg3.21, does not include in-situ cases in the statistical analysis. The total number of cases excludedfrom the analysis was 299.
Table 2-1 Distribution of Cancer Cases in Saudi Arabia by Nationality and Sex, 1999-2000
Based on the above, 14,557 cases were analyzed of which 11,330 (77.8%) were Saudis and3,227 (22.2%) were non-Saudis. Among the Saudis, 5,713 (50.4%) were male and 5,617 (49.6%) were female. The male to female ratio was 102:100. The crude incidence rate (CIR) of allcancers among the Saudi population was 37.2/100,000 (37.5/100,000 among males and 36.8/100,000 among females). The overall age-standardized incidence rate (ASR) for all Saudis with aworld standard population reference was 62.6/100,000 (61.6/100,000 in males and 63.5/100,000in females). For all sites, the age-specific incidence rate (AIR) increased with age for both malesand females. After the age of 65 years, the increase was twofold for males compared to females.The mean age at diagnosis was 52 years for men and 47years for women. The geographic regionswith the highest ASR were Riyadh region at 109.6/100,000, Eastern region at 80.3/100,000,Najran region at 60.7/100,000, Qassim region at 60.6/100,000, and Makkah and Madinah regionsat 58.4/100,000
25
Behavior Male Female Total Male Female Total Male Female Total TotalInvasive 5713 5617 11330 1765 1462 3227 120 111 231 14788
In-situ 14 39 53 4 11 15 0 0 0 68
Total 5727 5656 11383 1769 1473 3242 120 111 231 14856
Saudis Non-Saudis Unknown Nationality
Table 2-2 Number of New Cases by Primary Site and Sex among Saudis, 1999-2000
26
ICD(10) PRIMARY SITE Males Females AllAll sites 5713 5617 11330
C00 Lip 7 11 18C01-C02 Tongue 55 51 106C07-C08 Salivary gland 19 23 42C03-C06 Mouth 50 68 118C09-C10 Oropharynx 6 5 11C11 Nasopharynx 191 60 251C12-C13 Hypopharynx 10 27 37C14 Pharynx unspec. 0 2 2C15 Oesophagus 119 109 228C16 Stomach 210 124 334C17 Small intestine 24 17 41C18 Colon 201 201 402C19-C21 Rectum 188 163 351C22 Liver 512 184 696C23-C24 Gallbladder etc. 49 104 153C25 Pancreas 110 65 175C30-C31 Nose, sinuses etc. 19 13 32C32 Larynx 93 18 111C33-C34 Bronchus, lung 354 100 454C37-C38 Other thoracic organs 22 14 36C40-C41 Bone 112 74 186C47;C49 Connective tissue 123 94 217C45 Mesothelioma 8 5 13C46 Kaposi's sarcoma 30 11 41C43 Melanoma of skin 18 15 33C44 Other skin 226 154 380C50 Male breast 22 - 22C50 Female breast - 1157 1157C55 Uterus unspec. - 15 15C53 Cervix uteri - 167 167C58 Placenta - 18 18C54 Corpus uteri - 141 141C56 Ovary etc. - 205 205C51-C52;C57 Other female genital - 24 24C61 Prostate 304 - 304C62 Testis 70 - 70C60 Penis 2 - 2C63 Other male genital 4 - 4C67 Bladder 301 80 381C64-C66;C68 Kidney etc. 168 114 282C69 Eye 46 49 95C70-C72 Brain, nervous system 270 186 456C73 Thyroid 156 539 695C74-C75 Other endocrine 21 26 47C81 Hodgkin's disease 260 173 433C82-C85;C96 Non-Hodgkin lymphoma 528 354 882C88;C90 Multiple myeloma 71 49 120C91 Lymphoid leukaemia 278 191 469C92 Myeloid leukaemia 186 176 362C93 Monocytic leukaemia 6 3 9C94 Other leukaemia 1 3 4C95 Leukaemia unspec. 8 9 17
Other & unspecified 255 226 481
During 1999-2000, 9.6% of all cancers among Saudis occurred before the age of 15, and 20.6%occurred after the age of 64 years. For the total Saudi population the ten most common cancerswere as follows:
CANCER NO. OF CASES PERCENTAGE (%)
Female breastNon-Hodgkin’s lymphoma (NHL)LeukaemiaColo-rectalLiverThyroidBrain, nervous system (CNS)LungHodgkin’s diseaseBladder
Male
NHL 528 (9.2%)Liver 512 (9%)Leukaemia 479 (8.4%)Colo-rectal 389 (6.8%)Lung 354 (6.2%)Prostate 304 (5.3%)Bladder 301 (5.3%)Brain &CNS 270 (4.7%)Hodgkin’s 260 (4.6%)Skin 226 (4%)
Total = 5713
Female
Breast 1157 (20.6%)Thyroid 539 (9.6%)Leukaemia 382 (6.9%)Colo-rectal 364 (6.5%)NHL 354 (6.3%)Ovary 205 (3.6%)Brain & CNS 186 (3.3%)Liver 184 (3.3%)Hodgkin’s 173 (3.1%)Cervix uteri 167 (3%)
Total = 5617
Fig. 2-3 Ten Most Common Cancers for Saudis by Sex, 1999-2000
27
Ten Most Common Types of Cancer Among Saudis, 1999-2000 (All Ages)
10.2 7.8 7.6 6.6 6.1 6.1 4.0 4.0 3.8 3.4
1157 882 861 753 696 695 456 454 433 381
Fig. 2-4 Average Age-Specific Incidence Rates (AIR) for All Cancers among Saudis, 1999-2000
Male Female
0
50
100
150
200
250
300
350
400
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
Rat
e p
er 1
00,0
00
male female
Fig. 2-5Age Standardized Rate ( ASR) Regional Distribution of All Sites of Cancer among Saudis, 1999-2000
28
24.7
29.7
33
33.7
42.4
48.5
55.1
58.8
60.5
64.3
65.2
79.1
108.7
0 20 40 60 80 100 120
Baha
Asir
Jazan
Jouf
Tabuk
Hail
Najran
Northern
Makkah
Madinah
Qassim
Easterm
Riyadh
ASR (PER 100,000)
27.4
28.8
31
42.3
47.7
49.1
49.4
52.7
56.2
56.2
66.2
81.7
110.2
0 20 40 60 80 100 120
Baha
Asir
Jazan
Tabuk
Northern
Jouf
Hail
Madinah
Qasim
Makkah
Najran
Easterm
Riyadh
ASR (PER 100,000)
Adult Cancers in Saudi Arabia, 1999-2000 (above 14 years)Between January 1999 and December 2000, the total number of adult cancer cases reported tothe NCR was 13,463. Overall, cancer was more predominant in males than in females. Canceraffected 6,859 (50.9%) males and 6,604(49.1%) females, with a ratio of 104:100. Of all cases,there were 10,205 Saudis, 3,033 non-Saudis and 225 of unknown nationality. As explained above,cases with unknown nationality - in this case 210 cases- and in-situ cases (68) were excluded fromthe analysis. Table 2-3 illustrates the distribution of adult cancer cases by nationality and sex.
Table 2-3 Distribution of Adult’s Cancers Cases in Saudi Arabia by Nationality and Sex, 1999-2000
As shown in table 2-3, the total number of cases analyzed was 13,185 including 10,152 (77%)Saudis and 3,033 (23%) non-Saudis. Among Saudis, 5,086 (50.1%) cases were male and 5,066(49.9%) were female. The male to female ratio was 100.4:100. For all sites, the age-specificincidence rate (AIR) increased with age for both males and females. The mean age at diagnosiswas 58 years in males and 51 years in females.
During the 1999-2000, adult cancers accounted for 89.6% of all cancers among Saudis. Thirtypoint nine percent (30.9%) of these cases occurred after the age of 60 years. For the total adultSaudi population the ten most common cancers were as follows:
29
CANCER NO. OF CASES PERCENTAGE (%)
Female breastNon-Hodgkin’s lymphoma (NHL)Colo-rectalThyroidLiverLeukaemiaLungBladderSkin (non-melanoma)Stomach
11.4 7.9 7.4 6.7 6.7 4.7 4.5 3.8 3.6 3.3
1157 800 749 683 678 479 454 381 369 334
Behavior Male Female Total Male Female Total Male Female Total TotalInvasive 5086 5066 10152 1648 1385 3033 107 103 210 13395
In-situ 14 39 53 0 0 0 4 11 15 68
Total 5100 5105 10205 1648 1385 3033 111 114 225 13463
Saudis Non-Saudis Unknown Nationality
Fig. 2-6 Ten Most Common Types of Cancer among Adult Saudis by Sex, 1999-2000
Male
Liver 500 (9.8%)NHL 481 (9.5%)Colo-rectal 389 (7.6%)Lung 354 (7%)Prostate 303 (6%)Bladder 301 (5.9%)Leukaemia 280 (5.5%)Skin 220 (4.3%)Stomach 210 (4.1%)Nasopharynx 185 (3.6%)
Total = 5086
Female
Breast 1157 (22.8%)Thyroid 533 (10.5%)Colo-Rectal 360 (7.1%)NHL 319 (6.3%)Leukaemia 199 (4%)Ovary 191 (3.8%)Liver 178 (3.5%)Cervix uteri 166 (3.3%)Skin 149 (2.9%)Corpus uteri 141 (2.8%)
Total = 5066
Primary Site Morphology %*FemalesNo.
MalesNo. %*
Female breastcancer
Infiltrating duct carcinomaCarcinoma, NOSLobular carcinoma, NOSInfiltrating duct and lobular carcinomaMedullary carcinoma, NOSPaget’s disease and Infiltrating duct carcinomaAll other
-------
-------
913555218181685
78.94.84.51.61.61.47.3
NHL Malignant lymphoma large cell, diffuse NOSMalignant lymphoma, NOSMalignant lymphoma, non-Hodgkin’s, NOSMalignant lymphoma, small lymphocytic, NOSMalignant lymphoma, mixed small and large cell, diffuseMalignant lymphoma, follicular, NOSAll other
2105852161910
116
43.712.110.8
3.34.02.1
24.1
155402014
91467
48.612.5
6.34.42.84.4
21.0Colo-rectal Adenocarcinoma, NOS
Mucinous adenocarcinomaCarcinoma, NOSSignet ring cell carcinomaAdenocarcinoma in villous adenomaAll other
29734
996
34
76.38.72.32.31.58.7
2871615
57
30
79.74.44.21.41.98.3
Thyroid Papillary carcinoma, NOSPapillary and follicular carcinomaFollicular adenocarcinoma, NOSMedullary carcinoma, NOSAll other
11413
83
12
76.08.75.32.08.0
38478301130
72.014.6
5.62.15.6
Liver Hepatocellular carcinoma, NOSMalignant tumor, NOSCholangiocarcinomaAdenocarcinoma, NOSAll other
4253110
925
85.06.22.01.85.0
1358
157
13
75.84.58.43.97.3
30
31
Leukaemia Acute myeloid leukaemiaAcute lymphoblastic leukaemia, NOSChronic myeloid leukaemiaChronic lymphoblastic leukaemiaAll other
6863555143
24.322.519.618.215.4
5625672625
28.112.633.713.112.6
Lung Squamous cell carcinoma, NOSAdenocarcinoma, NOSCarcinoma, NOSSmall cell carcinoma, NOSAll other
10096383981
28.227.110.711.022.9
223910
524
22.039.010.0
5.024.0
Urinary bladder Papillary transitional cell carcinomaTransitional cell carcinoma, NOSSquamous cell carcinoma, NOSAdenocarcinoma, NOSAll other
134124
156
22
44.541.2
5.02.07.3
2938
418
36.347.5
5.01.3
10.0Skin(non-melanoma)
Basal cell carcinomaSquamous cell carcinomaDermatofibrosarcomaSquamous cell carcinoma, keratinizing, NOSBasosquamous carcinomaAll other
105681310
816
47.730.9
5.94.53.67.3
843410
73
11
56.422.8
6.74.72.07.4
Ovary Papillary serous cystadenocarcinomaAdenocarcinoma, NOSEndometrioid carcinomaSerous surface papillary carcinomaAll other
-----
-----
2922151480
15.211.57.97.3
41.9Nasopharynx Carcinoma, undifferentiated, NOS
Carcinoma, NOSSquamous cell carcinoma, large cell, nonkeratinizingSquamous cell carcinoma, NOSAll other
53523934
7
28.628.121.118.4
3.8
24111193
41.419.019.015.5
5.2
Cervix uteri Squamous cell carcinoma, NOSSquamous cell ca, non-keratinizing, NOSAdenocarcinoma, NOSSquamous cell, keratinizing, NOSAll other
-----
-----
9622161319
57.813.3
9.67.8
11.4
Stomach Adenocarcinoma, NOSSignet ring cell carcinomaAdenocarcinoma, intestinal typeCarcinoma, NOSAll other
12732191220
60.515.2
9.05.79.5
6036
76
15
48.429.0
5.64.8
12.1
Corpus uteri Adenocarcinoma, NOSEndometrioid carcinomaEndometrial stromal sarcomaMullerian mixed tumorAll other
-----
-----
6229
55
40
44.020.6
3.53.5
28.4
Prostate Adenocarcinoma, NOSCarcinoma, NOSAll other
2543613
83.811.94.3
---
---
Table 2-4 Number and Proportion of Morphological Types for the MostCommon Types of Cancer among Saudi Adults, 1999-2000
%*Primary Site Morphology FemalesNo.
MalesNo. %*
* Relative percentage of morphology type within primary site.
Childhood Cancers in Saudi Arabia 1999-2000 (14 years and under)The total of cases reported among children (0-14 years as defined by the WHO) between January1999 and December 2000 was 1,393. This represented 9.4 % of the total number of cancers inSaudi Arabia. The total reported incidence shows that cancer was more predominant in males thanin females. Seven hundred fifty eight (758) (54.4%) cases were reported among males and 635(45.6%) among females, with a male to female ratio of 119:100. Of all the cases reported, therewere 1,177 Saudis, 195 non-Saudis and 21 of “unknown nationality”.
Childhood cancer is very important not only because of the age of occurrence, but also becausemore than 45% of the Saudi population is under 15 years of age. In addition to this, recent yearshave shown a breakthrough for the cure of many childhood cancers. Childhood cancers accountedfor 10.4% of all cancers among Saudis.
As explained earlier, 21cases of unknown nationality were excluded from the statistical analysis.Table 2-5 demonstrates the distribution of childhood cancer cases by nationality and sex.
Table 2-5 Distribution of Childhood Cancer Cases in Saudi Arabia by Nationality and Sex, 1999-2000
Based on the above, the total number of cases analysed was 1,393 including 1,177 (85.8%)Saudis and 195(14.2%) non-Saudis. Among Saudis, 627 (53.3%) were male and 550(46.7%)were female. The male to female ratio was 114: 100. The leading cancer among the Saudi childrenwas leukaemia, which accounted for 32.5%, followed by Brain (CNS) and Hodgkin’s disease.The following is a listing of the ten most common types of cancer among Saudi children in order ofrelative frequency. Figure 2-7 shows the top ten sites by sex and frequency, and table 2-6 showsthe number and proportion of the morphological types for the most common types of cancer.
32
CANCER NO. OF CASES PERCENTAGE (%)
LeukaemiaBrain, nervous systemHodgkin’s diseaseNon-Hodgkin lymphomaBoneConnective tissueKidneyEyeLiverOvary
32.515.310.8 7.0
6.15.45.15.11.51.2
38218012782726460601814
Behavior Male Female Total Male Female Total Male Female Total TotalInvasive 627 550 1177 118 77 195 13 8 21 1393
In-situ 0 0 0 0 0 0 0 0 0 0
Total 627 550 1177 118 77 195 13 8 21 1393
Saudis Non-Saudis Unknown Nationality
Fig. 2-7 Ten Most Common Types of Cancer among Saudi Children by Sex, 1999-2000
33
Male
Leukaemia 199 (31.8%)Brain, nervous system 101 (16.1%)Hodgkin’s 76 (12.1%)NHL 47 (7.5%)Bone 39 (6.2%)Connective tissue 35 (5.6%)Kidney 30 (4.8%)Eye 28 (4.5%)Liver 12 (1.9%)Testes 10 (1.6%)
Total = 627
Female
Leukaemia 183 (33.3%)Brain, nervous system 79 (14.4%)Hodgkin’s 51 (9.3%)NHL 35 (6.4%)Bone 33 (6%)Eye 32 (5.8%)Kidney 30 (5.5%)Connective tissue 29 (5.3%)Ovary 14 (2.5%)Liver & Thyroid 6 (1.1%) each
Total = 550
Table 2-6 Number and Proportion of Morphological types of the Most Common Types of Childhood Canceramong Saudis, 1999-2000
* Relative percentage of morphology type within primary site
Primary Site Morphology %*FemalesNo.
MalesNo. %*
Leukaemia Acute lymphoblastic leukaemia, NOSAcute myeloid leukaemiaChronic myeloid leukaemiaAll other
15332
311
76.916.1
1.55.5
13428
714
73.215.3
3.87.7
Brain, nervoussystem
Medulloblastoma, NOSPilocytic astrocytomaGlioma, malignantEpendyomoma, NOSGlioblastoma, NOSAll other
391810
41119
38.617.8
104
10.918.8
142516
92
13
17.731.620.311.42.5
16.5Hodgkin’sdisease
Hodgkin’s disease, nodular sclerosis, NOSHodgkin’s disease, mixed cellularity, NOSHodgkin’s disease, lymphocytic predominance, NOSAll other
4216
315
55.321.1
3.919.7
31677
60.811.813.713.7
NHL Burkitt’s lymphoma, NOSMalignant lymphoma, large cell, diffuse, NOSMalignant lymphoma, lymphoblasticAll other
1877
15
38.314.914.931.9
1263
41
34.317.1
8.640.0
Bone Ewing’s sarcomaOsteosarcoma, NOSAll other
1716
6
43.641.015.4
1614
3
48.542.4
9.1Connectivetissue
Embryonal rhabdomyosarcomaGanglioneuroblastomaInfantile fibrosarcomaAll other
1055
15
28.614.314.342.9
491
15
13.831.0
3.451.7
Kidney Nephroblastoma, NOSAll other
282
93.30.7
273
90.010.0
Eye Retinoblastoma, NOSRetinoblastoma, undifferentiatedRetinoblastoma, differentiatedAll other
1783
-
60.728.610.7
-
161132
50.034.3
9.46.3
Liver HepatoblastomaAll other
93
7525
6-
100.0-
Ovary DysgerminomaEndodermal sinus tumorMixed germ cell tumorAll other
----
----
7223
50.014.314.321.4
Thyroid Papillary carcinoma, NOSMedullary carcinoma, NOSPapillary carcinoma, follicular variant
321
50.033.316.6
6--
100.0--
34
Cancer in the 13 Administrative Regions of the Kingdom
The following bar charts list the most common sites in the 13 administrative regions of SaudiArabia by sex. These sites are listed on the basis of the total number of cases reported by eachregion. In the majority of regions breast cancer was the leading cancer in women while amongmen, NHL, Liver, and Leukemia inter-change. It is worth noting that the major regions such asRiyadh, Makkah and Eastern Province reported the most cases. This can be attributed to theincreasing number of people seeking medical attention in these urbanized cities with modern hospitalfacilities.
Fig. 2-8-1 Riyadh Region, 1999-2000 (Percentage Distribution)
Fig. 2-8-2 Najran Region, 1999-2000 (Percentage Distribution)
35
36
4
4
5
5
6
6
6
8
9
12
0 10 20 30 40 50
Ot her sit es
Hodgkin's
Lung
Bladder
Skin
Brain, CNS
Colo-rectal
Prostat e
Leukaemia
NHL
Liver
M a l e s ( 18 2 5 )
34
3
3
3
4
4
6
7
7
12
18
0 10 20 30 40 50
Ot her sit es
Cervix ut er i
Hodgkin's
Ovary
Brain, CNS
Liver
NHL
Leukaemia
Colo-rect al
Thyroid
Breast
Fe ma le s ( 18 17 )
40
3
4
4
5
7
7
7
8
8
9
0 10 20 30 40 50
Ot her sit es
Prost at e
Hodgkin's
Skin
Brain, CNS
Colo-rectal
Leukaemia
Thyroid
NHL
Liver
Female breast
Al l ( 3 6 4 2 )
18
4
4
4
4
4
5
5
5
7
7
10
11
13
0 10 20 30 40 50
Ot her sit es
Hodgkin's
Kidney
Pancreas
St omach
Thyroid
Bone
Lung
Colo-rectal
Brain, CNS
Skin
Leukaemia
Liver
NHL
M a l e s ( 114 )
32
3
3
3
3
3
5
5
5
6
6
7
9
9
0 10 20 30 40 50
Other sit es
Thyroid
Brain, CNS
Bladder
Ovary
Salivary glands
Skin
Bone
St omach
Liver
Colo-rectal
Breast
Leukaemia
NHL
Fe ma l e s ( 8 7 )
31
3
3
3
4
4
5
6
6
6
9
10
11
0 10 20 30 40 50
Ot her sit es
Hodgkin's
Female breast
Lung
Thyroid
Stomach
Bone
Brain, CNS
Colo-rectal
Skin
Liver
Leukaemia
NHL
A l l ( 2 0 1)
Fig. 2-8-3 Eastern Region, 1999-2000 (Percentage Distribution)
Fig. 2-8-4 Makkah Region, 1999-2000 (Percentage Distribution)
Fig. 2-8-5 Northern Region, 1999-2000 (Percentage Distribution)36
34
4
4
5
6
6
6
8
9
9
10
0 10 20 30 40 50
Ot her sit es
Skin
Liver
Brain, CNS
Hodgkin's
Prostat e
Bladder
NHL
Leukaemia
Colo-rectal
Lung
M a le s ( 8 9 5 )
28
3
3
3
4
4
6
6
6
10
27
0 10 20 30 40 50
Ot her sit es
Corpus ut er i
Ovary
Cervix ut er i
Brain, CNS
Hodgkin's
Colo-rect al
Leukaemia
NHL
Thyroid
Breast
Fe ma l e s ( 8 6 4 )
37
3
4
4
5
6
6
7
7
7
13
0 10 20 30 40 50
Ot her sit es
Prost at e
Brain, CNS
Bladder
Hodgkin's
Lung
Thyroid
NHL
Leukaemia
Colo-rectal
Female breast
Al l ( 17 5 9 )
35
4
4
5
6
6
7
8
8
9
10
0 10 20 30 40 50
Ot her sit es
Brain, CNS
St omach
Hodkin's
Prostat e
Bladder
Colo-rectal
Lung
Liver
Leukaemia
NHL
M a l e s ( 12 0 9 )
31
3
3
3
4
4
6
6
7
7
27
0 10 20 30 40 50
Ot her sit es
Lung
Corpus ut er i
Liver
Cervix ut er i
Ovary
Leukaemia
NHL
Colo-rect al
Thyroid
Breast
Fe ma le s ( 12 5 2 )
39
3
3
4
4
5
6
7
7
8
14
0 10 20 30 40 50
Ot her sit es
Hodgkin's
Brain, CNS
Bladder
Thyroid
Lung
Liver
Colo-rectal
Leukaemia
NHL
Female breast
Al l ( 2 4 6 1)
12
4
4
4
4
8
8
8
8
10
12
12
0 10 20 30 40 50
Ot her sit es
Kidney
Bladder
Bone
Liver
Colo-rect al
Brain, CNS
Lung
Larynx
Nasopharynx
Leukaemia
NHL
M a l e s ( 4 9 )
15
5
5
5
5
5
5
10
10
13
21
0 10 20 30 40 50
Ot her sit es
NHL
Bladder
Lung
Liver
Colo-rect al
Tongue
Leukaemia
Pancreas
Thyroid
Breast
Fe ma l e s ( 3 9 )
22
5
5
5
5
5
6
7
7
7
9
9
11
0 10 20 30 40 50
Ot her sit es
Brain, CNS
Bladder
Larynx
Liver
Colo- rect al
Pancreas
Thyroid
Lung
Nasopharynx
NHL
Female breast
Leukaemia
Al l ( 8 8 )
Fig. 2-8-6 Qassim Region, 1999-2000 (Percentage Distribution)
Fig. 2-8-7 Jazan Region, 1999-2000 (Percentage Distribution)
Fig. 2-8-8 Hail Region, 1999-2000 (Percentage Distribution)37
34
4
5
5
5
6
6
7
9
10
10
0 10 20 30 40 50
Ot her sit es
Lung
Brain, CNS
Colo-rect al
Oesophagus
Hodgkin's
NHL
St omach
Liver
Leukaemia
Nasopharynx
M a l e s ( 2 8 2 )
32
3
3
4
5
5
7
8
8
13
14
0 10 20 30 40 50
Ot her sit es
Skin
Cervix ut er i
Corpus ut er i
Hodgkin's
Ovary
NHL
Leukaemia
Colo-rect al
Thyroid
Breast
Fe ma l e s ( 2 8 3 )
38
4
4
5
6
6
7
7
7
8
9
0 10 20 30 40 50
Ot her sit es
Oesophagus
St omach
Hodgkin's
Liver
Nasopharynx
Colo-rect al
NHL
Female breast
Thyroid
Leukaemia
Al l ( 5 6 5 )
36
4
4
5
5
5
6
7
7
9
12
0 10 20 30 40 50
Ot her sit es
Hodgkin's
Prostat e
Brain, CNS
Colo-rectal
Mout h
Skin
Bladder
Leukaemia
NHL
Liver
M a l e s ( 2 15 )
33
4
4
5
5
5
6
6
7
9
15
0 10 20 30 40 50
Other sit es
t hyroid
Ovary
NHL
Liver
Colo-rectal
Leukaemia
Skin
Tongue
Breast
Mout h
Fe ma l e s ( 2 0 3 )
39
4
4
5
5
5
6
7
7
8
10
0 10 20 30 40 50
Other sit es
Brain, CNS
Female breast
Bladder
Tongue
Colo-rectal
Skin
Leukaemia
NHL
Liver
Mout h
A l l ( 4 18 )
48
4
4
4
5
6
7
7
7
9
10
0 10 20 30 40 50
Ot her sit es
Pancreas
Prost at e
Lung
Bone
Liver
Hodgkin's
Colo-rect al
Nasopharynx
Leukaemia
NHL
M a l e s ( 13 9 )
30
3
3
4
4
4
5
6
6
18
19
0 10 20 30 40 50
Ot her sit es
Ovary
Nasopharynx
NHL
Hodgkin's
Skin
Leukaemia
Brain, CNS
Colo-rect al
Breast
Thyroid
Fe ma l e s ( 12 8 )
39
4
4
4
5
5
6
7
7
9
11
0 10 20 30 40 50
Ot her sit es
Bone
Brain, CNS
Liver
Nasopharynx
Hodgkin's
Colo-rect al
Leukaemia
NHL
Female breast
Thyroid
Al l ( 2 6 7 )
Fig. 2-8-9 Madinah Region, 1999-2000 (Percentage Distribution)
Fig. 2-8-10 Baha Region, 1999-2000 (Percentage Distribution)
Fig. 2-8-11 Tabuk Region, 1999-2000 (Percentage Distribution)38
30
4
4
6
6
6
7
8
9
10
11
0 10 20 30 40 50
Ot her sit es
Nasopharynx
Kidney
Brain, CNS
Bladder
Hodgkin's
Colo-rect al
Lung
NHL
Leukaemia
Liver
M a l e s ( 3 5 7 )
29
3
3
4
5
5
5
6
6
9
25
0 10 20 30 40 50
Other sit es
Brain, CNS
Bone
Ovary
NHL
Liver
Hodgkin's
Thyroid
Colo-rectal
Leukaemia
Breast
Fe ma l e s ( 3 7 1)
31
3
3
4
4
5
6
6
7
8
9
13
0 10 20 30 40 50
Other sit es
Kidney
Bladder
Thyroid
Brain, CNS
Lung
Hodgkin's
Colo-rectal
NHL
Liver
Leukaemia
Female breast
A l l ( 7 2 8 )
25
3
3
3
6
7
7
9
9
12
16
0 10 20 30 40 50
Ot her sit es
Thyroid
Prost at e
Bone
Lung
Skin
St omach
Leukaemia
Liver
Bladder
NHL
M a l e s ( 8 9 )
27
4
4
5
6
6
7
7
8
12
12
0 10 20 30 40 50
Ot her sit es
Corpus ut er i
Liver
St omach
Leukaemia
Oesophagus
Thyroid
Skin
NHL
Colo-rect al
Breast
Fe ma l e s ( 9 7 )
31
4
5
6
7
7
7
7
8
8
12
0 10 20 30 40 50
Ot her sit es
Oesophagus
Thyroid
St omach
Female breast
Liver
Bladder
Skin
Leukaemia
Colo-rect al
NHL
A l l ( 18 6 )
32
4
4
4
4
5
6
6
6
10
10
11
0 10 20 30 40 50
Other sit es
Thyroid
Bladder
Prost at e
Oesophagus
Brain, CNS
Bone
Hodgkin's
St omach
NHL
Lung
Leukaemia
M a le s ( 110 )
25
3
3
3
3
5
5
5
5
6
9
12
18
0 10 20 30 40 50
Ot her sit es
Brain, CNS
Kidney
Connect ive t issue
St omach
Hodgkin's
Thyroid
Ovary
Cervix ut eri
Colo-rectal
Leukaemia
NHL
Breast
Fe ma l e s ( 9 4 )
36
3
3
4
4
4
5
6
6
8
10
11
0 10 20 30 40 50
Ot her sit es
Bone
Oesophagus
Brain, CNS
Thyroid
Colo-rectal
St omach
Hodgkin's
Lung
Female breast
Leukaemia
NHL
Al l ( 2 0 4 )
Fig. 2-8-12 Asir Region, 1999-2000 (Percentage Distribution)
Fig. 2-8-13 Jouf Region, 1999-2000 (Percentage distribution)
39
38
4
4
4
4
5
6
8
9
10
11
0 10 20 30 40 50
Ot her sit es
Hodgkin's
Bone
Kidney
St omach
Skin
Bladder
Colo-rectal
Liver
NHL
Leukaemia
M a le s ( 2 8 7 )
29
3
4
4
4
4
7
10
11
12
14
0 10 20 30 40 50
Ot her sit es
Liver
Ovary
Cervix ut er i
Skin
Brain, CNS
Colo-rect al
NHL
Leukaemia
Thyroid
Breast
Fe ma l e s ( 2 8 6 )
38
3
4
4
4
6
7
7
8
10
11
0 10 20 30 40 50
Other sit es
Stomach
Brain, CNS
Bladder
Skin
Liver
Thyroid
Female breast
Colo-rectal
NHL
Leukaemia
A l l ( 5 7 3 )
11
3
3
3
3
3
3
3
3
4
6
6
7
9
10
11
14
0 10 20 30 40 50
Ot her sit es
Leukaemia
Mult iple myeloma
Test is
Connect ive t issue
Liver
Colo-rect al
Oesophagus
Salivary glands
Hodgkin's
Thyroid
Bladder
Prostate
Nasopharynx
Lung
Brain, CNS
NHL
M a l e s ( 7 1)
14
4
4
4
4
4
4
4
6
6
6
6
8
10
14
0 10 20 30 40 50
Ot her sit es
Thyroid
Eye
Kidney
Ovary
Larynx
Liver
Mout h
NHL
Hodgkin's
Cervix ut eri
Bone
Connect ive t issue
Leukaemia
Breast
Fe ma l e s ( 4 9 )
41
4
5
5
5
5
6
6
6
7
11
0 10 20 30 40 50
Ot her sit es
Prost ate
Hodgkin's
Thyroid
Connect ive t issue
Nasopharynx
Leukaemia
Female breast
Lung
Brain, CNS
NHL
A l l ( 12 0 )
International Comparison of Age-Standardized Incidence Rates
Worldwide, it is estimated that over 10,055,551 people developed cancer in 2000. Of these,53.5% were in developing countries and 46.5% were in more developed countries. According to2000 estimates, the most common cancer site in men was lung cancer. In developed countries itwas followed by prostate, colo-rectal and stomach cancers. In developing regions, stomach canceris the second most frequently appearing cancer, followed by liver, esophagus and colo-rectalcancers, with wide regional variations. In women, breast cancer was the most common followedby colo-rectal, lung and stomach cancers in developed countries and cancers of the cervix, stomachand lung in developing regions.
Comparison of ASR for Saudi Males and Females with 2000 ASR Estimation in Selected Countries
Fig. 2-9 Shows the 2000 ASR Estimation in Selected Countries among the Females and Male
40
63.5
71.1
78.0
87.1
102.7
111.1
111.6
174.0
176.8
182.5
250.1
253.4
275.9
283.0
296.9
303.2
0 50 100 150 200 250 300 350 400 450
* Saudi A rabia
Gambia
Oman
Congo Brazaville
Egypt
Jordan
Kuw ait
Mongolia
Haiti
Vanuatu
Sw eden
Netherlands
Hungary
United States of America
Denmark
New Zealand
ASR (per 100,000)
* Actual Rate (Not Estimation)
Mal
esFe
mal
es
55.8
61.6
70.7
96.0
97.1
120.2
123.6
163.3
184.9
238.6
262.0
278.7
299.6
361.4
375.3
405.0
0 50 100 150 200 250 300 350 400 450
Congo Brazav ille
* Saudi A rabia
Gambia
Oman
Kuw ait
Jordan
Egypt
V anuatu
Haiti
Mongolia
Sw eden
Denmark
Netherlands
United States of A merica
New Zealand
Hungary
ASR (pe r 100,000)
PART IIICANCER INCIDENCE FOR SPECIFIC SITES
1999-2000
41
Cancer Incidence for Specific Sites 1999-2000
In this section the incidence of the 14 most predominant cancers in Saudi Arabia is outlined inorder, according to their relative frequency in the whole Saudi population. The relevant dataincorporate details for all patients presented over the period of January 1999 through December2000.
42
CANCER NO. OF CASES PERCENTAGE (%)
Female breastNon-Hodgkin lymphomaLeukaemiaColo-rectalLiverThyroidBrain, nervous systemLungHodgkin’s diseaseBladderSkinProstateOvaryCervix uteri
1157882861753696695456454433381380304205167
10.27.87.66.66.16.14.04.03.83.43.42.71.81.5
Female Breast (C50)
Between January 1999 and December 2000, there were 1,157 cases of female breast cancer.Breast cancer is the most common cancer, ranked first among females and it accounted for 20.6%of all newly diagnosed female cancers (5,617). The ASR was 13.6/100,000 for female population.The mean age at diagnosis was 49 years. The five regions with the highest ASR were the Easternregion at 21.2/100,000, Riyadh region at 19.9/100,000, Madinah region at 16.9/100,000, Makkahregion at 16.4/100,000 and Hail Region at 9.4/100,000.
Cancer of the breast is the most common cancer in the world among women. The estimatednumber of cases diagnosed worldwide in 2000 was 1,050,346. Fifty-five point two percent (55.2%)were in more developed countries. Incidence rates were highest in Western Europe, North America,and Northern Europe.
0
5
10
15
20
25
30
35
40
45
50
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
AIR
(per
100
,000
)
Fig. 3-1 Average Age-Specific Incidence Rate (AIR) for Female Breast Cancer in Saudi Arabia, 1999-2000
43
AIR
(per
100
,000
)
3.0
3.2
3.4
4.4
5.8
8.2
8.5
9.0
9.4
16.4
16.9
19.9
21.2
0 5 10 15 20 25
Baha
Najran
Jazan
Asir
Jouf
Qasim
Tabuk
Northern
Hail
Makkah
Madinah
Riyadh
Eastern
Female (1157)
Fig. 3-2 ASR Regional Distribution of Female Breast Cancer in Saudi Arabia, 1999-2000
Table 3-1 Histology of Female Breast Cancer in Saudi Arabia, 1999-2000
ICD-0 Code Histology %8500801085208522851085418480850190208140
Infiltrating duct carcinomaCarcinoma, NOSLobular carcinoma, NOSInfiltrating duct and lobular carcinomaMedullary carcinoma, NOSPaget’s disease and infiltrating duct CarcinomaMucinous adenocarcinomaComedocarcnimoa, NOSPhyllodes tumor, malignantAdenocarcinoma, NOSAll others
78.94.84.51.61.61.41.01.00.90.83.5
44
20.4%
48.1%
12.6%
18.6%0.3%
InsituLocalizedRegionalDistantUnknown
Fig. 3-3 Stage Distribution of Female Breast Cancer in Saudi Arabia, 1999-2000
Table 3-2 Comparison of ASR for Breast Cancer among Saudi Females with 2000 ASR Estimation inSelected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon, 2001** Actual rate (not estimation)
45
CountryNetherlands 91.6United States of America 91.4France 83.2Pakistan 50.1Jordan 33.0Japan 31.4Saudi Arabia 13.6Korea, Republic 12.5Oman 11.7Haiti 4.7
ASR* (Female)
**
Non-Hodgkin’s Lymphoma (C82-C85;C96)
Between January 1999 and December 2000 there were 882 cases of non-Hodgkin’s lymphomaaccounting for 7.8% of all newly diagnosed cancers (11,330). The overall ASR was 4.9/100,000.The ASR was 5.7/100,1000 in males and 4.0/100,000 in females. This cancer ranked first inmales and fifth in females and affected 528(59.9%) males and 354(40.1%) females with a male tofemale ratio of 149:100. The mean age at diagnosis was 51 years in males and 48 years in females.The five regions with the highest incidence rates were Riyadh region at 8.5/100,000, Najranregion at 6.9/100,1000, the Eastern region at 5.8/100,000, the Northern region at 5.3/100,000and Tabuk region at 4.9/100,000.
NHL is the tenth most common cancer in the world. The estimated number of cases diagnosedworldwide in 2000 was 287,428, with 50.9% in more developed countries. Incidence rates werehighest in North America, Australia/New Zealand, Northern and Western Europe.
Fig. 3-4 Average Age-Specific Incidence Rates (AIR) for NHL in Saudi Arabia, 1999-2000
46
0
5
10
15
20
25
30
35
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age Groups
AIR
(per
100
,000
)
male female
Fig. 3-5 ASR Regional Distribution of NHL in Saudi Arabia, 1999-2000
Table 3-3 Histology of NHL, 1999-2000
ICD-0 Code Histology %9680959095919687967096759690
Malignant lymphoma large cell, diffuse, NOSMalignant lymphoma, NOSMalignant lymphoma, non-Hodgkin’s, NOSBurkitt’s lymphomaMalignant lymphoma, small lymphocytic, NOSMalignant lymphoma, mixed small and large cell, diffuseMalignant lymphoma, follicular, NOSAll other
42.911.98.84.53.43.32.7
22.5
2.9
2.9
3.0
3.7
4.4
5.2
5.3
5.7
6.0
6.3
7.9
10.0
10.0
0 5 10 15 20 25
Jazan
Asir
Qassim
Baha
Madinah
Northern
Hail
Makkah
Tabuk
Eastern
Jouf
Riyadh
Najran
Male (528)
1.4
1.5
2.1
2.2
2.8
3.1
3.6
3.7
3.8
5.0
5.3
5.5
7.0
0 5 10 15 20 25
Jazan
Jouf
Baha
Hail
Asir
Madinah
Makkah
Tabuk
Najran
Qassim
Eastern
Northern
Riyadh
Female (354)
47
Fig. 3-6 Stage Distribution of NHL in Saudi Arabia, 1999-2000
28.3%
17.7%32.9%
21.1%
LocalizedRegionalDistantUnknown
Table 3-4 Comparison of ASR for NHL among Saudis with 2000 ASR Estimation in Selected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon,2001** Actual rate (not estimation)
48
CountryUnited States of America 16.1 10.9Australia 14.4 10.8Germany 10.5 6.7China, Hong Kong 8.7 6.4Iraq 6.6 5.0Saudi Arabia 5.7 4.0Iran, Islamic Republic 4.1 3.8India 3.2 1.7Gambia 2.6 1.5Sri Lanka 1.0 0.4
ASR* (Male) ASR* (Female)
** **
Leukaemia (C91-C95)
Between January 1999 and December 2000 there were 861 cases of leukaemia accounting for7.6% of all 11,330 newly diagnosed cancers. The overall ASR was 3.3/100,000. The ASR was3.7/100,000 and 3.0/100,000 in males and females respectively. This cancer ranked third for bothmales and females and affected 479 (55.6%) males and 382 (44.4%) females with a male tofemale ratio of 125:100. The mean age at diagnosis is 28 years in males and 26 years in females.The five regions with the highest ASR were Riyadh region at 5.0/100,000, Najran region at 4.3/100,000, Madinah region at 4.0/100,000, the Eastern region at 3.9/100,000 and Qassim regionat 3.7/100,000.
Leukaemia is the twelveth most common cancer in the world. The estimated number of casesdiagnosed worldwide in 2000 was 257,076, with 58.8% in less developed countries. Incidencerates were highest in the Caribbean, Australia/New Zealand, Northern Europe, and Eastern Africa.
0
2
4
6
8
10
12
14
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
male female
AIR
(per
100
,000
)
Fig. 3-7 Average Age-Specific Incidence Rate (AIR) for Leukaemia in Saudi Arabia, 1999-2000
49
AIR
(per
100
,000
)
Table 3-5 Histology of Leukaemia, 1999-2000
ICD-0 Code Histology %9821986198639823986698679801
Acute lymphoblastic leukaemia, NOSAcute myeloid leukaemiaChronic myeloid leukaemiaChronic lymphocytic leukaemiaAcute promyelocytic leukaemiaAcute myelomonocytic leukaemiaAcute Leukaemia, NOSAll Others
43.621.415.38.91.71.61.56.0
Table 3-6 Comparison of ASR for Leukaemia among Saudis with 2000 ASR Estimation in Selected Countries
0.6
1.4
2.4
2.4
3.0
3.1
3.2
3.5
4.3
4.4
4.5
5.2
5.4
0 5 10 15 20 25
Jouf
Jazan
Tabuk
Asir
Baha
Hail
Makkah
Northern
Madinah
Qasim
Eastern
Riyadh
Najran
Male (479)
1.2
1.5
1.6
1.8
2
2.1
2.7
2.7
3
3.1
3.4
3.7
4.7
0 5 10 15 20 25
Jouf
Jazan
Hail
Tabuk
Baha
Northern
Makkah
Asir
Qasim
Najran
Eastern
Madinah
Riyadh
Female (382)
Fig. 3-8 ASR Regional Distribution of Leukaemia in Saudi Arabia, 1999-2000
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon, 2001** Actual rate (not estimation)
50
CountryHaiti 15.2 10.2New Zealand 11.9 8.7Jordan 8.1 5.0China, Hong Kong 6.7 4.8Cuba 6.1 4.8Tunisia 4.8 4.4Saudi Arabia 3.7 3.0India 3.1 2.1Algeria 2.8 1.5Senegal 0.9 0.2
ASR* (Male) ASR* (Female)
** **
Colo-rectal (C18-C21)
Between January 1999 and December 2000 there were 753 cases of colo-rectal cancer accountingfor 6.6% of all 11,330 newly diagnosed cases. The overall ASR was 4.9/100,000. The ASR was5.0/100,000 in males and 4.7/100,000 in females. This cancer ranked fourth in both males andfemales and affected 389 (51.7%) males and 364 (48.3%) females with a male to female ratio of107:100. The mean age at diagnosis was 59 years in males and 56 years for females. The fiveregions with the highest ASR were Riyadh region at 8.4/100,000, the Eastern region at 7.7/100,000,Qassim Region at 5.1/100,000, Makkah region at 4.5/100,000 and Madinah region at 4.2/100,000.
Colo-rectal cancer is the third most common cancer in the world. The estimated number of casesdiagnosed worldwide in 2000 was 944,717, with 64.6% in more developed countries. Incidencerates were highest in Australia/New Zealand, Eastern, Northern and Western Europe, and NorthernAmerica.
0
5
10
15
20
25
30
35
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
male female
AIR
(per
100
,000
)
Fig. 3-9 Average Age Specific Incidence rate (AIR) for Colo-rectal Cancer in Saudi Arabia, 1999-2000
51
AIR
(per
100
,000
)
Fig. 3-10 ASR Regional Distribution of Colo-rectal Cancer in Saudi Arabia, 1999-2000
Table 3-7 Histology of Colo-rectal Cancer, 1999-2000
ICD-0 Code Histology %814084808010849082618481
Adenocarcinoma, NOSMucinous adenocarcinomaCarcinoma, NOSSignet ring cell carcinomaAdenocarcinoma in villous adenomaMucin-producing adenocarcinomaAll Others
77.76.83.21.91.71.57.2
1.0
1.5
1.7
1.9
1.9
2.9
3.2
3.8
3.9
4.0
4.8
7.9
9.8
0 5 10 15 20 25
Baha
Tabuk
Jouf
Northern
Jazan
Asir
Najran
Qassim
Hail
Madinah
Makkah
Riyadh
Eastern
Male (389)
0.0
1.8
2.2
2.9
3.0
3.2
3.8
4.2
4.5
5.4
5.9
6.5
8.9
0 5 10 15 20 25
Jouf
Jazan
Asir
Hail
Baha
Tabuk
Najran
Makkah
Madinah
Eastern
Northern
Qassim
Riyadh
Female (364)
52
27.4%
38.7%
15.6%
17.9%0.3%
InsituLocalizedRegionalDistantUnknown
Fig. 3-11 Stage Distribution of Colo-rectal Cancer, 1999-2000
Table 3-8 Comparison of ASR for Colo-rectal among Saudis with 2000 ASR Estimation in Selected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon,2001** Actual rate (not estimation)
53
CountryNew Zealand 55.3 43.4United States of America 40.6 30.6China, Hong Kong 35.0 28.9Indonesia 12.0 10.6Bahrain 9.4 8.0Iraq 5.5 4.6Saudi Arabia 5.0 4.7India 4.7 3.2Malawi 3.5 1.6Bangladesh 1.0 0.9
ASR* (Male) ASR* (Female)
** **
Liver (C22)
Between January 1999 and December 2000 there were 696 cases of liver cancer accounting for6.1% of all 11,330 newly diagnosed cases. The overall ASR was 4.5/100,000. The ASR was 6.5/100,000 in males and 2.6/100,000 in females. This cancer ranked second in males, and eighth infemales and affected 512 (73.6%) males and 184 (26.4%) females with a male to female ratio of279:100. The mean age at diagnosis was 64 years in males and 58 years in females. The fiveregions with the highest ASR were Riyadh region at 10.4/100,000, Najran region at 7.3/100,000,Madinah region at 5.6/100,000, Qassim region at 3.9/100,000 and Makkah region at 3.6/100,000.
Liver cancer is the fifth most common cancer in the world. The estimated number of cases diagnosedworldwide in 2000 was 564,336, with 81.1% in less developed countries. Incidence rates werehighest in Eastern Asia, Eastern and Western Africa, and South-Eastern Asia.
0
5
10
15
20
25
30
35
40
45
50
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
male female
AIR
(per
100
,000
)
Fig. 3-12 Average Age-Specific Incidence Rate (AIR) for Liver Cancer in Saudi Arabia, 1999-2000
54
AIR
(per
100
,000
)
Fig. 3-13 ASR Regional Distribution of Liver Cancer in Saudi Arabia, 1999-2000
Table 3-9 Histology of Liver Cancer, 1999-2000
ICD-0 Code Histology %817080008160814089708230
Hepatocellular carcinoma, NOSMalignant tumor, NOSCholangiocarcinomaAdenocarcinoma, NOSHepatoblastomaSolid carcinoma, NOSAll Others
80.55.73.62.32.21.64.1
1.0
1.9
2.0
2.8
3.2
3.4
3.9
4.0
5.0
5.9
6.6
10.5
15.2
0 5 10 15 20 25
Jouf
Tabuk
Northern
Asir
Hail
Baha
Jazan
Eastern
Makkah
Qassim
Madinah
Najran
Riyadh
Male (512)
0.8
0.8
1.1
1.7
1.8
1.9
1.9
1.9
2.0
2.3
4.1
4.5
5.6
0 5 10 15 20 25
Eastern
Baha
Asir
Jazan
Tabuk
Qassim
Jouf
Hail
Northern
Makkah
Najran
Madinah
Riyadh
Female (184)
55
Fig. 3-14 Stage Distribution of Liver Cancer in Saudi Arabia, 1999-2000
29.7%
13.9%
22.7%
33.6%LocalizedRegionalDistantUnknown
Table 3-10 Comparison of ASR for Liver Cancer among Saudis with 2000 ASR Estimation in Selected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon,2001** Actual rate (not estimation)
56
CountryMongolia 98.9 57.3Thailand 36.9 15.2Japan 29.2 8.1Sudan 8.3 3.0Spain 7.5 2.4Kuwait 6.8 2.3Saudi Arabia 6.5 2.6Turkey 3.6 1.0United Kingdom 2.2 1.1Sri Lanka 0.7 0.4
ASR* (Male) ASR* (Female)
** **
Thyroid (C73)
Between January 1999 and December 2000 there were 695 cases of thyroid cancer accountingfor 6.1% of all 11,330 newly diagnosed cases. The overall ASR was 3.3/100,000. ASR in maleswas 1.6/100,000 and 5.1/100,000 in females. This cancer ranked fourth in males and second infemales and affected 156 (22.4%) males and 539 (77.6%) females with a male to female ratio of346:100. The mean age at diagnosis was 44 years in males and 39 years in females. The fiveregions with the highest ASR were Riyadh region at 6.3/100,000, Hail region at 4.8/100,000,Qassim region at 4.3/100,000, the Eastern region at 3.6/100,000, and Najran region at 2.4/100,000.
Thyroid cancer is the twelveth most common cancer in the world. The estimated number of casesdiagnosed worldwide in 2000 was 122,803, with 60.5% in less developed countries. Incidencerates were highest in Melanesia, Polynesia, Northern Europe, Western Asia, and South-EasternAsia.
0
2
4
6
8
10
12
14
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
male female
AIR
(per
10 0
,000
)
Fig. 3-15 Average Age-Specific Incidence Rate (AIR) for Thyroid Cancer in Saudi Arabia, 1999-2000
57
AIR
(per
100
,000
)
Fig. 3-16 ASR Regional Distribution of Thyroid Cancer in Saudi Arabia, 1999-2000
ICD-0 Code Histology %805083408330851080218290
Papillary carcinoma, NOSPapillary and follicular carcinomaFollicular adenocarcinoma, NOSMedullary carcinoma, NOSCarcinoma, anaplastic, NOSOxyphilic adenocarcinomaAll Others
72.913.25.52.31.61.43.1
Table 3-11 Histology of Thyroid Cancer, 1999-2000
0.3
0.6
0.6
0.7
1.0
1.1
1.5
1.5
1.5
2.0
2.4
2.9
3.3
0 5 10 15 20 25
Northern
Jazan
Asir
Tabuk
Makkah
Baha
Qassim
Hail
Madinah
Eastern
Jouf
Riyadh
Najran
Male (156)
1.5
1.5
1.7
1.9
1.9
3.1
3.3
3.4
3.8
5.4
7.2
8.1
9.9
0 5 10 15 20 25
Najran
Jazan
Jouf
Tabuk
Baha
Madinah
Asir
Makkah
Northern
Eastern
Qassim
Hail
Riyadh
Female (539)
58
Fig. 3-17 Stage Distribution of Thyroid Cancer in Saudi Arabia, 1999-2000
Table 3-12 Comparison of ASR for Thyroid Cancer among Saudis with 2000 ASR Estimation in Selected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon, 2001** Actual rate (not estimation)
59
CountryVanuatu 4.1 23.2Iceland 3.9 10.8Philippines 2.5 8.2China, Hong Kong 2.1 7.3Germany 2.0 3.7Saudi Arab ia 1.6 5.1Japan 1.4 4.8Yemen 1.5 3.1India 1.0 1.9Mongolia 0.1 1.0
ASR* (Male) ASR* (Female)
** **
44.0%
33.5%
7.1%
15.3%0.1%
InsituLocalizedRegionalDistantUnknown
Brain, nervous system (C70-C72)
Between January 1999 and December 2000 there were 456 cases of brain and central nervoussystem cancer accounting for 4% of all newly diagnosed cases. The overall ASR was 1.9/100,000.The ASR was 2.3/100,000 in males and 1.6/100,000 in females. This cancer ranked eighth inmales and seventh in females and affected 270(59.2%) males and 186 (40.8%) females with amale to female ratio of 145:100. The mean age diagnosis was 32 years in males and 30 years infemales. The five regions with the highest ASR were Riyadh region at 3.7/100,000, the Northernregion at 2.3/100,000, Qassim and the Eastern region at 2.0/100,000 for each, and both Hail andNajran regions at 1.9/100,000.
Brain and CNS cancer is the seventeenth most common cancer in the world. The estimated numberof cases diagnosed worldwide in 2000 was 176,056, with 58.2% in less developed countries.Incidence rates were highest in Northern and Southern Europe, and Western Asia.
0
1
2
3
4
5
6
7
8
9
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
male female
AIR
(per
100
,000
)
Fig. 3-18 Average Age-Specific Incidence Rate (AIR) for Brain, CNS Cancer in Saudi Arabia, 1999-2000
60
AIR
(per
100
,000
)
Fig. 3-19 ASR Regional Distribution of Brain, CNS Cancer in Saudi Arabia, 1999-2000
0.8
0.9
1.0
1.2
1.5
1.7
2.1
2.3
2.9
2.9
3.5
4.2
4.6
0 5 10 15 20 25
Asir
Hail
Baha
Tabuk
Jazan
Makkah
Eastern
Madinah
Qassim
Najran
Jouf
Riyadh
Northern
Male (270)
Table 3-13 Histology of Brain, CNS Cancer, 1999-2000
ICD-0 Code Histology %944094009470942193809391
Glioblastoma, NOSAstrocytoma, NOSMedulloblastoma, NOSPilocytic AstrocytomaMalignant gliomaEpendymoma, NOSAll Others
20.415.512.99.49.05.5
27.3
61
0.0
0.0
0.7
0.8
0.9
0.9
0.9
1.0
1.1
1.2
2.0
2.9
3.2
0 5 10 15 20 25
Northern
Jouf
Jazan
Baha
Tabuk
Najran
Asir
Madinah
Makkah
Qassim
Eastern
Hail
Riyadh
Female (186)
Fig. 3-20 Stage Distribution of Brain, CNS Cancer in Saudi Arabia, 1999-2000
61.0%16.4%
2.4%
20.2%
LocalizedRegionalDistantUnknown
Table 3-14 Comparison of ASR for Brain, CNS Cancer among Saudis with 2000 ASR Estimation inSelected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon,2001** Actual rate (not estimation)
62
CountrySweden 11.1 11.3Greece 10.6 7.1Norway 8.0 6.6United States of America 6.5 4.4China, Hong Kong 4.4 3.4Bahrain 4.7 2.6Saudi Arabia 2.3 1.6Tunisia 2.1 1.2Indonesia 1.4 0.8Zambia 0.1 0.1
ASR* (Male) ASR* (Female)
** **
Lung (C33-C34)
Between January 1999 and December 2000 there were 454 cases of lung cancer accounting for4.0% of all 11,330 newly diagnosed cases. The overall ASR was 2.9/100,000. The ASR was 4.5/100,000 in males and 1.4/100,000 in females and affected 354 (78%) males and 100 (22%)females with a male to female ratio of 355:100. Lung cancer ranked fifth in males and seventeenthin females. The mean age at diagnosis was 64 years for males and females. The five regions withthe highest ASR were the Eastern region at 6.3/100,000, Riyadh region at 4.2/100,000, bothMakkah and the Northern region at 3.4/100,000, and Madinah region at 3.2/100,000.
Lung cancer is the most common cancer in the world. The estimated number of cases diagnosedworldwide in 2000 was 1,238,861, with 52.2% in more developed countries. Incidence rateswere highest in Eastern Europe, Eastern Asia, South Europe, North America, and Western Europe.
0
5
10
15
20
25
30
35
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
male female
AIR
(per
100
,000
)
Fig. 3-21 Average Age-Specific Incidence Rate (AIR) for Lung Cancer in Saudi Arabia, 1999-2000
63
AIR
(per
100
,000
)
0.9
1.1
1.7
2.1
2.5
4.0
4.7
4.7
4.9
5.1
5.7
5.8
10.1
0 5 10 15 20 25
Asir
Jazan
Baha
Qassim
Hail
Najran
Tabuk
Madinah
Northern
Makkah
Jouf
Riyadh
Eastern
Male (354)
Fig. 3-22 ASR Regional Distribution of Lung Cancer in Saudi Arabia, 1999-2000
0.0
0.0
0.0
0.0
0.4
0.5
0.6
1.1
1.7
1.9
2.0
2.3
2.6
0 5 10 15 20 25
Najran
Jazan
Jouf
Asir
Baha
Hail
Tabuk
Qassim
Madinah
Makkah
Northern
Eastern
Riyadh
Female (100)
Table 3-15 Histology of Lung Cancer, 1999-2000
ICD-0 Code Histology %81408070801080418012
Adenocarcinoma, NOSSquamous cell carcinoma, NOSCarcinoma, NOSSmall cell carcinoma, NOSLarge cell carcinoma, NOSAll Others
29.726.910.69.76.2
16.9
64
Fig. 3-23 Stage Distribution of Lung Cancer in Saudi Arabia, 1999-2000
11.7%
22.5%
39.2%
26.7%
LocalizedRegionalDistantUnknown
Table 3-16 Comparison of ASR for Lung Cancer among Saudis with 2000 ASR Estimation in Selected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency forresearch on Cancer (IARC), Lyon,2001** Actual rate (not estimation)
65
CountryHungary 95.5 22.6China, Hong Kong 74.7 32.1United States of America 58.6 34.0Japan 40.3 12.1Yemen 31.2 4.8Morocco 25.6 2.7India 9.0 2.0Saudi Arabia 4.5 1.4Sri Lanka 1.9 1.1Senegal 1.3 0.1
ASR* (Male) ASR* (Female)
** **
Hodgkin’s Disease (C81)
Between January 1999 and December 2000 there were 433 cases of Hodgkin’s disease accountingfor 3.8% of all 11,330 newly diagnosed cases. The overall ASR was 1.5/100,000. The ASR was1.9/100,000 in males and 1.2/100,000 in females. This cancer ranked ninth in both males andfemales and affected 260 (60%) males and 173 (40%) females with a male to female ratio of150:100. The mean age at diagnosis was 27 years in males and 26 years in females. The fiveregions with the highest ASR were Riyadh region at 2.3/100,000, both the Eastern and Madinahregions at 2.2/100,000, Qassim region at 1.9/100,000 and Hail region at 1.7/100,000.
Hodgkin’s disease is the twenty-fourth most common cancer in the world. The estimated numberof cases diagnosed worldwide in 2000 was 62,158, with 56.5% in less developed countries.Incidence rates were highest in Western Asia, Western Europe, and Northern Africa.
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
male female
AIR
(per
100
,000
)
Fig. 3-24 Average Age-Specific Incidence Rate (AIR) for Hodgkin’s Disease in Saudi Arabia, 1999-2000
66
AIR
(per
100
,000
)
Fig. 3-25 ASR Regional Distribution of Hodgkin’s Disease in Saudi Arabia, 1999-2000
0.0
0.7
0.7
0.9
1.1
1.2
1.3
1.7
1.9
2.3
2.5
2.6
2.6
0 5 10 15 20 25
Northern
Jouf
Asir
Jazan
Baha
Tabuk
Najran
Makkah
Qassim
Madinah
Riyadh
Eastern
Hail
Male (260)
0.2
0.3
0.4
0.4
0.4
0.8
0.8
1.2
1.5
1.8
1.8
2.0
2.2
0 5 10 15 20 25
Baha
Asir
Northern
Najran
Jazan
Makkah
Hail
Jouf
Tabul
Eastern
Qassim
Riyadh
Madinah
Female (173)
Table 3-17 Histology of Hodgkin’s Disease, 1999-2000
ICD-0 Code Histology %9663965296509657
Hodgkin’s disease, nodular sclerosis, NOSHodgkin’s disease, mixed cellularity, NOSHodgkin’s disease, NOSHodgkin’se disease, lymphocytic predominanceAll Others
53.116.413.96.99.7
67
Fig. 3-26 Stage Distribution of Hodgkin’s Disease in Saudi Arabia, 1999-2000
26.7%
26.9%
28.3%
18.2%
LocalizedRegionalDistantUnknown
Table 3-18 Comparison of ASR for Hodgkin’s Disease among Saudis with 2000 ASR Estimation inSelected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon, 2001** Actual rate (not estimation)
68
CountryOman 8.0 5.5Jordan 7.0 6.1Kuwait 6.8 6.0Austria 6.4 6.3Bahrain 6.0 3.6Qatar 6.0 3.6United Arab Emirates 6.0 3.6Canada 2.7 2.2Saudi Arabia 1.9 1.2Egypt 0.1 0.1
ASR* (Male) ASR* (Female)
** **
Urinary Bladder (C67)
Between January 1999 and December 2000 there were 381cases of urinary bladder cancersaccounting for 3.4% of all 11,330 newly diagnosed cases. The overall ASR was 2.4/100,000. TheASR was 3.7/100,000 in males and 1.1/100,000 in females. This cancer ranked seventh in maleand nineteenth in females and affected 301 (79%) males and 80 (21%) females with a male tofemale ratio of 376:100. The mean age at diagnosis was 62 in males and 61 in females. The fiveregions with the highest ASR were the Northern region at 5.3/100,000, the Eastern region at 4.2/100,000, Riyadh region at 4.0/100,000, Jazan region at 2.3/100,000 and both Madinah andMakkah regions at 2.2/100,000 for each.
Bladder cancer is the ninth most common cancer in the world. The estimated number of casesdiagnosed worldwide in 2000 was 335,795, with 58.6% in less developed countries. Incidencerates were highest in Northern Africa, Western Asia, Southern Europe and Eastern Africa.
0
5
10
15
20
25
30
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
Male female
AIR
(per
100
,000
)
Fig. 3-27 Average Age-Specific Incidence Rate (AIR) for Urinary Bladder Cancer in Saudi Arabia, 1999-2000
69
AIR
(per
100
,000
)
Fig. 3-28 ASR Regional Distribution of Urinary Bladder Cancer in Saudi Arabia, 1999-2000
0.7
1.3
1.7
1.7
2.0
2.0
2.4
3.0
3.2
3.5
3.6
6.1
6.1
0 5 10 15 20 25
Najran
Qassim
Hail
Asir
Tabuk
Northern
Jazan
Jouf
Baha
Madinah
Makkah
Eastern
Riyadh
Male (301)
0.0
0.0
0.0
0.6
0.6
0.7
0.9
1.0
1.2
1.7
1.9
2.1
8.8
0 5 10 15 20 25
Qassim
Jouf
Hail
Tabuk
Baha
Asir
Makkah
Madinah
Jazan
Najran
Riyadh
Eastern
Northern
Female (80)
Table 3-19 Histology of Urinary Bladder Cancer, 1999-2000
ICD-0 Code Histology %81308120807081408010
Papillary transitional cell carcinomaTransitional cell carcinoma, NOSSquamous cell carcinoma, NOSAdenocarcinoma, NOSCarcinoma, NOSAll Others
42.842.5
51.81.66.3
70
47%
20%
10%
23%0.3%
InsituLocalizedRegionalDistantUnknown
Fig. 3-29 Stage Distribution of Urinary Bladder Cancer in Saudi Arabia, 1999-2000
Table 3-20 Comparison of ASR for Urinary Bladder Cancer among Saudis with 2000 ASR Estimationin Selected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon,2001** Actual rate (not estimation)
71
CountryEgypt 45.4 8.6Italy 28.0 5.0United States of America 23.4 5.4United Kingdom 19.0 6.0Algeria 13.8 2.0Japan 9.2 2.0Pakistan 8.8 3.4Saudi Arabia 3.7 1.1India 3.2 0.7Bangladesh 1.3 0.1
ASR* (Male) ASR* (Female)
** **
Skin (Non-Melanoma) (C44)
Between January 1999 and December 2000 there were 380 cases of skin cancers. Accountingfor 3.4% of all 11,330 newly diagnosed cases. The overall ASR was 2.2/100,000. The ASR was2.5/100,000 in males and 2.0/100,000 in females. This cancer ranked tenth in males and eleventhin females and affected 226 (59.5%) males and 154 (40.5%) females with a male to female ratioof 147:100. The mean age at diagnosis was 62 years in males and 58 years in females. The fiveregions with the highest ASR were Riyadh region at 4.6/100,000, Najran region at 3.8/100,000,the Eastern region at 2.5/100,000, Madinah region at 2.0/100,000 and both Qassim and Jazanregions at 1.9/100,000 for each.
0
5
10
15
20
25
30
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
male female
AIR
(per
100
,000
)
Fig. 3-30 Average Age-Specific Incidence Rates (AIR) for Skin Cancer in Saudi Arabia, 1999-2000
72
AIR
(per
100
,000
)
Fig. 3-31 ASR Regional Distribution of Skin Cancer in Saudi Arabia, 1999-2000
0.0
1.2
1.3
1.4
1.5
1.5
1.6
1.6
1.9
1.9
3.3
3.5
5.8
0 5 10 15 20 25
Jouf
Asir
Baha
Hail
Qassim
Madinah
Tabuk
Jazan
Northern
Makkah
Eastern
Najran
Riyadh
Male (226)
0.0
0.0
0.9
1.3
1.5
1.7
1.8
1.9
2.3
2.5
2.6
3.4
4.2
0 5 10 15 20 25
Northern
Jouf
Tabuk
Asir
Makkah
Eastern
Baha
Hail
Jazan
Qassim
Madinah
Riyadh
Najran
Female (154)
Table 3-21 Histology of Skin Cancer (Non-Melanoma), 1999-2000
ICD-0 Code Histology %80908070883280718094
Basal cell carcinomaSquamous cell carcinomaDermatofibrosarcoma, NOSSquamos cell carcinoma, keratinizing, NOSBasosquamous carcinomaAll Others
51.127.66.34.52.48.1
Fig. 3-32 Stage Distribution of Skin Cancer in Saudi Arabia, 1999-200
67.8%
7.7%
4.5%
20.0%
LocalizedRegionalDistantUnknown
73
Prostate (C61)
Between January 1999 and December 2000 there were 304 cases of prostate cancer accountingfor 5.3% of all 5,713 newly diagnosed cases among males. The ASR was 3.5/100,000 amongmales. This cancer ranked sixth in males. The mean age at diagnosis was 71 years. The five regionswith the highest ASR were Riyadh region at 8.0/100,000, the Eastern region at 5.9/100,000,Makkah region at 3.6/100,000, Jouf region at 3.5/100,000 and Najran region at 3.2/100,000.
Prostate cancer is the sixth most common cancer in the world among males. The estimated numberof cases diagnosed worldwide in 2000 was 542,990, with 76.5% in more developed countries.Incidence rates were highest in Northern America, Australia/New Zealand, Caribbean, and NorthernEurope.
0
5
10
15
20
25
30
35
40
45
50
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
M ale
AIR
(per
10 0
,000
)
Fig. 3-33 Average Age-Specific Incidence Rate (AIR) for Prostate Cancer in Saudi Arabia, 1999-2000
74
AIR
(per
100
,000
)
Fig. 3-34 ASR Regional Distribution of Prostate Cancer in Saudi Arabia, 1999-2000
0.6
0.9
1.0
1.2
1.6
1.7
1.7
2.2
3.2
3.5
3.6
5.9
8.0
0 5 10 15 20 25
Baha
Northern
Asir
Jazan
Qassim
Hail
Madinah
Tabuk
Najran
Jouf
Makkah
Eastern
Riyadh
Male (304)
Table 3-22 Histology of Prostate Cancer, 1999-2000
ICD-0 Code Histology %91408010
Adenocarcinoma, NOSCarcinoma, NOSAll Others
83.611.84.6
75
32.2%
11.6%27.3%
28.9%
LocalizedRegionalDistantUnknown
Fig. 3-35 Stage Distribution of Prostate Cancer in Saudi Arabia, 1999-2000
Table 3-23 Comparison of ASR for Prostate Cancer among Saudis with 2000 ASR Estimationin Selected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon, 2001** Actual rate (not estimation)
76
CountryUnited States of America 104.3Canada 102.2France 56.5Philippines 18.8Jordan 11.2Egypt 5.6Thailand 4.4Saudi Arab ia 3.5Iran, Islamic Republic 3.1China 1.7
ASR* (Male)
**
Ovary (C56)
Between January 1999 and December 2000 there were 205 cases of ovary cancer among femalesaccouning for 3.6% of all 5,617 newly diagnosed cases among females. The ASR was 2.3/100,000female populations. This cancer ranked sixth in females. The mean age at diagnosis was 46 years.The five regions with the highest ASR were Riyadh region at 3.4/100,000, Jouf region at 3.0/100,000 and Madinah, Makkah and Tabuk regions at 2.6/100,000 each.
Ovarian cancer is the sixth most common cancer in the world among women. The estimatednumber of cases diagnosed worldwide in 2000 was 192,379, with 53.3% in less developedcountries. Incidence rates were highest in Northern Europe, South America, Eastern Europe, andEastern Africa.
0
2
4
6
8
10
12
14
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
female
AIR
(per
100
,000
)
Fig. 3-36 Average Age-Specific Incidence Rate (AIR) for Ovary Cancer in Saudi Arabia, 1999-2000
77
AIR
(per
100
,000
)
0.0
0.2
1.1
1.3
1.5
2.2
2.4
2.5
2.6
2.6
2.6
3.0
3.4
0 5 10 15 20 25
Northern
Baha
Asir
Jazan
Hail
Najran
Eastern
Qassim
Tabuk
Makkah
Madinah
Jouf
Riyadh
Female (205)
Fig. 3-37 ASR Regional Distribution of Ovary Cancer in Saudi Arabia, 1999-2000
Table 3-24 Histology of Ovary Cancer, 1999-2000
ICD-0 Code Histology %846081409060838084619080846284418471
Papillary serous cystadenocarcinomaAdenocarcinoma, NOSDysgerminomaEndometrioid carcinomaSerous surface papillary carcinomaTeratoma, malignant, NOSPapillary serous cystadenoma, borderline malignancySerous cystadenocarcinoma, NOSMucinous cystadenocarcinoma, NOSAll Others
14.110.78.87.36.85.94.94.44.4
32.7
78
27.8%
15.6%41.5%
15.1%
LocalizedRegionalDistantUnknown
Fig. 3-38 Stage Distribution of Ovary Cancer in Saudi Arabia, 1999-2000
Table 3-25 Comparison of ASR for Ovary Cancer among Saudis with 2000 ASR Estimation inSelected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon, 2001** Actual rate (not estimation)
79
CountryDenmark 16.1Iceland 15.8Ethiopia 14.7United Kingdom 12.2China, Hong Kong 7.5Yemen 5.9India 4.9Tunisia 3.0Saudi Arabia 2.3Egypt 1.2
ASR* (Female)
**
Cervix Uteri (C53)
Between January 1999 and December 2000, there were 167 cases of cervix uteri cancer amongfemales accounting for 3.0 % of all 5,617 newly diagnosed cases for females. The ASR was 2.0/100,000 among female population. This cancer ranked tenth in females. The mean age at diagnosiswas 51 years. The five regions with the highest ASR were Jouf region at 3.8/100,000, Riyadhregion at 2.8/100,000, both Makkah and the Eastern regions at 2.7/100,000, and Qassim regionat 2.4/100,000.
Cervix uteri cancer is the second most common cancer in the world among women. The estimatednumber of cases diagnosed worldwide in 2000 was 470,606, with 80.6% in less developedcountries. Incidence rates were highest in the Caribbean, Eastern Africa, Central and South America.
0
1
2
3
4
5
6
7
8
9
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
female
AIR
(per
100
,000
)
Fig. 3-39 Average Age-Specific Incidence Rate (AIR) for Cervix Uteri Cancer in Saudi Arabia,1999-2000
80
AIR
(per
100
,000
)
0.0
0.4
0.5
0.6
0.8
1.1
1.2
2.3
2.4
2.7
2.7
2.8
3.8
0 5 10 15 20 25
Northern
Madinah
Najran
Baha
Jazan
Hail
Asir
Tabuk
Qassim
Eastern
Makkah
Riyadh
Jouf
Female (167)
Fig. 3-40 ASR Regional Distribution of Cervix Uteri Cancer in Saudi Arabia, 1999-2000
Table 3-26 Histology of Cervix Uteri, 1999-2000
ICD-0 Code Histology %8070807281408071
Squamous cell carcinoma, NOSSquamous cell carcinoma, non-keratinizing, NOSAdenocarcinoma, NOSSquamous cell, keratinizing, NOSAll Others
57.513.29.67.8
11.9
81
28.1%
41.9%
8.4%
21.0%0.6%
InsituLocalizedRegionalDistantUnknown
Fig. 3-41 Stage Distribution of Cervix Uteri Cancer in Saudi Arabia, 1999-2000
Table 3-27 Comparison of ASR for Cervix Uteri Cancer among Saudis with 2000 ASR Estimation inSelected Countries
* Source: GLOBOCAN 2000: Cancer Incidence Mortality and Prevalence Worldwide. International Agency for research onCancer (IARC), Lyon,2001** Actual rate (not estimation)
82
CountryHaiti 93.9Tanzania 61.4Zimbabwe 52.1Peru 40.0Egypt 14.0Japan 11.1China 5.2Yemen 4.8Turkey 3.9Syrian Arab Republic 3.0Saudi Arabia 2.0
ASR* (Female)
**
PART IVCANCER INCIDENCE AMONG NON-SAUDIS IN
SAUDI ARABIA, 1999-2000
83
Cancer among the non- Saudi Population 1999-2000
Between January 1999 and December 2000, 3,242 non-Saudi cases were reported to the NCR.Males accounted for 1,769 (54.6%) cases while females accounted for 1,473 (45.4%) . The maleto female ratio is 120:100.
The 15 in-situ cases reported during this period were excluded from the analysis as the currentsoftware program, CanReg 3.21, does not include in-situ cases in the statistical analysis. Therefore,the total number of cases analyzed was 3,227 (1,765 (54.7%) males and 1,462 (45.3%) females).The male to female ratio is 121:100.
Taking into consideration the population structure of non-Saudis and the fact that cancer is primarilya disease of the elderly, the pattern of cancer had some significant differences. Those over 60years represented only 1.7% and the 25 to 54 age-group represented 61% of non-Saudi population.During the 1999 and 2000, just over 6.0% of all cancers occurred before the age of 15, and 60%occurred between age 25 to 54 years. The mean age at diagnosis was 46 years in males and 45years in females. The crude incidence rate (CIR) of all cancers in the non-Saudi population was31.4/100,000 (25.8/100,000 in males and 42.7/100,000 in females). The ten most common cancersseen among the non-Saudi population are as follows:
The distribution of cancer cases among the different nationalities in order of relative frequency is asfollows 612 Yemenis (19%), 435 Sudanese (13.5%), 325 Egyptians (10.1%), 215 Pakistanis(6.7%), 210 Philippines (6.5%), 135 Syrians (4.2%), 133 Indians (4.1%), 118 Jordanians (3.7%),106 Bangladeshis (3.3%), 85 Palestinians (2.6%), 75 Americans (2.3%),71 Indonesians (2.2%),70 Eritreans (2.2%), 49 Bahrainis (1.5%), 48 Ethiopians (1.5%), 43 Lebanese (1.3%), 42 Somalis(1.3%), 41 Nigerians (1.3%), 41 British (1.3%), and 373 cases (11.6%) among other nationalities.
Figure 4-1 represents the most common sites of cancer among all non-Saudi patients designatedby sex. The data were ranked using ICD-9 to include the frequency for the two years.
84
CANCER NO. OF CASES PERCENTAGE (%)
Female breastColo-rectalLeukaemiaNon-Hodgkin lymphomaSkin (non-melanoma)BladderLiverLungBrain, CNSStomach
505255229208149134111110110107
15.67.97.16.44.64.23.43.43.43.3
Male
Colo-rectal 186(10.5%)Leukaemia 159 (9%)NHL 159 (9%)Bladder 110 (6.2%)Skin 102 (5.8%)Liver 89 (5%)Lung 85 (4.8%)Brain & CNS 81 (4.6%)Stomach 80 (4.5%)Prostate 65 (3.7%)
Total = 1765
Female
Breast 505 (34.5%)Cervix uteri 106 (7.3%)Leukaemia 70 (4.8%)Colo-rectal 69 (4.7%)Thyroid 65 (4.4%)Ovary 57 (3.9%)NHL 49 (3.4%)Skin 47 (3.2%)Corpus uteri 40 (2.7%)Hodgkin’s 31 (2.1%)
Total = 1462
Fig. 4-1 Ten Most Common Cancers among non-Saudis by Sex, 1999-2000
0
100
200
300
400
500
600
700
800
0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+
Age groups
male female
AIR
(pe r
100
,000
)
Fig. 4-2 Average Age-Specific Incidence Rate (AIR) for All Cancers among non-Saudis in SaudiArabia, 1999-2000
85
AIR
(per
100
,000
)
PART VTABLES
86
Tabl
e 5-
1-1
Age
Dis
trib
utio
n of
Can
cer
Cas
es a
mon
g Sa
udi M
ales
, 199
9
87
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
-5
-1
0-
15
-2
0-
25
-3
0-
35
-4
0-
45
-5
0-
55
-6
0-
65
-7
0-
75
+%
C
00
Lip
1-
--
--
--
--
--
--
--
-1
0.0
C0
1-C
02
To
ng
ue
25
--
--
--
1-
2-
1-
33
44
70
.9C
07
-C0
8S
aliv
ary
gla
nd
12
--
1-
--
11
21
-2
--
31
-0
.4C
03
-C0
6M
ou
th2
9-
--
--
11
1-
-3
23
14
67
1.0
C0
9-C
10
Oro
ph
ary
nx
6-
--
--
--
-1
1-
1-
2-
-1
0.2
C1
1N
as
op
ha
ryn
x1
03
--
11
54
24
81
51
47
13
10
69
43
.6C
12
-C1
3H
ypo
ph
ary
nx
6-
1-
--
-1
--
--
--
12
-1
0.2
C1
4P
ha
ryn
x u
ns
pe
c.
0-
--
--
--
--
--
--
--
--
0.0
C1
5O
es
op
ha
gu
s5
7-
--
--
--
--
-1
34
41
21
02
32
.0C
16
Sto
ma
ch
98
--
--
--
13
53
45
81
11
61
62
63
.4C
17
Sm
all
inte
sti
ne
13
--
--
--
-1
--
14
-2
12
20
.4C
18
Co
lon
10
2-
--
--
11
37
86
71
21
71
48
18
3.5
C1
9-C
21
Re
ctu
m9
6-
--
-1
12
3-
55
61
72
21
08
16
3.3
C2
2L
ive
r2
69
-4
12
11
23
34
14
16
36
44
44
36
58
9.3
C2
3-C
24
Ga
llbla
dd
er
etc
.2
5-
--
--
-1
1-
1-
3-
55
36
0.9
C2
5P
an
cre
as
50
--
--
--
-1
12
35
36
10
51
41
.7C
30
-C3
1N
os
e,
sin
us
es
etc
.1
3-
1-
--
21
-2
-2
-1
11
-2
0.4
C3
2L
ary
nx
44
--
--
--
--
3-
28
75
72
10
1.5
C3
3-C
34
Bro
nc
hu
s,
lun
g1
86
--
--
--
14
58
41
91
32
73
72
84
06
.4C
37
-C3
8O
the
r T
ho
rac
ic o
rga
ns
18
-5
1-
2-
11
-1
1-
-1
11
30
.6C
40
-C4
1B
on
e5
8-
28
14
14
4-
23
21
-1
2-
41
2.0
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
72
-1
03
64
67
3-
24
52
26
39
2.5
C4
5M
es
oth
elio
ma
2-
--
--
--
--
--
1-
1-
--
0.1
C4
6K
ap
os
i's s
arc
om
a1
1-
--
1-
--
12
21
1-
-1
11
0.4
C4
3M
ela
no
ma
of
sk
in9
--
--
--
--
-2
3-
-1
11
10
.3C
44
Oth
er
sk
in1
16
--
3-
--
25
79
97
71
11
31
03
34
.0C
50
Bre
as
t9
--
--
--
-1
-2
1-
1-
11
20
.3C
61
Pro
sta
te1
38
--
--
--
--
-1
25
81
82
93
14
44
.8C
62
Te
sti
s3
3-
4-
--
25
22
84
33
--
--
1.1
C6
0P
en
is1
--
--
--
--
--
-1
--
--
-0
.0C
63
Oth
er
ma
le g
en
ita
l2
--
--
-1
--
--
--
--
-1
-0
.1C
67
Bla
dd
er
15
1-
--
-1
--
39
81
11
11
51
51
62
24
05
.2C
64
-C6
6;C
68
Kid
ne
y e
tc.
83
-1
52
-1
2-
44
74
64
11
97
72
.9C
69
Eye
23
-1
2-
--
1-
--
-1
-1
41
12
0.8
C7
0-C
72
Bra
in,
ne
rvo
us
sys
tem
12
8-
17
24
77
44
85
46
41
16
99
34
.4C
73
Th
yro
id8
5-
-1
25
95
10
12
54
55
65
56
2.9
C7
4-C
75
Oth
er
en
do
cri
ne
10
-3
21
1-
11
--
--
--
1-
-0
.3C
81
Ho
dg
kin
's d
ise
as
e1
23
-6
14
21
21
12
14
55
66
32
12
32
4.2
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a2
69
-1
34
91
19
10
91
28
15
22
25
35
31
21
35
9.3
C8
8;C
90
Mu
ltip
le m
yelo
ma
34
--
--
--
--
22
22
66
23
91
.2C
91
Lym
ph
oid
le
uk
ae
mia
13
7-
31
35
13
11
73
22
22
33
83
57
4.7
C9
2M
yelo
id l
eu
ka
em
ia1
07
-7
98
71
05
13
51
32
83
23
48
3.7
C9
3M
on
oc
ytic
le
uk
ae
mia
2-
-1
--
--
--
--
--
1-
--
0.1
C9
4O
the
r le
uk
ae
mia
1-
--
-1
--
--
--
--
--
--
0.0
C9
5L
eu
ka
em
ia u
ns
pe
c.
5-
1-
--
2-
-1
--
--
1-
--
0.2
Oth
er
& u
ns
pe
cif
ied
13
4-
3-
-1
-2
25
88
12
18
13
19
18
25
4.6
All
sit
es
2,8
96
01
35
11
08
59
47
97
49
71
15
14
01
47
18
72
35
30
63
29
28
94
74
10
0
Tabl
e 5-
1-2
Age
Dis
trib
utio
n of
Can
cer
Cas
es a
mon
g Sa
udi F
emal
es, 1
999
88
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
-5
-1
0-
15
-2
0-
25
-3
0-
35
-4
0-
45
-5
0-
55
-6
0-
65
-7
0-
75
+%
C
00
Lip
7-
--
--
--
-1
--
1-
1-
22
0.3
C0
1-C
02
To
ng
ue
29
-1
--
--
--
--
13
75
36
31
.0
C
07
-C0
8S
aliv
ary
gla
nd
8-
-1
--
1-
-2
-2
1-
--
1-
0.3
C0
3-C
06
Mo
uth
41
--
--
--
1-
22
45
46
44
91
.5
C
09
-C1
0O
rop
ha
ryn
x1
--
--
--
-1
--
--
--
--
-0
.0
C
11
Na
so
ph
ary
nx
36
--
-1
11
-4
66
13
65
11
-1
.3
C
12
-C1
3H
yp
op
ha
ryn
x1
7-
--
--
-1
-1
22
22
-1
-6
0.6
C1
4P
ha
ryn
x u
ns
pe
c.
0-
--
--
--
--
--
--
--
--
-
C1
5O
es
op
ha
gu
s5
5-
--
--
--
-5
21
33
14
88
11
2.0
C1
6S
tom
ac
h6
8-
--
--
11
24
54
44
85
12
18
2.4
C1
7S
ma
ll in
tes
tin
e7
--
--
--
--
--
-1
2-
-1
30
.3
C
18
Co
lon
99
--
-1
-4
24
65
38
14
15
10
10
17
3.5
C1
9-C
21
Re
ctu
m8
6-
--
21
32
45
78
41
08
13
51
43
.1
C
22
Liv
er
82
-3
--
1-
12
12
24
12
15
91
61
42
.9
C
23
-C2
4G
allb
lad
de
r e
tc.
59
--
--
--
1-
24
76
78
94
11
2.1
C2
5P
an
cre
as
33
--
--
--
-1
-2
53
56
15
51
.2
C
30
-C3
1N
os
e,
sin
us
es
etc
.7
--
--
1-
-1
--
--
1-
21
10
.3
C
32
La
ryn
x1
0-
--
--
--
--
-1
31
-3
-2
0.4
C3
3-C
34
Bro
nc
hu
s,
lun
g5
2-
--
--
--
-2
33
68
10
33
14
1.9
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s6
-2
--
--
--
--
-1
-1
1-
10
.2
C
40
-C4
1B
on
e3
9-
-3
10
12
63
1-
-1
11
1-
--
1.4
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
49
-9
23
21
35
22
22
-5
35
31
.8
C
45
Me
so
the
liom
a4
--
--
--
--
--
--
11
11
-0
.1
C
46
Ka
po
si's
sa
rco
ma
8-
--
--
--
1-
13
--
1-
-2
0.3
C4
3M
ela
no
ma
of
sk
in8
--
--
-1
--
-1
-1
-1
1-
30
.3
C
44
Oth
er
sk
in7
51
-1
23
-1
52
17
67
13
41
01
22
.7
C
50
Bre
as
t5
43
--
--
-3
26
51
79
78
73
52
50
45
34
27
25
19
.4
C5
5U
teru
s u
ns
pe
c.
11
--
--
--
--
1-
-5
31
--
10
.4
C
53
Ce
rvix
ute
ri7
6-
--
--
12
68
13
10
68
12
62
22
.7
C
58
Pla
ce
nta
11
--
--
32
1-
12
-1
1-
--
-0
.4
C
54
Co
rpu
s u
teri
57
--
--
-1
11
54
45
81
43
74
2.0
C5
6O
va
ry e
tc.
10
3-
-1
73
81
07
51
05
61
47
12
44
3.7
C5
1-C
52
;C5
7O
the
r fe
ma
le g
en
ita
l1
0-
--
--
--
--
-2
11
21
21
0.4
C6
7B
lad
de
r4
3-
--
--
-1
14
-3
45
37
87
1.5
C6
4-C
66
;C6
8K
idn
ey
etc
.6
7-
12
12
21
11
49
64
48
44
42
.4
C
69
Ey
e2
5-
15
2-
1-
--
-1
-1
-2
12
-0
.9
C
70
-C7
2B
rain
, n
erv
ou
s s
ys
tem
83
-1
31
11
25
15
44
-4
51
43
74
3.0
C7
3T
hy
roid
29
1-
-3
31
72
53
74
84
03
62
12
01
11
66
71
10
.4
C7
4-C
75
Oth
er
en
do
cri
ne
12
-7
3-
--
-1
-1
--
--
--
-0
.4
C
81
Ho
dg
kin
's d
ise
as
e8
4-
28
11
22
56
42
64
42
34
-1
3.0
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
ly
mp
ho
ma
17
3-
57
65
11
11
69
51
11
61
51
81
41
42
06
.2
C
88
;C9
0M
ult
iple
my
elo
ma
25
--
--
--
-1
2-
13
67
-3
20
.9
C
91
Ly
mp
ho
id l
eu
ka
em
ia9
2-
38
23
10
6-
11
12
-1
23
22
-3
.3
C
92
My
elo
id l
eu
ka
em
ia8
7-
79
55
45
51
28
87
33
22
23
.1
C
93
Mo
no
cy
tic
le
uk
ae
mia
2-
--
--
-1
--
--
--
1-
--
0.1
C9
4O
the
r le
uk
ae
mia
2-
--
1-
--
--
--
--
--
1-
0.1
C9
5L
eu
ka
em
ia u
ns
pe
c.
4-
1-
1-
--
--
--
1-
-1
--
0.1
Oth
er
& u
ns
pe
cif
ied
11
1-
72
11
15
24
99
59
15
12
11
18
4.0
All
sit
es
2,7
98
11
22
77
78
91
81
12
91
70
22
22
29
21
82
15
23
82
88
19
41
98
24
71
00
Tabl
e 5-
1-3
Inci
denc
e R
ates
for
Can
cer
Cas
es a
mon
g Sa
udi M
ales
by
Age
Gro
up (p
er 1
00,0
00),
1999
89
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
-5
-1
0 -
15
-2
0 -
25
-3
0 -
35
-4
0 -
45
-5
0 -
55
-6
0-
65
-7
0-
75
+C
IRA
SR
C0
0L
ip1
--
--
--
--
--
--
--
--
0.8
--
C0
1-C
02
To
ng
ue
25
--
--
--
0.2
-0
.5-
0.5
-2
.33
3.1
4.6
5.5
0.3
0.6
C0
7-C
08
Sa
liva
ry g
lan
d1
2-
-0
.1-
--
0.2
0.2
0.5
0.3
-1
.2-
-2
.41
.1-
0.2
0.2
C0
3-C
06
Mo
uth
29
--
--
-0
.20
.20
.2-
-1
.41
.22
.31
3.1
6.9
5.5
0.4
0.7
C0
9-C
10
Oro
ph
ary
nx
6-
--
--
--
-0
.30
.3-
0.6
-2
--
0.8
0.1
0.2
C1
1N
aso
ph
ary
nx
10
3-
-0
.10
.10
.60
.70
.40
.92
.25
.26
.54
.21
0.2
9.9
4.7
10
.33
.21
.42
.5C
12
-C1
3H
ypo
ph
ary
nx
6-
0.1
--
--
0.2
--
--
--
11
.6-
0.8
0.1
0.1
C1
4P
ha
ryn
x u
ns
pe
c.0
--
--
--
--
--
--
--
--
--
-C
15
Oe
so
ph
ag
us
57
--
--
--
--
--
0.5
1.8
3.1
49
.41
1.4
18
.10
.81
.3C
16
Sto
ma
ch
98
--
--
--
0.2
0.7
1.4
11
.93
6.3
10
.91
2.6
18
.32
0.5
1.3
2.3
C1
7S
ma
ll in
test
ine
13
--
--
--
-0
.2-
-0
.52
.4-
20
.82
.31
.60
.20
.3C
18
Co
lon
10
2-
--
--
0.2
0.2
0.7
1.9
2.8
2.8
4.2
9.4
16
.81
19
.11
4.2
1.4
2.6
C1
9-C
21
Re
ctu
m9
6-
--
-0
.10
.20
.40
.7-
1.7
2.3
3.6
13
.32
1.8
7.8
9.1
12
.61
.32
.6C
22
Liv
er
26
9-
0.3
0.1
0.2
0.1
0.2
0.4
0.7
0.8
1.4
6.5
9.7
28
.14
3.6
34
.54
1.1
45
.83
.66
.8C
23
-C2
4G
allb
lad
de
r e
tc.
25
--
--
--
0.2
0.2
-0
.3-
1.8
-5
3.9
3.4
4.7
0.3
0.6
C2
5P
an
cre
as
50
--
--
--
-0
.20
.30
.71
.43
2.3
5.9
7.8
5.7
11
0.7
1.2
C3
0-C
31
No
se,
sin
use
s e
tc.
13
-0
.1-
--
0.3
0.2
-0
.5-
0.9
-0
.81
0.8
-1
.60
.20
.3C
32
La
ryn
x4
4-
--
--
--
-0
.8-
0.9
4.8
5.5
55
.52
.37
.90
.61
.1C
33
-C3
4B
ron
chu
s, lu
ng
18
6-
--
--
-0
.20
.91
.42
.81
.91
1.5
10
.22
6.8
29
32
31
.62
.54
.6C
37
-C3
8O
the
r T
ho
raci
c o
rga
ns
18
-0
.40
.1-
0.2
-0
.20
.2-
0.3
0.5
--
10
.81
.12
.40
.20
.3C
40
-C4
1B
on
e5
8-
0.1
0.7
1.4
1.7
0.7
-0
.50
.80
.70
.5-
0.8
2-
4.6
0.8
0.8
0.8
C4
7;C
49
Co
nn
ec
tive
tis
sue
72
-0
.70
.30
.60
.51
1.3
0.7
-0
.71
.93
1.6
24
.73
.47
.11
1.2
C4
5M
eso
the
liom
a2
--
--
--
--
--
-0
.6-
1-
--
-0
.1C
46
Ka
po
si's
sa
rco
ma
11
--
-0
.1-
--
0.2
0.5
0.7
0.5
0.6
--
0.8
1.1
0.8
0.1
0.2
C4
3M
ela
no
ma
of
skin
9-
--
--
--
--
0.7
1.4
--
10
.81
.10
.80
.10
.2C
44
Oth
er
skin
11
6-
-0
.3-
--
0.4
1.2
1.9
3.1
4.2
4.2
5.5
10
.91
0.2
11
.42
61
.62
.6C
50
Bre
ast
9-
--
--
--
0.2
-0
.70
.5-
0.8
-0
.81
.11
.60
.10
.2C
61
Pro
sta
te1
38
--
--
--
--
-0
.30
.93
6.3
17
.82
2.8
35
.43
4.7
1.9
3.3
C6
2T
est
is3
3-
0.3
--
-0
.31
0.5
0.5
2.8
1.9
1.8
2.3
--
--
0.4
0.7
C6
0P
en
is1
--
--
--
--
--
-0
.6-
--
--
--
C6
3O
the
r m
ale
ge
nita
l2
--
--
-0
.2-
--
--
--
--
1.1
--
-C
67
Bla
dd
er
15
1-
--
-0
.1-
-0
.72
.52
.85
.16
.71
1.7
14
.91
2.6
25
.13
1.6
23
.6C
64
-C6
6;C
68
Kid
ne
y e
tc.
83
-1
.10
.2-
0.1
0.3
-0
.91
.12
.41
.93
.63
.11
0.9
7.1
85
.51
.11
.8C
69
Eye
23
-0
.9-
--
0.2
--
--
0.5
-0
.84
0.8
1.1
1.6
0.3
0.4
C7
0-C
72
Bra
in,
ne
rvo
us
syst
em
12
8-
1.3
2.1
0.7
0.9
0.7
0.8
1.9
1.4
1.4
2.8
2.4
8.6
5.9
7.1
10
.32
.41
.72
.2C
73
Th
yro
id8
5-
-0
.10
.20
.61
.51
2.3
3.3
1.7
1.9
33
.95
.93
.95
.74
.71
.11
.7C
74
-C7
5O
the
r e
nd
oc
rin
e1
0-
0.2
0.2
0.1
0.1
-0
.20
.2-
--
--
-0
.8-
-0
.10
.1C
81
Ho
dg
kin
's d
ise
as
e1
23
-0
.41
.22
.12
.62
2.7
1.2
1.4
2.1
2.8
1.8
1.6
11
.63
.41
.61
.71
.8C
82
-C8
5;C
96
No
n0
Ho
dg
kin
lym
ph
om
a2
69
-1
0.3
0.9
1.4
1.5
1.9
2.1
3.3
2.8
71
3.3
19
.53
4.7
24
.32
42
7.6
3.6
6.1
C8
8;C
90
Mu
ltip
le m
yelo
ma
34
--
--
--
--
0.5
0.7
0.9
1.2
4.7
5.9
1.6
3.4
7.1
0.5
0.9
C9
1L
ymp
ho
id l
eu
ka
em
ia1
37
-2
.33
1.3
1.4
1.2
0.6
0.5
0.5
0.7
0.9
1.8
2.3
7.9
2.4
5.7
5.5
1.8
1.9
C9
2M
yelo
id l
eu
ka
em
ia1
07
-0
.50
.80
.80
.91
.71
31
.44
.50
.94
.82
.32
2.4
4.6
6.3
1.4
1.8
C9
3M
on
oc
ytic
leu
ka
em
ia2
--
0.1
--
--
--
--
--
1-
--
--
C9
4O
the
r le
uk
ae
mia
1-
--
-0
.1-
--
--
--
--
--
--
-C
95
Le
uk
ae
mia
un
spe
c.5
-0
.1-
--
0.3
--
0.3
--
--
1-
--
0.1
0.1
Oth
er
& u
nsp
eci
fied
13
4-
0.2
--
0.1
-0
.40
.51
.42
.83
.77
.31
4.1
12
.91
4.9
20
.61
9.7
1.8
3.3
All
site
s2
,89
60
.01
0.0
9.7
8.5
11
.51
3.4
14
.52
2.4
31
.44
8.4
68
.71
12
.71
83
.73
03
.42
58
.43
29
.83
74
.03
8.8
63
.3
Tabl
e 5-
1-4
Inci
denc
e R
ates
for
Can
cer
Cas
es a
mon
g Sa
udi F
emal
es b
y A
ge G
roup
(per
100
,000
), 19
99
90
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
5-
10
-1
5-
20
-2
5-
30
-3
5-
40
-4
5-
50
-5
5-
60
-6
5-
70
-7
5+
CIR
AS
RC
00
Lip
7-
--
--
--
-0
.3-
-0
.6-
0.9
-3
.62
.40
.10
.2C
01
-C0
2T
on
gu
e2
9-
0.1
--
--
--
--
0.5
1.7
4.9
4.4
3.3
10
.93
.60
.40
.9C
07
-C0
8S
aliv
ary
gla
nd
8-
-0
.1-
-0
.1-
-0
.5-
0.9
0.6
--
-1
.8-
0.1
0.2
C0
3-C
06
Mo
uth
41
--
--
--
0.2
-0
.50
.71
.82
.92
.85
.34
.47
.31
0.9
0.6
1.2
C0
9-C
10
Oro
ph
ary
nx
1-
--
--
--
0.2
--
--
--
--
--
-C
11
Na
so
ph
ary
nx
36
--
-0
.10
.10
.1-
0.9
1.6
2.1
0.5
1.7
4.2
4.4
1.1
1.8
-0
.50
.8C
12
-C1
3H
ypo
ph
ary
nx
17
--
--
--
0.2
-0
.30
.70
.91
.21
.4-
1.1
-7
.30
.20
.4C
14
Ph
ary
nx
un
sp
ec
.0
--
--
--
--
--
--
--
--
--
-C
15
Oe
so
ph
ag
us
55
--
--
--
--
1.4
0.7
0.5
1.7
2.1
12
.48
.71
4.6
13
.30
.71
.6C
16
Sto
ma
ch
68
--
--
-0
.10
.20
.51
.11
.71
.82
.32
.87
.15
.52
1.8
21
.80
.91
.9C
17
Sm
all
inte
sti
ne
7-
--
--
--
--
--
0.6
1.4
--
1.8
3.6
0.1
0.2
C1
8C
olo
n9
9-
--
0.1
-0
.60
.40
.91
.61
.71
.44
.69
.91
3.3
10
.91
8.2
20
.61
.32
.7C
19
-C2
1R
ec
tum
86
--
-0
.20
.10
.40
.40
.91
.42
.43
.62
.37
7.1
14
.29
.11
6.9
1.2
2.2
C2
2L
ive
r8
2-
0.2
--
0.1
-0
.20
.50
.30
.70
.92
.38
.51
3.3
9.8
29
.11
6.9
1.1
2.4
C2
3-C
24
Ga
llbla
dd
er
etc
.5
9-
--
--
-0
.2-
0.5
1.4
3.2
3.5
4.9
7.1
9.8
7.3
13
.30
.81
.7C
25
Pa
nc
rea
s3
3-
--
--
--
0.2
-0
.72
.31
.73
.55
.31
.19
.16
0.4
1C
30
-C3
1N
os
e,
sin
us
es
etc
.7
--
--
0.1
--
0.2
--
--
0.7
-2
.21
.81
.20
.10
.2C
32
La
ryn
x1
0-
--
--
--
--
-0
.51
.70
.7-
3.3
-2
.40
.10
.3C
33
-C3
4B
ron
ch
us
, lu
ng
52
--
--
--
--
0.5
11
.43
.55
.68
.93
.35
.51
6.9
0.7
1.5
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s6
-0
.2-
--
--
--
--
0.6
-0
.91
.1-
1.2
0.1
0.1
C4
0-C
41
Bo
ne
39
--
0.3
11
.50
.90
.50
.2-
-0
.50
.60
.70
.9-
--
0.5
0.5
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
49
-0
.70
.20
.30
.20
.10
.51
.10
.50
.70
.91
.2-
4.4
3.3
9.1
3.6
0.7
1C
45
Me
so
the
liom
a4
--
--
--
--
--
--
0.7
0.9
1.1
1.8
-0
.10
.1C
46
Ka
po
si's
sa
rco
ma
8-
--
--
--
0.2
-0
.31
.4-
-0
.9-
-2
.40
.10
.2C
43
Me
lan
om
a o
f s
kin
8-
--
--
0.1
--
-0
.3-
0.6
-0
.91
.1-
3.6
0.1
0.2
C4
4O
the
r s
kin
75
1-
0.1
0.2
0.4
-0
.21
.10
.50
.33
.23
.54
.91
1.5
4.4
18
.21
4.5
12
C5
0B
rea
st
54
3-
--
--
0.4
4.7
11
.52
1.4
26
.93
3.3
30
35
.23
9.9
37
.24
9.1
30
.27
.31
3.2
C5
5U
teru
s u
ns
pe
c.
11
--
--
--
--
0.3
--
2.9
2.1
0.9
--
1.2
0.1
0.3
C5
3C
erv
ix u
teri
76
--
--
-0
.10
.41
.42
.24
.54
.63
.55
.61
0.6
6.6
3.6
2.4
11
.9C
58
Pla
ce
nta
11
--
--
0.4
0.3
0.2
-0
.30
.7-
0.6
0.7
--
--
0.1
0.2
C5
4C
orp
us
ute
ri5
7-
--
--
0.1
0.2
0.2
1.4
1.4
1.8
2.9
5.6
12
.43
.31
2.7
4.8
0.8
1.6
C5
6O
va
ry e
tc.
10
3-
-0
.10
.70
.41
.21
.81
.61
.43
.42
.33
.59
.96
.21
3.1
7.3
4.8
1.4
2.3
C5
1-C
52
;C5
7O
the
r fe
ma
le g
en
ita
l1
0-
--
--
--
--
-0
.90
.60
.71
.81
.13
.61
.20
.10
.3C
67
Bla
dd
er
43
--
--
--
0.2
0.2
1.1
-1
.42
.33
.52
.77
.61
4.6
8.5
0.6
1.2
C6
4-C
66
;C6
8K
idn
ey
etc
.6
7-
0.9
0.1
0.2
0.2
0.1
0.2
0.2
1.1
3.1
2.7
2.3
2.8
7.1
4.4
7.3
4.8
0.9
1.5
C6
9E
ye2
5-
1.2
0.2
-0
.1-
--
-0
.3-
0.6
-1
.81
.13
.6-
0.3
0.4
C7
0-C
72
Bra
in,
ne
rvo
us
sys
tem
83
-1
11
.20
.60
.10
.90
.91
.1-
1.8
2.9
0.7
3.5
3.3
12
.74
.81
.11
.5C
73
Th
yro
id2
91
--
0.3
0.3
2.1
3.6
6.7
10
.91
0.8
12
.49
.61
1.5
7.8
14
.26
.61
2.7
1.2
3.9
5.6
C7
4-C
75
Oth
er
en
do
cri
ne
12
-0
.50
.3-
--
-0
.2-
0.3
--
--
--
-0
.20
.1C
81
Ho
dg
kin
's d
ise
as
e8
4-
0.2
0.7
1.1
2.7
0.7
1.1
0.9
0.5
2.1
1.8
2.3
1.4
2.7
4.4
-1
.21
.11
.3C
82
-C8
5;C
96
No
n0
Ho
dg
kin
lym
ph
om
a1
73
-0
.40
.60
.60
.61
.62
1.4
2.4
1.7
59
.21
0.6
16
15
.32
5.5
24
.22
.34
.1C
88
;C9
0M
ult
iple
mye
lom
a2
5-
--
--
--
0.2
0.5
-0
.51
.74
.26
.2-
5.5
2.4
0.3
0.7
C9
1L
ymp
ho
id l
eu
ka
em
ia9
2-
2.9
21
0.7
-0
.20
.20
.30
.7-
0.6
1.4
2.7
2.2
3.6
-1
.21
.1C
92
Mye
loid
le
uk
ae
mia
87
-0
.50
.80
.50
.60
.60
.91
.13
.32
.83
.64
2.1
2.7
2.2
3.6
2.4
1.2
1.6
C9
3M
on
oc
ytic
le
uk
ae
mia
2-
--
--
-0
.2-
--
--
-0
.9-
--
--
C9
4O
the
r le
uk
ae
mia
2-
--
0.1
--
--
--
--
--
-1
.8-
--
C9
5L
eu
ka
em
ia u
ns
pe
c.
4-
0.1
-0
.1-
--
--
--
0.6
--
1.1
--
0.1
0.1
Oth
er
& u
ns
pe
cif
ied
11
1-
0.5
0.2
0.1
0.1
0.1
0.9
0.5
1.1
3.1
4.1
2.9
6.3
13
.31
3.1
20
21
.81
.52
.9
All
sit
es
2,7
98
19
.47
7.8
11
11
.32
3.6
38
.36
0.2
78
.89
9.6
12
4.3
16
7.3
25
5.5
21
2.3
36
02
98
.33
7.4
65
.4
Tabl
e 5-
1-5
Age
Dis
trib
utio
n of
Can
cer
Cas
es a
mon
g Sa
udi M
ales
, 200
0
91
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
-5
-1
0-
15
-2
0-
25
-3
0-
35
-4
0-
45
-5
0-
55
-6
0-
65
-7
0-
75
+%
C
00
Lip
6-
--
--
--
-1
1-
--
-2
11
0.2
C0
1-C
02
To
ng
ue
30
--
--
11
-1
3-
12
58
23
31
.1C
07
-C0
8S
aliv
ary
gla
nd
7-
--
1-
-1
1-
-1
-1
1-
1-
0.2
C0
3-C
06
Mo
uth
21
--
--
-2
--
12
-2
13
21
70
.7C
09
-C1
0O
rop
ha
ryn
x0
--
--
--
--
--
--
--
--
-0
C1
1N
as
op
ha
ryn
x8
8-
-2
21
36
26
15
11
81
19
53
43
.1C
12
-C1
3H
ypo
ph
ary
nx
4-
--
--
--
--
--
--
11
11
0.1
C1
4P
ha
ryn
x u
ns
pe
c.
0-
--
--
--
--
--
--
--
--
0C
15
Oe
so
ph
ag
us
62
--
--
--
--
-2
32
51
05
62
92
.2C
16
Sto
ma
ch
11
2-
--
--
-1
21
78
67
18
12
21
29
4C
17
Sm
all
inte
sti
ne
11
--
--
--
--
1-
-1
4-
21
20
.4C
18
Co
lon
99
--
--
-1
12
36
86
15
16
14
72
03
.5C
19
-C2
1R
ec
tum
92
--
--
--
-5
41
11
01
11
19
12
11
83
.3C
22
Liv
er
24
3-
4-
12
--
2-
43
19
29
38
48
42
51
8.6
C2
3-C
24
Ga
llbla
dd
er
etc
.2
4-
--
--
--
--
--
13
55
37
0.9
C2
5P
an
cre
as
60
--
--
-1
--
17
51
59
12
61
32
.1C
30
-C3
1N
os
e,
sin
us
es
etc
.6
--
-1
--
--
--
11
--
11
10
.2C
32
La
ryn
x4
9-
--
--
--
13
25
76
77
38
1.7
C3
3-C
34
Bro
nc
hu
s,
lun
g1
68
--
--
-1
-2
35
88
19
31
28
30
33
6C
37
-C3
8O
the
r T
ho
rac
ic o
rga
ns
4-
--
-1
--
-1
-1
--
--
-1
0.1
C4
0-C
41
Bo
ne
54
-4
29
18
71
22
21
21
12
--
1.9
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
51
-1
31
23
62
23
11
21
35
24
1.8
C4
5M
es
oth
elio
ma
6-
--
--
--
--
2-
-1
1-
2-
0.2
C4
6K
ap
os
i's s
arc
om
a1
9-
--
--
--
-3
-1
12
11
37
0.7
C4
3M
ela
no
ma
of
sk
in9
--
--
--
-1
--
1-
-2
12
20
.3C
44
Oth
er
sk
in1
10
-1
-2
11
27
33
26
21
41
51
83
33
.9C
50
Bre
as
t1
3-
--
--
--
12
-1
22
12
-2
0.5
C6
1P
ros
tate
16
6-
-1
--
--
-1
2-
36
18
30
33
72
5.9
C6
2T
es
tis
37
-5
1-
31
94
43
3-
-3
--
11
.3C
60
Pe
nis
1-
--
--
--
--
--
--
-1
--
0C
63
Oth
er
ma
le g
en
ita
l2
--
--
--
--
--
--
--
1-
10
.1C
67
Bla
dd
er
15
0-
--
--
42
37
78
13
11
28
20
26
21
5.3
C6
4-C
66
;C6
8K
idn
ey
etc
.8
5-
93
11
--
35
44
85
13
91
19
3C
69
Eye
23
-1
41
1-
--
--
--
1-
-1
32
0.8
C7
0-C
72
Bra
in,
ne
rvo
us
sys
tem
14
2-
15
27
11
96
31
07
74
61
06
11
46
5C
73
Th
yro
id7
1-
--
33
46
87
84
95
13
46
2.5
C7
4-C
75
Oth
er
en
do
cri
ne
11
-3
2-
11
1-
-1
--
11
--
-0
.4C
81
Ho
dg
kin
's d
ise
as
e1
37
-8
72
03
11
51
44
75
26
13
13
10
4.9
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a2
59
-6
78
14
48
17
14
10
21
20
13
20
26
24
47
9.2
C8
8;C
90
Mu
ltip
le m
yelo
ma
37
--
--
--
--
12
21
25
89
71
.3C
91
Lym
ph
oid
le
uk
ae
mia
14
1-
41
24
12
19
53
11
32
24
58
65
5C
92
Mye
loid
le
uk
ae
mia
79
-9
51
36
56
68
16
65
26
42
.8C
93
Mo
no
cyt
ic l
eu
ka
em
ia4
--
--
-1
--
--
1-
-2
--
-0
.1C
94
Oth
er
leu
ka
em
ia0
--
--
--
--
--
--
--
--
-0
C9
5L
eu
ka
em
ia u
ns
pe
c.
3-
1-
1-
--
--
--
1-
--
--
0.1
Oth
er
& u
ns
pe
cif
ied
12
1-
41
-1
-1
61
11
66
12
17
91
53
14
.3
All
sit
es
2,8
17
01
37
84
76
11
27
06
69
31
02
14
11
30
17
02
07
31
53
14
31
24
88
10
0
Tabl
e 5-
1-6
Age
Dis
trib
utio
n of
Can
cer
Cas
es a
mon
g Sa
udi F
emal
es, 2
000
92
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
-5
-1
0-
15
-2
0-
25
-3
0-
35
-4
0-
45
-5
0-
55
-6
0-
65
-7
0-
75
+%
C
00
Lip
4-
--
--
--
--
-1
-1
-1
-1
0.1
C0
1-C
02
To
ng
ue
22
--
--
-1
2-
1-
3-
17
3-
40
.8C
07
-C0
8S
aliv
ary
gla
nd
15
--
-1
11
4-
22
1-
2-
--
10
.5C
03
-C0
6M
ou
th2
7-
--
1-
-1
12
2-
44
34
23
1C
09
-C1
0O
rop
ha
ryn
x4
--
--
-1
--
--
-1
1-
-1
-0
.1C
11
Na
so
ph
ary
nx
24
--
-1
1-
14
24
34
-1
11
10
.9C
12
-C1
3H
yp
op
ha
ryn
x1
0-
--
--
--
1-
-1
-1
33
-1
0.4
C1
4P
ha
ryn
x u
ns
pe
c.
2-
--
--
--
--
--
-1
-1
--
0.1
C1
5O
es
op
ha
gu
s5
4-
--
--
--
-2
22
47
10
81
18
1.9
C1
6S
tom
ac
h5
6-
--
--
21
-4
36
-7
71
16
92
C1
7S
ma
ll in
tes
tin
e1
0-
--
--
--
11
--
-3
--
23
0.4
C1
8C
olo
n1
02
--
-1
-3
44
79
61
31
61
01
33
13
3.6
C1
9-C
21
Re
ctu
m7
7-
--
--
-1
47
41
08
81
18
79
2.7
C2
2L
ive
r1
02
-3
--
11
11
74
10
91
51
81
51
07
3.6
C2
3-C
24
Ga
llbla
dd
er
etc
.4
5-
--
--
--
1-
44
45
79
11
01
.6C
25
Pa
nc
rea
s3
2-
--
-1
1-
-4
-3
24
33
56
1.1
C3
0-C
31
No
se
, s
inu
se
s e
tc.
6-
--
--
--
-1
-1
--
-1
-3
0.2
C3
2L
ary
nx
8-
--
--
--
--
-1
11
11
12
0.3
C3
3-C
34
Bro
nc
hu
s,
lun
g4
8-
--
--
--
--
22
94
59
61
11
.7C
37
-C3
8O
the
r T
ho
rac
ic o
rga
ns
8-
-1
-1
--
--
-1
1-
2-
11
0.3
C4
0-C
41
Bo
ne
35
-1
71
26
41
2-
-1
-1
--
--
1.2
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
45
-8
61
43
31
22
32
44
-1
11
.6C
45
Me
so
the
liom
a1
--
--
--
--
--
-1
--
--
-0
C4
6K
ap
os
i's s
arc
om
a3
--
--
--
--
-1
--
--
1-
10
.1C
43
Me
lan
om
a o
f s
kin
7-
--
--
--
2-
21
1-
--
-1
0.2
C4
4O
the
r s
kin
79
--
-1
12
-6
55
44
41
11
08
18
2.8
C5
0B
rea
st
61
4-
--
--
82
25
27
81
01
91
71
54
64
29
23
21
21
.8C
55
Ute
rus
un
sp
ec
.4
--
--
--
--
21
--
--
--
10
.1C
53
Ce
rvix
ute
ri9
1-
--
1-
-1
71
31
46
11
96
85
10
3.2
C5
8P
lac
en
ta7
--
--
--
1-
-2
3-
1-
--
-0
.2C
54
Co
rpu
s u
teri
84
--
--
-1
13
16
61
41
11
61
08
73
C5
6O
va
ry e
tc.
10
2-
-3
38
54
89
47
51
31
08
69
3.6
C5
1-C
52
;C5
7O
the
r fe
ma
le g
en
ita
l1
4-
--
--
11
1-
42
1-
2-
11
0.5
C6
7B
lad
de
r3
7-
--
--
-1
-1
24
24
93
56
1.3
C6
4-C
66
;C6
8K
idn
ey
etc
.4
7-
96
-1
21
23
31
35
44
-3
1.7
C6
9E
ye
24
-1
31
1-
-1
1-
-1
-1
-3
11
0.9
C7
0-C
72
Bra
in,
ne
rvo
us
sy
ste
m1
03
-1
61
89
65
17
33
59
95
22
33
.7C
73
Th
yro
id2
48
--
--
51
83
94
14
23
02
01
11
51
13
58
8.8
C7
4-C
75
Oth
er
en
do
cri
ne
14
-8
-1
-2
-1
--
1-
-1
--
-0
.5C
81
Ho
dg
kin
's d
ise
as
e8
9-
-1
31
71
91
36
63
1-
21
12
32
3.2
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
ly
mp
ho
ma
18
1-
65
68
83
14
18
10
81
11
72
41
41
11
86
.4C
88
;C9
0M
ult
iple
my
elo
ma
24
--
--
--
-1
11
-2
38
31
40
.9C
91
Ly
mp
ho
id l
eu
ka
em
ia9
9-
39
17
85
12
11
12
-2
59
24
3.5
C9
2M
ye
loid
le
uk
ae
mia
89
-4
51
11
04
38
87
48
49
-2
23
.2C
93
Mo
no
cy
tic
le
uk
ae
mia
1-
--
--
--
--
-1
--
--
--
0C
94
Oth
er
leu
ka
em
ia1
--
1-
--
--
--
--
--
--
-0
C9
5L
eu
ka
em
ia u
ns
pe
c.
5-
-2
11
--
--
--
--
1-
--
0.2
Oth
er
& u
ns
pe
cif
ied
11
5-
4-
11
11
66
10
66
12
16
12
11
22
4.1
All
sit
es
2,8
19
01
11
85
77
80
88
10
71
87
23
62
46
23
22
24
25
12
95
21
21
52
23
61
00
Tabl
e 5-
1-7
Inci
denc
e R
ates
for
Can
cer
Cas
es a
mon
g Sa
udi M
ales
by
Age
Gro
up (p
er 1
00,0
00),
2000
93
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
5-
10
-1
5-
20
-2
5-
30
-3
5-
40
-4
5-
50
-5
5-
60
-6
5-
70
-7
5+
CIR
AS
RC
00
Lip
6-
--
--
--
-0
.30
.3-
--
-1
.81
.10
.80
.10
.1C
01
-C0
2T
on
gu
e3
0-
--
-0
.10
.2-
0.2
0.8
-0
.41
.13
.67
.71
.83
.32
.30
.40
.8C
07
-C0
8S
aliv
ary
gla
nd
7-
--
0.1
--
0.2
0.2
--
0.4
-0
.71
-1
.1-
0.1
0.2
C0
3-C
06
Mo
uth
21
--
--
-0
.3-
-0
.30
.6-
1.1
0.7
2.9
1.8
1.1
5.4
0.3
0.5
C0
9-C
10
Oro
ph
ary
nx
0-
--
--
--
--
--
--
--
--
--
C1
1N
aso
ph
ary
nx
88
--
0.2
0.2
0.1
0.5
1.1
0.4
1.6
4.8
4.6
4.5
7.9
8.7
4.4
3.3
3.1
1.1
2C
12
-C1
3H
ypo
ph
ary
nx
4-
--
--
--
--
--
--
10
.91
.10
.80
.10
.1C
14
Ph
ary
nx
un
sp
ec.
0-
--
--
--
--
--
--
--
--
--
C1
5O
es
op
ha
gu
s6
2-
--
--
--
--
0.6
1.3
1.1
3.6
9.7
4.4
6.6
22
.30
.81
.4C
16
Sto
ma
ch
11
2-
--
--
-0
.20
.40
.32
.23
.43
.35
17
.41
0.7
23
22
.31
.42
.7C
17
Sm
all
inte
stin
e1
1-
--
--
-0
.2-
0.3
--
0.6
2.9
-1
.81
.11
.50
.10
.3C
18
Co
lon
99
--
--
-0
.2-0
.20
.40
.81
.93
.43
.31
0.8
15
.51
2.4
7.7
15
.41
.32
.5C
19
-C2
1R
ect
um
92
--
--
--
-1
.11
.13
.54
.26
.17
.98
.71
0.7
12
6.2
1.2
2.2
C2
2L
ive
r2
43
-0
.3-
0.1
0.2
--
0.4
-1
.31
.31
0.6
20
.83
6.7
42
.64
5.9
39
.33
.16
.1C
23
-C2
4G
allb
lad
de
r e
tc.
24
--
--
--
--
--
-0
.62
.24
.84
.43
.35
.40
.30
.6C
25
Pa
nc
rea
s6
0-
--
--
0.2
--
0.3
2.2
2.1
0.6
3.6
8.7
10
.76
.61
00
.81
.5C
30
-C3
1N
ose
, si
nu
ses
etc
.6
--
-0
.1-
--
--
-0
.40
.6-
-0
.91
.10
.80
.10
.1C
32
La
ryn
x4
9-
--
--
--
0.2
0.8
0.6
2.1
3.9
4.3
6.8
6.2
3.3
6.2
0.6
1.2
C3
3-C
34
Bro
nch
us,
lun
g1
68
--
--
-0
.2-
0.4
0.8
1.6
3.4
4.5
13
.62
9.9
24
.93
2.8
25
.42
.14
.3C
37
-C3
8O
the
r T
ho
raci
c o
rga
ns
4-
--
-0
.1-
--
0.3
-0
.4-
--
--
0.8
0.1
0.1
C4
0-C
41
Bo
ne
54
-0
.30
.20
.92
.11
.10
.20
.40
.50
.60
.41
.10
.71
1.8
--
0.7
0.7
C4
7;C
49
Co
nn
ec
tive
tis
sue
51
-1
0.1
0.2
0.3
0.9
0.4
0.4
0.8
0.3
0.4
1.1
0.7
2.9
4.4
2.2
3.1
0.7
0.8
C4
5M
eso
the
liom
a6
--
--
--
--
-0
.6-
-0
.71
-2
.2-
0.1
0.1
C4
6K
ap
osi
's s
arc
om
a1
9-
--
--
--
-0
.8-
0.4
0.6
1.4
10
.93
.35
.40
.20
.4C
43
Me
lan
om
a o
f sk
in9
--
--
--
-0
.2-
-0
.4-
-1
.90
.92
.21
.50
.10
.2C
44
Oth
er
skin
11
0-
0.1
-0
.20
.10
.20
.41
.50
.81
0.8
3.3
1.4
13
.51
3.3
19
.72
5.4
1.4
2.4
C5
0B
rea
st1
3-
--
--
--
0.2
0.5
-0
.41
.11
.41
1.8
-1
.50
.20
.3C
61
Pro
sta
te1
66
--
0.1
--
--
-0
.30
.6-
1.7
4.3
17
.42
6.6
36
.15
5.4
2.1
3.6
C6
2T
est
is3
7-
0.4
0.1
-0
.30
.21
.70
.91
.11
1.3
--
2.9
--
0.8
0.5
0.6
C6
0P
en
is1
--
--
--
--
--
--
--
0.9
--
--
C6
3O
the
r m
ale
ge
nita
l2
--
--
--
--
--
--
--
0.9
-0
.8-
-C
67
Bla
dd
er
15
0-
--
--
0.6
0.4
0.7
1.8
2.2
3.4
7.2
7.9
27
17
.82
8.4
16
.21
.93
.7C
64
-C6
6;C
68
Kid
ne
y e
tc.
85
-0
.70
.20
.10
.1-
-0
.71
.31
.31
.74
.53
.61
2.6
81
26
.91
.11
.9C
69
Eye
23
-1
.10
.10
.1-
--
--
--
0.6
--
0.9
3.3
1.5
0.3
0.3
C7
0-C
72
Bra
in,
ne
rvo
us
syst
em
14
2-
1.2
2.1
1.1
10
.90
.62
.21
.82
.21
.73
.37
.25
.89
.84
.44
.61
.82
.3C
73
Th
yro
id7
1-
--
0.1
0.3
0.6
1.1
1.8
1.8
2.6
1.7
53
.61
2.7
4.4
4.6
0.9
1.4
C7
4-C
75
Oth
er
en
do
cri
ne
11
-0
.20
.2-
0.1
0.2
0.2
--
0.3
--
0.7
1-
--
0.1
0.2
C8
1H
od
gk
in's
dis
ea
se
13
7-
0.6
0.6
1.9
3.5
2.3
2.6
0.9
1.8
1.6
0.8
3.3
0.7
2.9
0.9
3.3
7.7
1.8
1.9
C8
2-C
85
;C9
6N
on
0H
od
gk
in ly
mp
ho
ma
25
9-
0.5
0.6
0.1
1.6
0.6
1.5
3.8
3.7
3.2
8.8
11
.19
.31
9.3
23
.12
6.3
36
.23
.35
.3C
88
;C9
0M
ulti
ple
mye
lom
a3
7-
--
--
--
-0
.30
.60
.80
.61
.44
.87
.19
.85
.40
.50
.9C
91
Lym
ph
oid
le
uk
ae
mia
14
1-
3.2
1.9
1.2
2.2
0.8
0.6
0.2
0.3
10
.81
.12
.94
.87
.16
.63
.81
.81
.9C
92
Mye
loid
le
uk
ae
mia
79
-0
.70
.10
.10
.30
.90
.91
.31
.62
.60
.43
.34
.34
.81
.86
.63
.11
1.4
C9
3M
on
oc
ytic
leu
ka
em
ia4
--
--
-0
.2-
--
-0
.4-
-1
.9-
--
0.1
0.1
C9
4O
the
r le
uk
ae
mia
0-
--
--
--
--
--
--
--
--
--
C9
5L
eu
ka
em
ia u
nsp
ec.
3-
0.1
-0
.1-
--
--
--
0.6
--
--
--
-O
the
r &
un
spe
cifie
d1
21
-0
.30
.1-
0.1
-0
.21
.30
.33
.52
.53
.38
.61
6.4
81
6.4
23
.91
.52
.7
All
site
s2
81
70
10
.76
.66
.61
2.5
11
.11
2.3
20
.22
7.2
44
.85
4.5
94
.71
48
.43
04
.42
79
.13
41
.63
75
.83
6.1
59
.8
Tabl
e 5-
1-8
Inci
denc
e R
ates
for
Can
cer
Cas
es a
mon
g Sa
udi F
emal
es b
y A
ge G
roup
(per
100
,000
), 20
00
94
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
5-
10
-1
5-
20
-2
5-
30
-3
5-
40
-4
5-
50
-5
5-
60
-6
5-
70
-7
5+
CIR
AS
RC
00
Lip
4-
--
--
--
--
-0
.4-
0.7
-1
.3-
1.1
0.1
0.1
C0
1-C
02
To
ng
ue
22
--
--
-0
.10
.3-
0.3
-1
.2-
0.7
5.7
3.8
-4
.30
.30
.6C
07
-C0
8S
aliv
ary
gla
nd
15
--
-0
.10
.10
.10
.7-
0.5
0.6
0.4
-1
.3-
--
1.1
0.2
0.3
C0
3-C
06
Mo
uth
27
--
-0
.1-
-0
.20
.20
.50
.6-
2.1
2.6
2.5
52
.73
.20
.30
.7C
09
-C1
0O
rop
ha
ryn
x4
--
--
-0
.1-
--
--
0.5
0.7
--
1.4
-0
.10
.1C
11
Na
so
ph
ary
nx
24
--
-0
.10
.1-
0.2
0.8
0.5
1.3
1.2
2.1
-0
.81
.31
.41
.10
.30
.5C
12
-C1
3H
ypo
ph
ary
nx
10
--
--
--
-0
.2-
-0
.4-
0.7
2.5
3.8
-1
.10
.10
.3C
14
Ph
ary
nx
un
sp
ec
.2
--
--
--
--
--
--
0.7
-1
.3-
--
0.1
C1
5O
es
op
ha
gu
s5
4-
--
--
--
-0
.50
.60
.82
.14
.68
.21
01
4.9
8.7
0.7
1.5
C1
6S
tom
ac
h5
6-
--
--
0.3
0.2
-1
0.9
2.4
-4
.65
.71
3.8
8.1
9.7
0.7
1.5
C1
7S
ma
ll in
tes
tin
e1
0-
--
--
--
0.2
0.3
--
-2
--
2.7
3.2
0.1
0.2
C1
8C
olo
n1
02
--
-0
.1-
0.4
0.7
0.8
1.8
2.8
2.4
6.9
10
.58
.21
6.3
4.1
14
.11
.32
.5C
19
-C2
1R
ec
tum
77
--
--
--
0.2
0.8
1.8
1.3
4.1
4.3
5.3
91
09
.59
.71
2C
22
Liv
er
10
2-
0.2
--
0.1
0.1
0.2
0.2
1.8
1.3
4.1
4.8
9.9
14
.81
8.8
13
.57
.61
.32
.7C
23
-C2
4G
allb
lad
de
r e
tc.
45
--
--
--
-0
.2-
1.3
1.6
2.1
3.3
5.7
11
.31
.41
0.8
0.6
1.2
C2
5P
an
cre
as
32
--
--
0.1
0.1
--
1-
1.2
1.1
2.6
2.5
3.8
6.8
6.5
0.4
0.8
C3
0-C
31
No
se
, s
inu
se
s e
tc.
6-
--
--
--
-0
.3-
0.4
--
-1
.3-
3.2
0.1
0.1
C3
2L
ary
nx
8-
--
--
--
--
-0
.40
.50
.70
.81
.31
.42
.20
.10
.2C
33
-C3
4B
ron
ch
us
, lu
ng
48
--
--
--
--
-0
.60
.84
.82
.64
.11
1.3
8.1
11
.90
.61
.3C
37
-C3
8O
the
r T
ho
rac
ic o
rga
ns
8-
-0
.1-
0.1
--
--
-0
.40
.5-
1.6
-1
.41
.10
.10
.2C
40
-C4
1B
on
e3
5-
0.1
0.6
1.2
0.7
0.5
0.2
0.4
--
0.4
-0
.7-
--
-0
.40
.4C
47
;C4
9C
on
ne
cti
ve
tis
su
e4
5-
0.6
0.5
0.1
0.5
0.4
0.5
0.2
0.5
0.6
1.2
1.1
2.6
3.3
-1
.41
.10
.60
.7C
45
Me
so
the
liom
a1
--
--
--
--
--
-0
.5-
--
--
--
C4
6K
ap
os
i's s
arc
om
a3
--
--
--
--
-0
.3-
--
-1
.3-
1.1
-0
.1C
43
Me
lan
om
a o
f s
kin
7-
--
--
--
0.4
-0
.60
.40
.5-
--
-1
.10
.10
.1C
44
Oth
er
sk
in7
9-
--
0.1
0.1
0.3
-1
.31
.31
.61
.62
.12
.69
12
.61
0.8
19
.51
1.9
C5
0B
rea
st
61
4-
--
--
1.1
3.7
10
.91
9.9
31
.63
7.1
37
.73
5.6
52
.53
6.4
31
.12
2.7
7.9
13
.9C
55
Ute
rus
un
sp
ec
.4
--
--
--
--
0.5
0.3
--
--
--
1.1
0.1
0.1
C5
3C
erv
ix u
teri
91
--
-0
.1-
-0
.21
.53
.34
.42
.45
.85
.94
.91
06
.81
0.8
1.2
2.1
C5
8P
lac
en
ta7
--
--
--
0.2
--
0.6
1.2
-0
.7-
--
-0
.10
.2C
54
Co
rpu
s u
teri
84
--
--
-0
.10
.20
.60
.31
.92
.47
.47
.21
3.1
12
.61
0.8
7.6
1.1
2.3
C5
6O
va
ry e
tc.
10
2-
-0
.20
.30
.90
.70
.71
.72
.31
.32
.92
.78
.68
.21
08
.19
.71
.32
.2C
51
-C5
2;C
57
Oth
er
fem
ale
ge
nit
al
14
--
--
-0
.10
.20
.2-
1.3
0.8
0.5
-1
.6-
1.4
1.1
0.2
0.3
C6
7B
lad
de
r3
7-
--
--
-0
.2-
0.3
0.6
1.6
1.1
2.6
7.4
3.8
6.8
6.5
0.5
1C
64
-C6
6;C
68
Kid
ne
y e
tc.
47
-0
.70
.5-
0.1
0.3
0.2
0.4
0.8
0.9
0.4
1.6
3.3
3.3
5-
3.2
0.6
0.9
C6
9E
ye2
4-
10
.10
.1-
-0
.20
.2-
-0
.4-
0.7
-3
.81
.41
.10
.30
.4C
70
-C7
2B
rain
, n
erv
ou
s s
yste
m1
03
-1
.31
.50
.90
.70
.70
.21
.50
.80
.92
4.8
5.9
4.1
2.5
2.7
3.2
1.3
1.7
C7
3T
hyr
oid
24
8-
--
-0
.62
.56
.58
.61
0.7
9.4
8.1
5.8
9.9
93
.86
.88
.73
.24
.5C
74
-C7
5O
the
r e
nd
oc
rin
e1
4-
0.6
-0
.1-
0.3
-0
.2-
-0
.4-
-0
.8-
--
0.2
0.2
C8
1H
od
gk
in's
dis
ea
se
89
--
1.1
1.7
2.2
1.8
11
.30
.80
.3-
1.1
0.7
0.8
2.5
4.1
2.2
1.1
1.1
C8
2-C
85
;C9
6N
on
0H
od
gk
in l
ymp
ho
ma
18
1-
0.5
0.4
0.6
0.9
1.1
0.5
2.9
4.6
3.1
3.3
5.8
11
.21
9.7
17
.61
4.9
19
.52
.33
.9C
88
;C9
0M
ult
iple
mye
lom
a2
4-
--
--
--
0.2
0.3
0.3
-1
.12
6.6
3.8
1.4
4.3
0.3
0.7
C9
1L
ymp
ho
id l
eu
ka
em
ia9
9-
3.1
1.4
0.8
0.6
0.1
0.3
0.2
0.3
0.3
0.8
-1
.34
.11
1.3
2.7
4.3
1.3
1.5
C9
2M
yelo
id l
eu
ka
em
ia8
9-
0.3
0.4
1.1
1.2
0.5
0.5
1.7
22
.21
.64
.32
.67
.4-
2.7
2.2
1.1
1.5
C9
3M
on
oc
ytic
le
uk
ae
mia
1-
--
--
--
--
-0
.4-
--
--
--
-C
94
Oth
er
leu
ka
em
ia1
--
0.1
--
--
--
--
--
--
--
--
C9
5L
eu
ka
em
ia u
ns
pe
c.
5-
-0
.20
.10
.1-
--
--
--
-0
.8-
--
0.1
0.1
Oth
er
& u
ns
pe
cif
ied
11
5-
0.3
-0
.10
.10
.10
.21
.31
.53
.12
.43
.27
.91
3.1
15
.11
4.9
23
.81
.52
.8
All
sit
es
2,8
19
08
.77
.17
.79
.21
1.8
18
.43
9.1
60
.57
6.9
94
11
8.9
16
5.5
24
1.8
26
6.5
20
6.2
25
5.4
36
.26
1.5
Tabl
e 5-
2-1
Age
Sta
ndar
ized
Rat
es a
nd R
elat
ive
Freq
uenc
ies f
or A
ll C
ance
r C
ases
am
ong
Saud
is b
y Si
te a
nd S
ex, R
iyad
h R
egio
n, 1
999-
2000
95
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
30
.30
.31
0.1
0.2
00
0C
01
-C0
2T
on
gu
e6
0.7
0.9
10
1.1
1.6
70
.81
70
.80
.9C
07
-C0
8S
aliv
ary
gla
nd
30
.30
.41
0.1
0.1
30
.30
.44
0.4
0.4
C0
3-C
06
Mo
uth
40
.40
.57
0.8
0.9
60
.70
.84
0.4
0.5
C0
9-C
10
Oro
ph
ary
nx
20
.20
.30
00
00
00
00
C1
1N
as
op
ha
ryn
x3
03
.33
.42
22
.42
.81
41
.61
.81
01
.11
.1C
12
-C1
3H
ypo
ph
ary
nx
00
01
0.1
0.1
40
.50
.60
00
C1
4P
ha
ryn
x u
ns
pe
c.
00
00
00
00
00
00
C1
5O
es
op
ha
gu
s2
32
.53
.12
12
.32
.51
92
.13
.12
02
.13
C1
6S
tom
ac
h2
42
.63
.23
64
.05
.32
22
.53
.52
52
.73
.5C
17
Sm
all
inte
sti
ne
70
.81
30
.30
.32
0.2
0.3
40
.40
.5C
18
Co
lon
31
3.4
4.2
36
4.0
5.3
35
4.0
5.5
41
4.4
5.4
C1
9-C
21
Re
ctu
m2
42
.63
.32
52
.83
30
3.4
4.4
19
2.0
2.4
C2
2L
ive
r1
16
12
.61
6.8
95
10
.51
3.5
35
4.0
5.9
36
3.9
5.3
C2
3-C
24
Ga
llbla
dd
er
etc
.7
0.8
18
0.9
1.3
27
3.1
4.3
20
2.1
3C
25
Pa
nc
rea
s1
61
.72
.22
02
.22
.81
11
.21
.81
61
.72
.1C
30
-C3
1N
os
e,
sin
us
es
etc
.3
0.3
0.4
20
.20
.21
0.1
0.2
20
.20
.2C
32
La
ryn
x8
0.9
1.1
10
1.1
1.7
10
.10
.21
0.1
0.2
C3
3-C
34
Bro
nc
hu
s,
lun
g4
65
.06
.33
43
.85
.31
92
.12
.91
51
.62
.3C
37
-C3
8O
the
r T
ho
rac
ic o
rga
ns
60
.70
.43
0.3
0.2
30
.30
.62
0.2
0.2
C4
0-C
41
Bo
ne
16
1.7
1.1
15
1.7
0.8
11
1.2
0.7
12
1.3
0.6
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
29
3.1
2.6
15
1.7
1.3
14
1.6
1.4
12
1.3
1C
45
Me
so
the
liom
a0
00
20
.20
.20
00
00
0C
46
Ka
po
si's
sa
rco
ma
50
.50
.68
0.9
0.8
50
.60
.61
0.1
0.1
C4
3M
ela
no
ma
of
sk
in5
0.5
0.7
40
.40
.51
0.1
0.1
10
.10
.1C
44
Oth
er
sk
in4
75
.16
.33
74
.15
.33
03
.44
.21
71
.82
.6C
50
Bre
as
t3
0.3
0.4
40
.40
.4-
--
--
-C
61
Pro
sta
te4
95
.37
.46
87
.58
.6-
--
--
-C
62
Te
sti
s8
0.9
0.7
60
.70
.4-
--
--
-C
60
Pe
nis
00
00
00
--
--
--
C6
3O
the
r m
ale
ge
nit
al
10
.10
.10
00
--
--
--
C5
0B
rea
st
--
--
--
13
81
5.6
17
.21
86
19
.92
2.5
C5
5U
teru
s u
ns
pe
c.
--
--
--
30
.30
.41
0.1
0.1
C5
3C
erv
ix u
teri
--
--
--
18
2.0
23
13
.33
.6C
58
Pla
ce
nta
--
--
--
20
.20
.22
0.2
0.2
C5
4C
orp
us
ute
ri-
--
--
-1
51
.72
.23
13
.34
.7C
56
Ov
ary
etc
.-
--
--
-3
54
.04
25
2.7
2.8
C5
1-C
52
;C5
7O
the
r fe
ma
le g
en
ita
l-
--
--
-5
0.6
0.8
40
.40
.3C
67
Bla
dd
er
39
4.2
5.5
45
5.0
6.6
15
1.7
2.4
70
.81
.3C
64
-C6
6;C
68
Kid
ne
y e
tc.
28
3.0
43
23
.54
.12
83
.23
.32
02
.12
.1C
69
Ey
e1
41
.51
.65
0.6
0.2
18
2.0
1.4
50
.50
.4C
70
-C7
2B
rain
, n
erv
ou
s s
ys
tem
50
5.4
4.2
50
5.5
4.2
28
3.2
34
04
.33
.3C
73
Th
yro
id3
43
.73
.42
42
.72
.31
13
12
.81
0.8
10
01
0.7
8.9
C7
4-C
75
Oth
er
en
do
cri
ne
20
.20
.12
0.2
0.1
50
.60
.26
0.6
0.3
C8
1H
od
gk
in's
dis
ea
se
29
3.1
2.1
43
4.8
2.9
24
2.7
1.9
31
3.3
2.1
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a7
78
.39
.99
01
0.0
10
45
5.1
6.1
64
6.9
7.8
C8
8;C
90
Mu
ltip
le m
ye
lom
a1
51
.62
18
2.0
2.6
60
.70
.86
0.6
1C
91
Lym
ph
oid
le
uk
ae
mia
38
4.1
2.5
43
4.8
32
83
.21
.53
63
.92
.8C
92
My
elo
id l
eu
ka
em
ia3
23
.52
.92
12
.31
.82
52
.82
.22
62
.82
.7C
93
Mo
no
cyt
ic l
eu
ka
em
ia0
00
00
00
00
00
0C
94
Oth
er
leu
ka
em
ia0
00
00
00
00
10
.10
C9
5L
eu
ka
em
ia u
ns
pe
c.
10
.10
.11
0.1
0.1
10
.10
.21
0.1
0O
the
r &
un
sp
ec
ifie
d4
54
.96
.23
23
.54
31
3.5
4.3
41
4.4
5.6
All
sit
es
92
31
00
11
39
02
10
01
07
.98
84
10
01
09
.39
33
10
01
08
.1
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-
2-2
Age
Sta
ndar
ized
Rat
es a
nd R
elat
ive
Freq
uenc
ies f
or A
ll C
ance
r C
ases
am
ong
Saud
is b
y Si
te a
nd S
ex, N
ajra
n R
egio
n, 1
999-
2000
96
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
00
00
00
00
0C
01
-C0
2T
on
gu
e0
00
00
00
00
00
0C
07
-C0
8S
aliv
ary
gla
nd
00
00
00
00
03
61
.9C
03
-C0
6M
ou
th1
1.8
10
00
12
.70
.90
00
C0
9-C
10
Oro
ph
ary
nx
00
00
00
00
02
42
.9C
11
Na
so
ph
ary
nx
00
00
00
00
00
00
C1
2-C
13
Hyp
op
ha
ryn
x0
00
00
00
00
00
0C
14
Ph
ary
nx
un
sp
ec
.0
00
00
00
00
12
1.5
C1
5O
es
op
ha
gu
s0
00
23
.51
.70
00
00
0C
16
Sto
ma
ch
23
.52
.52
3.5
1.7
41
0.8
5.7
00
0C
17
Sm
all
inte
sti
ne
00
00
00
00
00
00
C1
8C
olo
n2
3.5
1.2
00
01
2.7
1.5
12
0.6
C1
9-C
21
Re
ctu
m2
3.5
3.5
23
.51
.71
2.7
3.7
24
1.7
C2
2L
ive
r9
15
.81
3.9
47
.07
12
.73
48
5.1
C2
3-C
24
Ga
llbla
dd
er
etc
.0
00
23
.51
.71
2.7
1.9
12
2.8
C2
5P
an
cre
as
23
.51
.62
3.5
1.7
00
00
00
C3
0-C
31
No
se
, s
inu
se
s e
tc.
00
00
00
00
01
21
.7C
32
La
ryn
x0
00
00
00
00
00
0C
33
-C3
4B
ron
ch
us
, lu
ng
47
.05
.12
3.5
2.8
00
00
00
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s2
3.5
0.7
00
01
2.7
0.9
00
0C
40
-C4
1B
on
e1
1.8
0.6
58
.85
.73
8.1
2.9
12
0.5
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
00
01
1.8
0.5
00
01
20
.4C
45
Me
so
the
liom
a0
00
00
00
00
00
0C
46
Ka
po
si's
sa
rco
ma
00
00
00
00
00
00
C4
3M
ela
no
ma
of
sk
in0
00
00
00
00
00
0C
44
Oth
er
sk
in3
5.3
1.9
58
.85
.12
5.4
4.4
24
3.9
C5
0B
rea
st
11
.80
.62
3.5
4.1
--
--
--
C6
1P
ros
tate
35
.36
.40
00
--
--
--
C6
2T
es
tis
23
.52
.80
00
--
--
--
C6
0P
en
is0
00
00
0-
--
--
-C
63
Oth
er
ma
le g
en
ita
l0
00
00
0-
--
--
-C
50
Bre
as
t-
--
--
-2
5.4
2.1
48
4.2
C5
5U
teru
s u
ns
pe
c.
--
--
--
12
.71
.90
00
C5
3C
erv
ix u
teri
--
--
--
12
.70
.90
00
C5
8P
lac
en
ta-
--
--
-0
00
00
0C
54
Co
rpu
s u
teri
--
--
--
25
.45
.60
00
C5
6O
va
ry e
tc.
--
--
--
12
.71
.42
42
.9C
51
-C5
2;C
57
Oth
er
fem
ale
ge
nit
al
--
--
--
00
01
21
C6
7B
lad
de
r1
1.8
0.6
11
.80
.81
2.7
0.9
24
2.5
C6
4-C
66
;C6
8K
idn
ey
etc
.2
3.5
4.7
23
.53
.71
2.7
1.9
00
0C
69
Ey
e0
00
00
01
2.7
0.4
00
0C
70
-C7
2B
rain
, n
erv
ou
s s
ys
tem
47
.03
47
.02
.82
5.4
11
20
.8C
73
Th
yro
id1
1.8
1.4
47
.05
.21
2.7
0.8
24
2.1
C7
4-C
75
Oth
er
en
do
cri
ne
00
00
00
00
00
00
C8
1H
od
gk
in's
dis
ea
se
11
.80
.63
5.3
20
00
24
0.8
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a7
12
.37
.58
14
.01
2.5
38
.12
.25
10
5.4
C8
8;C
90
Mu
ltip
le m
ye
lom
a0
00
00
00
00
00
0C
91
Lym
ph
oid
le
uk
ae
mia
11
.80
.63
5.3
3.3
00
03
62
.5C
92
My
elo
id l
eu
ka
em
ia4
7.0
4.5
35
.32
.42
5.4
1.3
36
2.3
C9
3M
on
oc
ytic
le
uk
ae
mia
00
00
00
00
00
00
C9
4O
the
r le
uk
ae
mia
00
00
00
00
00
00
C9
5L
eu
ka
em
ia u
ns
pe
c.
00
00
00
00
00
00
Oth
er
& u
ns
pe
cif
ied
23
.51
.20
00
41
0.8
8.5
61
28
.8
All
sit
es
57
10
06
6.1
57
10
06
6.4
37
10
05
4.1
50
10
05
6.3
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-
2-3
Age
Sta
ndar
ized
Rat
es a
nd R
elat
ive
Freq
uenc
ies f
or A
ll C
ance
r C
ases
am
ong
Saud
is b
y Si
te a
nd S
ex, E
aste
rn R
egio
n, 1
999-
2000
97
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
10
.20
.11
0.3
0.1
00
0C
01
-C0
2T
on
gu
e4
0.9
0.8
51
.10
.91
0.3
0.2
30
.60
.8C
07
-C0
8S
aliv
ary
gla
nd
10
.20
.12
0.4
0.5
20
.50
.32
0.4
0.2
C0
3-C
06
Mo
uth
81
.91
.42
0.4
0.4
41
.01
.53
0.6
0.5
C0
9-C
10
Oro
ph
ary
nx
00
00
00
00
00
00
C1
1N
as
op
ha
ryn
x2
04
.73
.95
1.1
0.8
41
.00
.64
0.8
0.7
C1
2-C
13
Hyp
op
ha
ryn
x1
0.2
0.2
00
04
1.0
0.6
30
.60
.9C
14
Ph
ary
nx
un
sp
ec
.0
00
00
00
00
00
0C
15
Oe
so
ph
ag
us
10
.20
.57
1.5
1.5
82
.02
.59
1.9
2.3
C1
6S
tom
ac
h1
43
.33
.11
63
.43
.11
12
.82
.37
1.5
1.6
C1
7S
ma
ll in
tes
tin
e0
00
30
.60
.70
00
00
0C
18
Co
lon
23
5.4
5.3
17
3.6
4.1
13
3.3
3.1
14
3.0
2.7
C1
9-C
21
Re
ctu
m2
04
.75
.42
14
.54
.71
02
.52
.31
22
.52
.7C
22
Liv
er
13
3.1
2.9
23
4.9
5.1
51
.31
.12
0.4
0.4
C2
3-C
24
Ga
llbla
dd
er
etc
.5
1.2
12
0.4
0.5
61
.51
.75
1.1
1.3
C2
5P
an
cre
as
40
.90
.87
1.5
1.6
41
.01
40
.80
.9C
30
-C3
1N
os
e,
sin
us
es
etc
.4
0.9
0.4
10
.20
.21
0.3
0.2
10
.20
.3C
32
La
ryn
x6
1.4
1.6
18
3.8
3.9
30
.80
.72
0.4
0.4
C3
3-C
34
Bro
nc
hu
s,
lun
g3
99
.29
.45
01
0.7
10
.73
0.8
1.1
13
2.8
3.5
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s2
0.5
0.3
10
.20
.21
0.3
0.1
10
.20
.1C
40
-C4
1B
on
e9
2.1
0.7
61
.30
.64
1.0
0.3
40
.80
.3C
47
;C4
9C
on
ne
cti
ve
tis
su
e1
74
.02
.98
1.7
1.2
92
.31
.67
1.5
0.9
C4
5M
es
oth
elio
ma
00
00
00
10
.30
.20
00
C4
6K
ap
os
i's s
arc
om
a1
0.2
0.1
10
.20
.20
00
00
0C
43
Me
lan
om
a o
f s
kin
00
03
0.6
0.6
10
.30
.21
0.2
0.1
C4
4O
the
r s
kin
17
4.0
3.4
18
3.8
3.1
51
.31
.21
12
.32
.1C
50
Bre
as
t2
0.5
0.3
20
.40
.5-
--
--
-C
61
Pro
sta
te1
84
.24
.13
77
.97
.7-
--
--
-C
62
Te
sti
s5
1.2
19
1.9
1.3
--
--
--
C6
0P
en
is0
00
00
0-
--
--
-C
63
Oth
er
ma
le g
en
ita
l1
0.2
0.1
00
0-
--
--
-C
50
Bre
as
t-
--
--
-1
03
26
.21
9.9
12
62
6.8
22
.5C
55
Ute
rus
un
sp
ec
.-
--
--
-0
00
00
0C
53
Ce
rvix
ute
ri-
--
--
-1
64
.13
.21
32
.82
.2C
58
Pla
ce
nta
--
--
--
20
.50
.32
0.4
0.3
C5
4C
orp
us
ute
ri-
--
--
-1
12
.83
.21
63
.43
.8C
56
Ov
ary
etc
.-
--
--
-1
12
.81
.91
73
.62
.9C
51
-C5
2;C
57
Oth
er
fem
ale
ge
nit
al
--
--
--
20
.50
.63
0.6
0.8
C6
7B
lad
de
r1
84
.24
.13
88
.18
.17
1.8
1.7
10
2.1
2.5
C6
4-C
66
;C6
8K
idn
ey
etc
.1
63
.82
.61
53
.22
.31
12
.82
.57
1.5
1.2
C6
9E
ye
10
.20
.23
0.6
0.2
20
.50
.14
0.8
0.3
C7
0-C
72
Bra
in,
ne
rvo
us
sy
ste
m2
04
.72
.12
04
.32
.11
23
.11
.71
83
.82
.2C
73
Th
yro
id1
33
.12
.31
32
.81
.74
21
0.7
5.4
45
9.6
5.3
C7
4-C
75
Oth
er
en
do
cri
ne
40
.90
.23
0.6
0.4
10
.30
.12
0.4
0.4
C8
1H
od
gk
in's
dis
ea
se
31
7.3
3.3
19
4.1
1.8
14
3.6
1.3
21
4.5
2.2
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a3
68
.56
.83
37
.05
.72
15
.34
.83
26
.85
.8C
88
;C9
0M
ult
iple
my
elo
ma
10
.20
.35
1.1
0.8
30
.80
.84
0.8
1.1
C9
1L
ymp
ho
id l
eu
ka
em
ia2
14
.92
.32
45
.12
.41
02
.50
.61
22
.51
.8C
92
My
elo
id l
eu
ka
em
ia1
22
.81
14
3.0
1.9
92
.31
.51
94
.02
.1C
93
Mo
no
cyt
ic l
eu
ka
em
ia1
0.2
0.5
30
.60
.60
00
10
.20
.2C
94
Oth
er
leu
ka
em
ia0
00
00
00
00
00
0C
95
Le
uk
ae
mia
un
sp
ec
.1
0.2
0.1
10
.20
.11
0.3
0.2
10
.20
.3O
the
r &
un
sp
ec
ifie
d1
63
.83
13
2.8
2.6
14
3.6
2.8
10
2.1
2
All
sit
es
42
61
00
78
.34
69
10
08
4.8
39
31
00
75
.84
71
10
08
2.4
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-2
-4 A
ge S
tand
ariz
ed R
ates
and
Rel
ativ
e Fre
quen
cies
for A
ll C
ance
r Cas
es a
mon
g Sa
udis
by S
ite a
nd S
ex, M
akka
h R
egio
n, 1
999-
2000
98
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
00
00
00
20
.30
.2C
01
-C0
2T
on
gu
e5
0.8
0.5
61
.00
.62
0.3
0.3
20
.30
.2C
07
-C0
8S
aliv
ary
gla
nd
30
.50
.31
0.2
0.1
20
.30
.14
0.7
0.3
C0
3-C
06
Mo
uth
61
.00
.63
0.5
0.3
40
.60
.55
0.8
0.7
C0
9-C
10
Oro
ph
ary
nx
30
.50
.30
00
10
.20
.11
0.2
0.1
C1
1N
as
op
ha
ryn
x1
93
.11
.92
23
.72
.16
0.9
0.6
50
.80
.5C
12
-C1
3H
ypo
ph
ary
nx
20
.30
.12
0.3
0.2
50
.80
.52
0.3
0.2
C1
4P
ha
ryn
x u
ns
pe
c.
00
00
00
00
00
00
C1
5O
es
op
ha
gu
s1
62
.61
.41
22
.01
.31
01
.61
.31
11
.81
.4C
16
Sto
ma
ch
26
4.2
2.7
22
3.7
2.2
11
1.7
1.1
11
1.8
1.2
C1
7S
ma
ll in
tes
tin
e1
0.2
0.2
00
03
0.5
0.4
30
.50
.3C
18
Co
lon
22
3.6
2.5
23
3.9
2.3
24
3.8
2.3
20
3.3
2.1
C1
9-C
21
Re
ctu
m1
82
.92
.12
54
.22
.62
13
.32
.11
72
.81
.8C
22
Liv
er
43
7.0
4.5
52
8.7
5.4
15
2.3
1.6
28
4.6
3C
23
-C2
4G
allb
lad
de
r e
tc.
50
.80
.53
0.5
0.3
12
1.9
1.5
50
.80
.6C
25
Pa
nc
rea
s1
11
.81
.11
42
.31
.48
1.3
13
0.5
0.4
C3
0-C
31
No
se
, s
inu
se
s e
tc.
30
.50
.22
0.3
0.1
30
.50
.21
0.2
0.1
C3
2L
ary
nx
15
2.5
1.5
12
2.0
1.3
20
.30
.22
0.3
0.2
C3
3-C
34
Bro
nc
hu
s,
lun
g4
26
.94
.64
98
.25
.51
93
.02
.21
42
.31
.5C
37
-C3
8O
the
r T
ho
rac
ic o
rga
ns
20
.30
.20
00
00
01
0.2
0.1
C4
0-C
41
Bo
ne
91
.50
.67
1.2
0.5
60
.90
.37
1.1
0.3
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
91
.50
.61
11
.80
.81
11
.71
12
2.0
1C
45
Me
so
the
liom
a0
00
40
.70
.42
0.3
0.3
00
0C
46
Ka
po
si's
sa
rco
ma
30
.50
.29
1.5
0.9
30
.50
.41
0.2
0.1
C4
3M
ela
no
ma
of
sk
in2
0.3
0.3
00
01
0.2
0.1
50
.80
.4C
44
Oth
er
sk
in1
93
.12
21
3.5
1.8
13
2.0
1.4
17
2.8
1.5
C5
0B
rea
st
20
.30
.22
0.3
0.2
--
--
--
C6
1P
ros
tate
36
5.9
3.7
35
5.9
3.4
--
--
--
C6
2T
es
tis
81
.30
.76
1.0
0.5
--
--
--
C6
0P
en
is0
00
00
0-
--
--
-C
63
Oth
er
ma
le g
en
ita
l0
00
00
0-
--
--
-C
50
Bre
as
t-
--
--
-1
65
25
.81
6.9
16
92
7.6
15
.8C
55
Ute
rus
un
sp
ec
.-
--
--
-5
0.8
0.6
10
.20
.1C
53
Ce
rvix
ute
ri-
--
--
-2
43
.82
.62
33
.82
.7C
58
Pla
ce
nta
--
--
--
00
02
0.3
0.2
C5
4C
orp
us
ute
ri-
--
--
-1
32
.01
.42
43
.92
.9C
56
Ov
ary
etc
.-
--
--
-2
33
.62
.43
04
.92
.7C
51
-C5
2;C
57
Oth
er
fem
ale
ge
nit
al
--
--
--
10
.20
.22
0.3
0.2
C6
7B
lad
de
r4
26
.94
32
5.4
3.2
91
.41
71
.10
.8C
64
-C6
6;C
68
Kid
ne
y e
tc.
14
2.3
1.1
12
2.0
18
1.3
0.7
81
.30
.5C
69
Ey
e3
0.5
0.1
50
.80
.30
00
40
.70
.5C
70
-C7
2B
rain
, n
erv
ou
s s
ys
tem
16
2.6
1.3
30
5.0
2.1
14
2.2
11
82
.91
.2C
73
Th
yro
id1
22
.01
.19
1.5
0.8
54
8.5
4.2
34
5.5
2.6
C7
4-C
75
Oth
er
en
do
cri
ne
10
.20
.11
0.2
0.1
10
.20
40
.70
.2C
81
Ho
dg
kin
's d
ise
as
e2
84
.61
.72
64
.41
.71
32
.01
11
1.8
0.6
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a6
61
0.8
6.7
53
8.9
4.7
44
6.9
4.4
32
5.2
2.8
C8
8;C
90
Mu
ltip
le m
ye
lom
a9
1.5
1.2
50
.80
.59
1.4
1.1
40
.70
.5C
91
Lym
ph
oid
le
uk
ae
mia
29
4.7
1.5
30
5.0
1.6
17
2.7
1.2
17
2.8
0.9
C9
2M
ye
loid
le
uk
ae
mia
26
4.2
1.9
13
2.2
1.1
22
3.4
1.8
17
2.8
1.2
C9
3M
on
oc
ytic
le
uk
ae
mia
10
.20
10
.20
.11
0.2
0.1
00
0C
94
Oth
er
leu
ka
em
ia0
00
00
00
00
00
0C
95
Le
uk
ae
mia
un
sp
ec
.2
0.3
0.2
10
.16
75
00
00
20
.30
.1O
the
r &
un
sp
ec
ifie
d3
35
.43
.33
66
.03
.23
25
.03
.52
54
.12
.6
All
sit
es
61
21
00
57
.85
97
10
05
4.9
63
91
00
63
.66
13
10
05
7.1
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-
2-5
Age
Sta
ndar
ized
Rat
es a
nd R
elat
ive
Freq
uenc
ies f
or A
ll C
ases
am
ong
Saud
is b
y Si
te a
nd S
ex, N
orth
ern
Reg
ion,
199
9-20
00
99
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
00
00
00
00
0C
01
-C0
2T
on
gu
e0
00
00
01
5.3
15
.81
50
.9C
07
-C0
8S
aliv
ary
gla
nd
00
00
00
00
00
00
C0
3-C
06
Mo
uth
00
00
00
00
00
00
C0
9-C
10
Oro
ph
ary
nx
00
00
00
00
00
00
C1
1N
as
op
ha
ryn
x3
8.6
6.7
21
4.3
3.3
00
01
52
.2C
12
-C1
3H
ypo
ph
ary
nx
00
00
00
00
00
00
C1
4P
ha
ryn
x u
ns
pe
c.
00
00
00
00
00
00
C1
5O
es
op
ha
gu
s0
00
00
00
00
00
0C
16
Sto
ma
ch
00
00
00
15
.33
.60
00
C1
7S
ma
ll in
tes
tin
e0
00
00
00
00
00
0C
18
Co
lon
25
.73
.80
00
00
00
00
C1
9-C
21
Re
ctu
m0
00
00
00
00
21
01
1.7
C2
2L
ive
r1
2.9
2.2
17
.11
.80
00
21
04
C2
3-C
24
Ga
llbla
dd
er
etc
.0
00
00
00
00
00
0C
25
Pa
nc
rea
s1
2.9
1.4
00
01
5.3
1.9
31
51
1.4
C3
0-C
31
No
se
, s
inu
se
s e
tc.
12
.92
.40
00
00
00
00
C3
2L
ary
nx
41
1.4
8.7
00
00
00
00
0C
33
-C3
4B
ron
ch
us
, lu
ng
12
.91
.83
21
.47
.91
5.3
1.8
15
2.2
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s0
00
00
00
00
00
0C
40
-C4
1B
on
e2
5.7
3.8
00
00
00
00
0C
47
;C4
9C
on
ne
cti
ve
tis
su
e0
00
00
00
00
15
0.6
C4
5M
es
oth
elio
ma
00
00
00
00
00
00
C4
6K
ap
os
i's s
arc
om
a0
00
00
00
00
00
0C
43
Me
lan
om
a o
f s
kin
00
00
00
00
00
00
C4
4O
the
r s
kin
00
01
7.1
3.8
00
00
00
C5
0B
rea
st
00
00
00
--
--
--
C6
1P
ros
tate
12
.91
.80
00
--
--
--
C6
2T
es
tis
00
01
7.1
1-
--
--
-C
60
Pe
nis
00
00
00
--
--
--
C6
3O
the
r m
ale
ge
nit
al
00
00
00
--
--
--
C5
0B
rea
st
--
--
--
52
6.3
13
.33
15
4.7
C5
5U
teru
s u
ns
pe
c.
--
--
--
00
00
00
C5
3C
erv
ix u
teri
--
--
--
00
00
00
C5
8P
lac
en
ta-
--
--
-0
00
00
0C
54
Co
rpu
s u
teri
--
--
--
15
.31
.90
00
C5
6O
va
ry e
tc.
--
--
--
00
00
00
C5
1-C
52
;C5
7O
the
r fe
ma
le g
en
ita
l-
--
--
-0
00
00
0C
67
Bla
dd
er
25
.74
00
01
5.3
15
.81
51
.7C
64
-C6
6;C
68
Kid
ne
y e
tc.
12
.92
.71
7.1
3.8
00
01
50
.6C
69
Ey
e0
00
00
00
00
00
0C
70
-C7
2B
rain
, n
erv
ou
s s
ys
tem
38
.67
.81
7.1
1.4
00
00
00
C7
3T
hy
roid
00
01
7.1
0.6
42
1.1
6.4
15
1.1
C7
4-C
75
Oth
er
en
do
cri
ne
00
00
00
00
00
00
C8
1H
od
gk
in's
dis
ea
se
00
00
00
00
01
50
.7C
82
-C8
5;C
96
No
n-H
od
gk
in l
ymp
ho
ma
51
4.3
9.4
17
.10
.92
10
.51
10
00
C8
8;C
90
Mu
ltip
le m
ye
lom
a0
00
00
00
00
00
0C
91
Lym
ph
oid
le
uk
ae
mia
12
.90
.80
00
15
.30
.71
50
.6C
92
My
elo
id l
eu
ka
em
ia4
11
.43
.81
7.1
2.4
15
.31
.81
51
.1C
93
Mo
no
cyt
ic l
eu
ka
em
ia0
00
00
00
00
00
0C
94
Oth
er
leu
ka
em
ia0
00
00
00
00
00
0C
95
Le
uk
ae
mia
un
sp
ec
.0
00
00
00
00
00
0O
the
r &
un
sp
ec
ifie
d3
8.6
61
7.1
1.4
00
00
00
All
sit
es
35
10
06
71
41
00
28
.31
91
00
73
.72
01
00
43
.5
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-
2-6
Age
Sta
ndar
ized
Rat
es a
nd R
elat
ive
Freq
uenc
ies f
or A
ll C
ance
r C
ases
am
ong
Saud
is b
y Si
te a
nd S
ex, Q
assi
m R
egio
n, 1
999-
2000
100
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip1
0.8
0.3
10
.60
.41
0.7
0.9
10
.70
.4C
01
-C0
2T
on
gu
e0
00
31
.81
.11
0.7
0.5
00
0C
07
-C0
8S
aliv
ary
gla
nd
00
00
00
00
01
0.7
0.3
C0
3-C
06
Mo
uth
10
.80
.81
0.6
0.6
21
.41
.20
00
C0
9-C
10
Oro
ph
ary
nx
00
00
00
00
00
00
C1
1N
as
op
ha
ryn
x1
21
0.1
6.9
15
9.2
6.6
42
.81
.71
0.7
0.4
C1
2-C
13
Hyp
op
ha
ryn
x0
00
00
01
0.7
0.5
00
0C
14
Ph
ary
nx
un
sp
ec
.0
00
00
00
00
00
0C
15
Oe
so
ph
ag
us
65
.02
.59
5.5
33
2.1
1.8
42
.92
.6C
16
Sto
ma
ch
86
.73
.11
16
.73
.63
2.1
1.9
21
.41
.2C
17
Sm
all
inte
sti
ne
00
01
0.6
0.3
00
00
00
C1
8C
olo
n1
0.8
0.3
21
.21
53
.52
.68
5.7
3.8
C1
9-C
21
Re
ctu
m5
4.2
2.4
63
.73
.93
2.1
1.2
75
5.3
C2
2L
ive
r1
31
0.9
6.8
13
8.0
53
2.1
1.2
32
.12
.6C
23
-C2
4G
allb
lad
de
r e
tc.
10
.80
.33
1.8
1.1
53
.52
.71
0.7
0.7
C2
5P
an
cre
as
10
.80
.32
1.2
1.3
00
01
0.7
1.2
C3
0-C
31
No
se
, s
inu
se
s e
tc.
00
00
00
00
00
00
C3
2L
ary
nx
21
.71
.22
1.2
0.8
00
00
00
C3
3-C
34
Bro
nc
hu
s,
lun
g5
4.2
1.8
53
.12
.42
1.4
11
0.7
14
29
1.2
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s0
00
00
00
00
00
0C
40
-C4
1B
on
e2
1.7
0.8
31
.80
.60
00
10
.70
.2C
47
;C4
9C
on
ne
cti
ve
tis
su
e0
00
21
.20
.51
0.7
0.5
32
.11
.1C
45
Me
so
the
liom
a0
00
00
00
00
00
0C
46
Ka
po
si's
sa
rco
ma
10
.80
.30
00
00
00
00
C4
3M
ela
no
ma
of
sk
in0
00
00
01
0.7
0.4
00
0C
44
Oth
er
sk
in2
1.7
0.8
74
.32
.12
1.4
0.8
64
.34
.1C
50
Bre
as
t0
00
00
0-
--
--
-C
61
Pro
sta
te1
0.8
0.3
84
.92
.8-
--
--
-C
62
Te
sti
s1
0.8
0.3
21
.20
.5-
--
--
-C
60
Pe
nis
00
00
00
--
--
--
C6
3O
the
r m
ale
ge
nit
al
00
00
00
--
--
--
C5
0B
rea
st
--
--
--
16
11
.26
.72
41
7.1
9.7
C5
5U
teru
s u
ns
pe
c.
--
--
--
10
.70
.42
1.4
1.1
C5
3C
erv
ix u
teri
--
--
--
32
.11
.56
4.3
3.2
C5
8P
lac
en
ta-
--
--
-1
0.7
0.2
00
0C
54
Co
rpu
s u
teri
--
--
--
53
.52
.65
3.6
2.9
C5
6O
va
ry e
tc.
--
--
--
96
.33
.54
2.9
1.5
C5
1-C
52
;C5
7O
the
r fe
ma
le g
en
ita
l-
--
--
-0
00
00
0C
67
Bla
dd
er
43
.41
.63
1.8
10
00
00
0C
64
-C6
6;C
68
Kid
ne
y e
tc.
32
.51
.14
2.5
2.5
42
.81
.42
1.4
0.6
C6
9E
ye
10
.80
.21
0.6
0.2
00
01
0.7
0.6
C7
0-C
72
Bra
in,
ne
rvo
us
sy
ste
m1
08
.44
.24
2.5
1.6
32
.10
.84
2.9
1.5
C7
3T
hy
roid
32
.51
.16
3.7
1.8
21
14
.78
.11
51
0.7
6.3
C7
4-C
75
Oth
er
en
do
cri
ne
00
00
00
00
01
0.7
0.2
C8
1H
od
gk
in's
dis
ea
se
65
.01
.71
06
.12
.17
4.9
1.8
64
.31
.8C
82
-C8
5;C
96
No
n-H
od
gk
in l
ymp
ho
ma
43
.41
.61
48
.64
.49
6.3
3.9
11
7.9
6.1
C8
8;C
90
Mu
ltip
le m
ye
lom
a2
1.7
0.6
21
.20
.71
0.7
0.9
42
.92
.9C
91
Lym
ph
oid
le
uk
ae
mia
86
.72
.16
3.7
2.1
12
8.4
2.5
42
.90
.9C
92
My
elo
id l
eu
ka
em
ia6
5.0
27
4.3
2.6
53
.52
.31
0.7
0.3
C9
3M
on
oc
ytic
le
uk
ae
mia
00
00
00
00
00
00
C9
4O
the
r le
uk
ae
mia
00
00
00
00
00
00
C9
5L
eu
ka
em
ia u
ns
pe
c.
00
00
00
00
00
00
Oth
er
& u
ns
pe
cif
ied
97
.65
.41
06
.15
96
.35
10
7.1
5.1
All
sit
es
11
91
00
50
.81
63
10
06
1.5
14
31
00
60
.41
40
10
06
9.6
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-
2-7
Age
Sta
ndar
ized
Rat
es a
nd R
elat
ive
Freq
uenc
ies f
or A
ll C
ance
r C
ases
am
ong
Saud
is b
y Si
te a
nd S
ex, J
azan
Reg
ion,
199
9-20
00
101
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
00
02
2.0
0.6
11
.00
.3C
01
-C0
2T
on
gu
e6
5.8
1.6
10
.90
.49
8.9
3.9
54
.91
.4C
07
-C0
8S
aliv
ary
gla
nd
00
00
00
00
00
00
C0
3-C
06
Mo
uth
54
.81
.66
5.4
1.3
18
17
.87
.71
21
1.8
3.7
C0
9-C
10
Oro
ph
ary
nx
11
.00
.60
00
00
00
00
C1
1N
as
op
ha
ryn
x1
1.0
0.6
21
.80
.40
00
00
0C
12
-C1
3H
ypo
ph
ary
nx
00
00
00
11
.00
.41
1.0
0.3
C1
4P
ha
ryn
x u
ns
pe
c.
00
00
00
00
00
00
C1
5O
es
op
ha
gu
s0
00
00
05
5.0
1.5
11
.00
.3C
16
Sto
ma
ch
21
.90
.72
1.8
0.3
00
01
1.0
0.3
C1
7S
ma
ll in
tes
tin
e0
00
00
00
00
11
.00
.3C
18
Co
lon
11
.00
.24
3.6
03
61
00
06
5.9
2C
19
-C2
1R
ec
tum
32
.91
.43
2.7
1.2
22
.00
.63
2.9
1C
22
Liv
er
12
11
.54
13
11
.73
.72
2.0
0.8
87
.82
.6C
23
-C2
4G
allb
lad
de
r e
tc.
21
.90
.63
2.7
1.1
11
.00
.54
3.9
1.3
C2
5P
an
cre
as
00
01
0.9
0.4
00
00
00
C3
0-C
31
No
se
, s
inu
se
s e
tc.
11
.00
.61
0.9
0.4
00
00
00
C3
2L
ary
nx
43
.81
.72
1.8
0.8
22
.00
.80
00
C3
3-C
34
Bro
nc
hu
s,
lun
g5
4.8
21
0.9
0.2
00
00
00
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s2
1.9
0.5
00
00
00
22
.00
.8C
40
-C4
1B
on
e1
1.0
0.1
43
.60
.61
1.0
0.1
11
.00
.1C
47
;C4
9C
on
ne
cti
ve
tis
su
e2
1.9
0.3
43
.60
.90
00
11
.00
.2C
45
Me
so
the
liom
a0
00
00
00
00
00
0C
46
Ka
po
si's
sa
rco
ma
00
00
00
00
00
00
C4
3M
ela
no
ma
of
sk
in1
1.0
0.3
00
01
1.0
0.3
00
0C
44
Oth
er
sk
in4
3.8
1.5
87
.21
.65
5.0
2.3
87
.82
.3C
50
Bre
as
t0
00
10
.90
.4-
--
--
-C
61
Pro
sta
te4
3.8
0.8
54
.51
.5-
--
--
-C
62
Te
sti
s1
1.0
0.5
21
.80
.7-
--
--
-C
60
Pe
nis
00
01
0.9
0.4
--
--
--
C6
3O
the
r m
ale
ge
nit
al
00
01
0.9
0.4
--
--
--
C5
0B
rea
st
--
--
--
10
9.9
4.3
87
.82
.5C
55
Ute
rus
un
sp
ec
.-
--
--
-1
1.0
0.4
00
0C
53
Ce
rvix
ute
ri-
--
--
-2
2.0
0.9
32
.90
.7C
58
Pla
ce
nta
--
--
--
00
00
00
C5
4C
orp
us
ute
ri-
--
--
-1
1.0
0.4
11
.00
.3C
56
Ov
ary
etc
.-
--
--
-4
4.0
1.1
54
.91
.4C
51
-C5
2;C
57
Oth
er
fem
ale
ge
nit
al
--
--
--
00
00
00
C6
7B
lad
de
r1
11
0.6
3.5
43
.61
.33
3.0
1.4
32
.90
.9C
64
-C6
6;C
68
Kid
ne
y e
tc.
11
.00
.20
00
22
.00
.41
1.0
0.3
C6
9E
ye
11
.00
.13
2.7
0.8
22
.00
.52
2.0
0.5
C7
0-C
72
Bra
in,
ne
rvo
us
sy
ste
m5
4.8
1.6
54
.51
.44
4.0
0.9
22
.00
.4C
73
Th
yro
id2
1.9
11
0.9
0.1
22
.00
.97
6.9
2C
74
-C7
5O
the
r e
nd
oc
rin
e2
1.9
0.5
21
.80
.41
1.0
0.1
00
0C
81
Ho
dg
kin
's d
ise
as
e4
3.8
0.7
54
.51
11
.00
.52
2.0
0.3
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a8
7.7
31
19
.92
.86
5.9
24
3.9
0.7
C8
8;C
90
Mu
ltip
le m
ye
lom
a0
00
00
00
00
00
0C
91
Lym
ph
oid
le
uk
ae
mia
76
.71
.16
5.4
0.9
33
.00
.62
2.0
0.5
C9
2M
ye
loid
le
uk
ae
mia
21
.90
.51
0.9
0.2
44
.01
.13
2.9
0.6
C9
3M
on
oc
ytic
le
uk
ae
mia
00
00
00
00
00
00
C9
4O
the
r le
uk
ae
mia
00
00
00
00
00
00
C9
5L
eu
ka
em
ia u
ns
pe
c.
00
00
00
00
01
1.0
0.1
Oth
er
& u
ns
pe
cif
ied
32
.91
.38
7.2
1.9
65
.92
32
.90
.9
All
sit
es
10
41
00
33
.21
11
10
02
8.3
10
11
00
37
.21
02
10
02
8.9
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-
2-8
Age
Sta
ndar
ized
Rat
es a
nd R
elat
ive
Freq
uenc
ies f
or A
ll C
ance
r C
ases
am
ong
Saud
is b
y Si
te a
nd S
ex, H
ail R
egio
n, 1
999-
2000
102
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
00
00
00
00
0C
01
-C0
2T
on
gu
e0
00
00
01
1.3
0.8
00
0C
07
-C0
8S
aliv
ary
gla
nd
11
.61
11
.30
.50
00
00
0C
03
-C0
6M
ou
th0
00
00
00
00
00
0C
09
-C1
0O
rop
ha
ryn
x0
00
00
00
00
00
0C
11
Na
so
ph
ary
nx
23
.31
.47
9.0
54
53
.30
00
C1
2-C
13
Hyp
op
ha
ryn
x1
1.6
0.7
00
01
1.3
0.9
00
0C
14
Ph
ary
nx
un
sp
ec
.0
00
00
00
00
00
0C
15
Oe
so
ph
ag
us
00
04
5.1
3.7
00
00
00
C1
6S
tom
ac
h1
1.6
0.6
33
.82
.92
2.5
1.7
00
0C
17
Sm
all
inte
sti
ne
00
00
00
11
.30
.91
2.1
0.7
C1
8C
olo
n3
4.9
2.6
45
.13
.43
3.8
2.9
36
.32
.3C
19
-C2
1R
ec
tum
00
02
2.6
1.8
00
01
2.1
0.6
C2
2L
ive
r3
4.9
25
6.4
4.4
11
.31
.72
4.2
2.1
C2
3-C
24
Ga
llbla
dd
er
etc
.0
00
00
01
1.3
0.9
00
0C
25
Pa
nc
rea
s2
3.3
1.6
33
.83
33
.83
.60
00
C3
0-C
31
No
se
, s
inu
se
s e
tc.
00
00
00
11
.31
00
0C
32
La
ryn
x2
3.3
1.2
11
.30
.60
00
00
0C
33
-C3
4B
ron
ch
us
, lu
ng
23
.31
.54
5.1
3.4
11
.30
.90
00
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s0
00
00
00
00
00
0C
40
-C4
1B
on
e4
6.6
1.2
33
.81
.21
1.3
0.3
24
.20
.6C
47
;C4
9C
on
ne
cti
ve
tis
su
e3
4.9
1.6
22
.61
.61
1.3
0.6
24
.21
.2C
45
Me
so
the
liom
a1
1.6
10
00
00
.00
00
0C
46
Ka
po
si's
sa
rco
ma
00
01
1.3
0.4
00
00
00
C4
3M
ela
no
ma
of
sk
in1
1.6
1.5
00
01
1.3
0.8
00
0C
44
Oth
er
sk
in3
4.9
1.8
11
.30
.92
2.5
1.7
36
.32
.1C
50
Bre
as
t0
00
00
0-
--
--
-C
61
Pro
sta
te3
4.9
2.1
33
.81
.3-
--
--
-C
62
Te
sti
s0
00
33
.82
--
--
--
C6
0P
en
is0
00
00
0-
--
--
-C
63
Oth
er
ma
le g
en
ita
l0
00
00
0-
--
--
-C
50
Bre
as
t-
--
--
-1
01
2.5
9.2
13
27
.19
.5C
55
Ute
rus
un
sp
ec
.-
--
--
-0
00
00
0C
53
Ce
rvix
ute
ri-
--
--
-2
2.5
2.1
00
0C
58
Pla
ce
nta
--
--
--
22
.51
.51
2.1
0.7
C5
4C
orp
us
ute
ri-
--
--
-1
1.3
0.4
00
0C
56
Ov
ary
etc
.-
--
--
-2
2.5
1.5
24
.21
.4C
51
-C5
2;C
57
Oth
er
fem
ale
ge
nit
al
--
--
--
00
00
00
C6
7B
lad
de
r1
1.6
13
3.8
2.3
00
00
00
C6
4-C
66
;C6
8K
idn
ey
etc
.2
3.3
1.3
33
.83
.31
1.3
0.7
12
.10
.7C
69
Ey
e0
00
00
00
00
00
0C
70
-C7
2B
rain
, n
erv
ou
s s
ys
tem
11
.60
.33
3.8
1.5
56
.35
.12
4.2
0.7
C7
3T
hy
roid
34
.92
.51
1.3
0.5
19
23
.81
3.5
51
0.4
2.6
C7
4-C
75
Oth
er
en
do
cri
ne
00
01
1.3
0.3
11
.30
.40
00
C8
1H
od
gk
in's
dis
ea
se
46
.61
.85
6.4
3.4
33
.81
24
.20
.6C
82
-C8
5;C
96
No
n-H
od
gk
in l
ymp
ho
ma
58
.24
.29
11
.56
.32
2.5
0.9
36
.33
.4C
88
;C9
0M
ult
iple
my
elo
ma
11
.60
.61
1.3
0.8
00
00
00
C9
1L
ymp
ho
id l
eu
ka
em
ia7
11
.53
.43
3.8
1.6
00
02
4.2
0.7
C9
2M
ye
loid
le
uk
ae
mia
11
.60
.71
1.3
0.5
33
.81
.71
2.1
0.7
C9
3M
on
oc
ytic
le
uk
ae
mia
00
00
00
00
00
00
C9
4O
the
r le
uk
ae
mia
00
00
00
00
00
00
C9
5L
eu
ka
em
ia u
ns
pe
c.
00
00
00
00
00
00
Oth
er
& u
ns
pe
cif
ied
46
.63
.31
1.3
1.2
56
.34
.72
4.2
1.6
All
sit
es
61
10
04
0.8
78
10
05
7.9
80
10
06
4.4
48
10
03
2.1
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-
2-9
Age
Sta
ndar
ized
Rat
es a
nd R
elat
ive
Freq
uenc
ies f
or A
ll C
ance
r C
ases
am
ong
Saud
is b
y Si
te a
nd S
ex, M
adin
ah R
egio
n, 1
999-
2000
103
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
00
01
0.5
0.5
00
0C
01
-C0
2T
on
gu
e3
1.4
0.8
10
.70
.43
1.5
1.7
10
.60
.6C
07
-C0
8S
aliv
ary
gla
nd
00
01
0.7
0.1
00
00
00
C0
3-C
06
Mo
uth
10
.50
.50
00
21
.01
.11
0.6
0.5
C0
9-C
10
Oro
ph
ary
nx
00
00
00
00
00
00
C1
1N
as
op
ha
ryn
x7
3.3
26
4.2
2.3
21
.00
.30
00
C1
2-C
13
Hyp
op
ha
ryn
x0
00
00
01
0.5
0.4
21
.10
.7C
14
Ph
ary
nx
un
sp
ec
.0
00
00
00
00
10
.60
.6C
15
Oe
so
ph
ag
us
31
.41
10
.70
.44
2.1
1.9
42
.31
.6C
16
Sto
ma
ch
73
.32
.35
3.5
1.5
42
.12
.11
0.6
0.5
C1
7S
ma
ll in
tes
tin
e4
1.9
1.8
10
.70
.40
00
00
0C
18
Co
lon
52
.31
.64
2.8
1.4
84
.13
.45
2.8
2C
19
-C2
1R
ec
tum
12
5.6
4.2
32
.10
.84
2.1
1.7
52
.81
.9C
22
Liv
er
23
10
.77
.71
71
2.0
5.5
10
5.1
5.1
95
.13
.9C
23
-C2
4G
allb
lad
de
r e
tc.
20
.90
.70
00
31
.51
.31
0.6
0.4
C2
5P
an
cre
as
73
.32
.35
3.5
13
1.5
1.5
31
.71
.1C
30
-C3
1N
os
e,
sin
us
es
etc
.1
0.5
0.3
00
00
00
00
0C
32
La
ryn
x1
0.5
0.3
21
.40
.60
00
00
0C
33
-C3
4B
ron
ch
us
, lu
ng
21
9.8
7.4
64
.22
42
.11
.83
1.7
1.5
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s1
0.5
0.3
00
00
00
21
.10
.8C
40
-C4
1B
on
e2
0.9
0.6
10
.70
.21
05
.11
.92
1.1
0.3
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
52
.31
.14
2.8
0.7
31
.51
.31
0.6
0.1
C4
5M
es
oth
elio
ma
00
00
00
00
00
00
C4
6K
ap
os
i's s
arc
om
a0
00
00
00
00
00
0C
43
Me
lan
om
a o
f s
kin
00
00
00
10
.50
.50
00
C4
4O
the
r s
kin
83
.72
.71
0.7
0.2
84
.14
.32
1.1
0.9
C5
0B
rea
st
00
00
00
--
--
--
C6
1P
ros
tate
73
.32
.43
2.1
1-
--
--
-C
62
Te
sti
s3
1.4
10
00
--
--
--
C6
0P
en
is0
00
00
0-
--
--
-C
63
Oth
er
ma
le g
en
ita
l0
00
00
0-
--
--
-C
50
Bre
as
t-
--
--
-4
42
2.6
15
.84
92
7.8
17
.9C
55
Ute
rus
un
sp
ec
.-
--
--
-0
00
00
0C
53
Ce
rvix
ute
ri-
--
--
-2
1.0
0.5
10
.60
.2C
58
Pla
ce
nta
--
--
--
21
.00
.40
00
C5
4C
orp
us
ute
ri-
--
--
-2
1.0
0.9
00
0C
56
Ov
ary
etc
.-
--
--
-5
2.6
1.2
95
.13
.9C
51
-C5
2;C
57
Oth
er
fem
ale
ge
nit
al
--
--
--
00
01
0.6
0.3
C6
7B
lad
de
r1
04
.73
.51
07
.03
.51
0.5
0.5
42
.31
.4C
64
-C6
6;C
68
Kid
ne
y e
tc.
83
.72
.87
4.9
1.8
52
.61
.75
2.8
1.9
C6
9E
ye
00
00
00
21
.00
.73
1.7
0.4
C7
0-C
72
Bra
in,
ne
rvo
us
sy
ste
m1
04
.72
10
7.0
2.6
73
.61
.14
2.3
0.8
C7
3T
hy
roid
62
.81
.64
2.8
1.3
11
5.6
31
05
.73
.1C
74
-C7
5O
the
r e
nd
oc
rin
e0
00
10
.70
.30
00
10
.60
.1C
81
Ho
dg
kin
's d
ise
as
e9
4.2
1.7
13
9.2
2.8
13
6.7
37
4.0
1.3
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a2
09
.35
.91
39
.22
.97
3.6
2.4
12
6.8
3.7
C8
8;C
90
Mu
ltip
le m
ye
lom
a2
0.9
0.8
21
.40
.61
0.5
0.5
63
.42
.7C
91
Lym
ph
oid
le
uk
ae
mia
10
4.7
31
28
.52
.25
2.6
0.8
84
.51
.5C
92
My
elo
id l
eu
ka
em
ia1
04
.72
.44
2.8
18
4.1
1.3
84
.52
.7C
93
Mo
no
cyt
ic l
eu
ka
em
ia0
00
00
00
00
00
0C
94
Oth
er
leu
ka
em
ia0
00
00
01
0.5
0.7
00
0C
95
Le
uk
ae
mia
un
sp
ec
.0
00
00
02
1.0
0.3
00
0O
the
r &
un
sp
ec
ifie
d7
3.3
25
3.5
1.2
63
.12
.15
2.8
1.5
All
sit
es
21
51
00
66
.71
42
10
03
8.5
19
51
00
67
.51
76
10
06
1
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-
2-10
Age
Sta
ndar
ized
Rat
es a
nd R
elat
ive
Freq
uenc
ies f
or A
ll C
ance
r C
ases
am
ong
Saud
is b
y Si
te a
nd S
ex, B
aha
Reg
ion,
199
9-20
00
104
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
00
00
00
00
0C
01
-C0
2T
on
gu
e0
00
00
00
00
00
0C
07
-C0
8S
aliv
ary
gla
nd
23
.81
.70
00
00
00
00
C0
3-C
06
Mo
uth
11
.90
.70
00
12
0.3
00
0C
09
-C1
0O
rop
ha
ryn
x0
00
00
00
00
00
0C
11
Na
so
ph
ary
nx
00
00
00
00
01
2.2
0.6
C1
2-C
13
Hyp
op
ha
ryn
x0
00
00
00
00
00
0C
14
Ph
ary
nx
un
sp
ec
.0
00
00
00
00
00
0C
15
Oe
so
ph
ag
us
11
.90
.30
00
47
.82
.12
4.3
0.9
C1
6S
tom
ac
h3
5.7
1.5
38
.31
.13
5.9
1.7
24
.30
.9C
17
Sm
all
inte
sti
ne
00
01
2.8
0.8
00
01
2.2
0.3
C1
8C
olo
n2
3.8
1.4
00
05
9.8
2.7
24
.30
.9C
19
-C2
1R
ec
tum
00
00
00
12
0.5
48
.72
.2C
22
Liv
er
71
3.2
5.9
12
.80
.84
7.8
1.5
00
0C
23
-C2
4G
allb
lad
de
r e
tc.
00
00
00
00
01
2.2
0.3
C2
5P
an
cre
as
11
.90
.50
00
12
0.7
00
0C
30
-C3
1N
os
e,
sin
us
es
etc
.0
00
00
00
00
12
.20
.6C
32
La
ryn
x0
00
00
00
00
00
0C
33
-C3
4B
ron
ch
us
, lu
ng
35
.72
.42
5.6
11
20
.80
00
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s0
00
00
00
00
00
0C
40
-C4
1B
on
e1
1.9
0.3
25
.61
.80
00
00
0C
47
;C4
9C
on
ne
cti
ve
tis
su
e0
00
00
01
20
.30
00
C4
5M
es
oth
elio
ma
00
00
00
00
01
2.2
0.6
C4
6K
ap
os
i's s
arc
om
a1
1.9
0.5
00
00
00
12
.20
.6C
43
Me
lan
om
a o
f s
kin
00
00
00
00
00
00
C4
4O
the
r s
kin
47
.51
.22
5.6
1.4
12
0.3
61
3.0
3.3
C5
0B
rea
st
00
01
2.8
0.3
--
--
--
C6
1P
ros
tate
35
.71
.10
00
--
--
--
C6
2T
es
tis
23
.81
.30
00
--
--
--
C6
0P
en
is0
00
00
0-
--
--
-C
63
Oth
er
ma
le g
en
ita
l0
00
00
0-
--
--
-C
50
Bre
as
t-
--
--
-1
01
9.6
5.1
24
.30
.9C
55
Ute
rus
un
sp
ec
.-
--
--
-0
00
00
0C
53
Ce
rvix
ute
ri-
--
--
-0
00
24
.31
.1C
58
Pla
ce
nta
--
--
--
00
00
00
C5
4C
orp
us
ute
ri-
--
--
-1
20
.53
6.5
1.7
C5
6O
va
ry e
tc.
--
--
--
12
0.3
00
0C
51
-C5
2;C
57
Oth
er
fem
ale
ge
nit
al
--
--
--
00
00
00
C6
7B
lad
de
r5
9.4
2.3
61
6.7
4.1
23
.91
.10
00
C6
4-C
66
;C6
8K
idn
ey
etc
.0
00
00
01
20
.40
00
C6
9E
ye
00
00
00
00
01
2.2
0.4
C7
0-C
72
Bra
in,
ne
rvo
us
sy
ste
m1
1.9
1.2
12
.80
.71
20
.52
4.3
1.1
C7
3T
hy
roid
00
03
8.3
2.1
35
.92
48
.71
.8C
74
-C7
5O
the
r e
nd
oc
rin
e0
00
00
01
20
.70
00
C8
1H
od
gk
in's
dis
ea
se
23
.81
.31
2.8
0.8
00
01
2.2
0.3
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a9
17
5.1
51
3.9
2.3
47
.82
.24
8.7
2C
88
;C9
0M
ult
iple
my
elo
ma
11
.90
.30
00
00
00
00
C9
1L
ymp
ho
id l
eu
ka
em
ia1
1.9
1.2
25
.60
.72
3.9
1.1
24
.30
.7C
92
My
elo
id l
eu
ka
em
ia1
1.9
0.5
41
1.1
3.3
00
01
2.2
0.8
C9
3M
on
oc
ytic
le
uk
ae
mia
00
00
00
12
0.6
00
0C
94
Oth
er
leu
ka
em
ia0
00
00
00
00
00
0C
95
Le
uk
ae
mia
un
sp
ec
.0
00
00
00
00
00
0O
the
r &
un
sp
ec
ifie
d2
3.8
1.4
25
.61
.42
3.9
1.3
24
.30
.7
All
sit
es
53
10
03
2.1
36
10
02
2.8
51
10
02
6.8
46
10
02
2.4
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-2
-11 A
ge S
tand
ariz
ed R
ates
and
Rel
ativ
e Fre
quen
cies
for A
ll C
ance
r Cas
es a
mon
g Sa
udis
by S
ite a
nd S
ex, T
abuk
Reg
ion,
199
9-20
00
105
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
11
.60
.90
00
00
0C
01
-C0
2T
on
gu
e0
00
11
.60
.70
00
12
.61
.8C
07
-C0
8S
aliv
ary
gla
nd
00
00
00
00
00
00
C0
3-C
06
Mo
uth
00
00
00
00
01
2.6
31
58
1.8
C0
9-C
10
Oro
ph
ary
nx
00
00
00
00
00
00
C1
1N
as
op
ha
ryn
x1
2.1
10
00
11
.80
.30
00
C1
2-C
13
Hyp
op
ha
ryn
x0
00
00
00
00
12
.61
.8C
14
Ph
ary
nx
un
sp
ec
.0
00
00
00
00
00
0C
15
Oe
so
ph
ag
us
12
.11
.43
4.8
4.5
23
.63
.50
00
C1
6S
tom
ac
h2
4.3
1.5
57
.95
.82
3.6
2.6
12
.61
.8C
17
Sm
all
inte
sti
ne
12
.11
.40
00
11
.81
.20
00
C1
8C
olo
n0
00
23
.21
.81
1.8
1.2
00
0C
19
-C2
1R
ec
tum
12
.11
.10
00
35
.42
.72
5.3
2.5
C2
2L
ive
r1
2.1
1.4
23
.22
.41
1.8
1.7
12
.61
.8C
23
-C2
4G
allb
lad
de
r e
tc.
24
.32
.40
00
00
01
2.6
0.4
C2
5P
an
cre
as
00
01
1.6
0.6
11
.81
.70
00
C3
0-C
31
No
se
, s
inu
se
s e
tc.
00
00
00
00
00
00
C3
2L
ary
nx
00
01
1.6
0.5
00
01
2.6
1.3
C3
3-C
34
Bro
nc
hu
s,
lun
g5
10
.64
.36
9.5
5.1
11
.81
.20
00
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s1
2.1
0.4
00
01
1.8
0.3
00
0C
40
-C4
1B
on
e1
2.1
0.2
57
.91
.50
00
00
0C
47
;C4
9C
on
ne
cti
ve
tis
su
e1
2.1
0.9
00
03
5.4
1.7
00
0C
45
Me
so
the
liom
a0
00
00
00
00
00
0C
46
Ka
po
si's
sa
rco
ma
00
00
00
00
00
00
C4
3M
ela
no
ma
of
sk
in0
00
00
00
00
00
0C
44
Oth
er
sk
in1
2.1
0.9
23
.22
.21
1.8
1.2
12
.60
.5C
50
Bre
as
t1
2.1
0.6
11
.61
.1-
--
--
-C
61
Pro
sta
te4
8.5
4.4
00
0-
--
--
-C
62
Te
sti
s0
00
34
.81
.2-
--
--
-C
60
Pe
nis
00
00
00
--
--
--
C6
3O
the
r m
ale
ge
nit
al
00
00
00
--
--
--
C5
0B
rea
st
--
--
--
10
17
.91
0.7
71
8.4
6.3
C5
5U
teru
s u
ns
pe
c.
--
--
--
00
00
00
C5
3C
erv
ix u
teri
--
--
--
11
.80
.84
10
.53
.8C
58
Pla
ce
nta
--
--
--
00
00
00
C5
4C
orp
us
ute
ri-
--
--
-0
00
00
0C
56
Ov
ary
etc
.-
--
--
-3
5.4
3.3
25
.31
.9C
51
-C5
2;C
57
Oth
er
fem
ale
ge
nit
al
--
--
--
00
01
2.6
1.3
C6
7B
lad
de
r2
4.3
1.5
23
.22
.51
1.8
1.2
00
0C
64
-C6
6;C
68
Kid
ne
y e
tc.
12
.10
.31
1.6
0.9
11
.80
.82
5.3
0.7
C6
9E
ye
12
.10
.30
00
00
00
00
C7
0-C
72
Bra
in,
ne
rvo
us
sy
ste
m1
2.1
14
6.3
1.4
11
.80
.32
5.3
1.5
C7
3T
hy
roid
36
.41
.11
1.6
0.3
35
.42
.52
5.3
1.2
C7
4-C
75
Oth
er
en
do
cri
ne
12
.10
.31
1.6
0.3
00
00
00
C8
1H
od
gk
in's
dis
ea
se
24
.30
.75
7.9
1.6
35
.42
.22
5.3
0.7
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a6
12
.84
.75
7.9
7.3
11
19
.67
.30
00
C8
8;C
90
Mu
ltip
le m
ye
lom
a1
2.1
0.6
00
00
00
00
0C
91
Lym
ph
oid
le
uk
ae
mia
36
.40
.93
4.8
0.7
23
.60
.83
7.9
0.8
C9
2M
ye
loid
le
uk
ae
mia
24
.30
.64
6.3
2.5
23
.61
.11
2.6
0.8
C9
3M
on
oc
ytic
le
uk
ae
mia
00
00
00
00
00
00
C9
4O
the
r le
uk
ae
mia
00
00
00
00
00
00
C9
5L
eu
ka
em
ia u
ns
pe
c.
00
00
00
00
00
00
Oth
er
& u
ns
pe
cif
ied
12
.10
.94
6.3
40
00
25
.31
.7
All
sit
es
47
10
03
4.9
63
10
05
0.2
56
10
05
0.2
38
10
03
4.1
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-
2-12
Age
Sta
ndar
ized
Rat
es a
nd R
elat
ive
Freq
uenc
ies f
or A
ll C
ance
r C
ases
am
ong
Saud
is b
y Si
te a
nd S
ex, A
sir
Reg
ion,
199
9-20
00
106
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
00
01
0.7
0.3
00
0C
01
-C0
2T
on
gu
e1
0.6
0.2
21
.50
.74
2.8
11
0.7
0.3
C0
7-C
08
Sa
liva
ry g
lan
d1
0.6
0.2
00
01
0.7
0.3
10
.70
.2C
03
-C0
6M
ou
th2
1.3
0.4
10
.80
.11
0.7
0.3
00
0C
09
-C1
0O
rop
ha
ryn
x0
00
00
00
00
10
.70
.1C
11
Na
so
ph
ary
nx
31
.90
.53
2.3
0.8
10
.70
.32
1.4
0.3
C1
2-C
13
Hyp
op
ha
ryn
x2
1.3
0.5
10
.80
.20
00
10
.70
.3C
14
Ph
ary
nx
un
sp
ec
.0
00
00
00
00
00
0C
15
Oe
so
ph
ag
us
21
.30
.23
2.3
0.8
00
03
2.1
0.8
C1
6S
tom
ac
h7
4.5
1.3
53
.81
.31
0.7
0.3
64
.11
.2C
17
Sm
all
inte
sti
ne
00
01
0.8
0.3
00
00
00
C1
8C
olo
n7
4.5
1.9
75
.31
.54
2.8
1.1
10
.70
.3C
19
-C2
1R
ec
tum
74
.51
.63
2.3
0.8
11
7.8
2.4
32
.10
.6C
22
Liv
er
12
7.7
2.7
13
9.8
2.8
42
.81
.14
2.8
1C
23
-C2
4G
allb
lad
de
r e
tc.
10
.60
.32
1.5
0.4
21
.40
.45
3.4
1.2
C2
5P
an
cre
as
31
.90
.84
30
.90
00
10
.70
.3C
30
-C3
1N
os
e,
sin
us
es
etc
.0
00
00
01
0.7
0.3
00
0C
32
La
ryn
x0
00
10
.80
.20
00
21
.40
.3C
33
-C3
4B
ron
ch
us
, lu
ng
42
.61
.13
2.3
0.7
00
00
00
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s1
0.6
0.1
00
00
00
00
0C
40
-C4
1B
on
e8
5.2
0.8
21
.50
.22
1.4
0.2
32
.10
.5C
47
;C4
9C
on
ne
cti
ve
tis
su
e5
3.2
0.7
32
.30
.53
2.1
0.4
32
.10
.5C
45
Me
so
the
liom
a1
0.6
0.3
00
01
0.7
0.3
00
0C
46
Ka
po
si's
sa
rco
ma
00
00
00
00
00
00
C4
3M
ela
no
ma
of
sk
in0
00
21
.50
.50
00
00
0C
44
Oth
er
sk
in6
3.9
17
5.3
1.3
53
.51
.36
4.1
1.2
C5
0M
ale
Bre
as
t0
00
00
0-
--
--
-C
61
Pro
sta
te4
2.6
0.6
53
.81
.3-
--
--
-C
62
Te
sti
s3
1.9
0.6
32
.30
.4-
--
--
-C
60
Pe
nis
10
.60
.20
00
--
--
--
C6
3O
the
r m
ale
ge
nit
al
00
01
0.8
0.1
--
--
--
C5
0F
em
ale
Bre
as
t-
--
--
-2
11
4.9
4.5
18
12
.44
.3C
55
Ute
rus
un
sp
ec
.-
--
--
-0
00
00
0C
53
Ce
rvix
ute
ri-
--
--
-5
3.5
1.3
53
.41
C5
8P
lac
en
ta-
--
--
-2
1.4
0.2
00
0C
54
Co
rpu
s u
teri
--
--
--
53
.51
.12
1.4
0.3
C5
6O
va
ry e
tc.
--
--
--
42
.81
64
.11
.2C
51
-C5
2;C
57
Oth
er
fem
ale
ge
nit
al
--
--
--
21
.40
.50
00
C6
7B
lad
de
r1
27
.72
.44
31
21
.40
.43
2.1
0.9
C6
4-C
66
;C6
8K
idn
ey
etc
.7
4.5
1.5
43
12
1.4
0.4
00
0C
69
Ey
e2
1.3
0.4
53
.80
.80
00
21
.40
.4C
70
-C7
2B
rain
, n
erv
ou
s s
ys
tem
42
.60
.75
3.8
0.8
32
.10
.49
6.2
1.4
C7
3T
hy
roid
42
.60
.82
1.5
0.4
12
8.5
2.6
21
14
.53
.9C
74
-C7
5O
the
r e
nd
oc
rin
e0
00
00
01
0.7
0.1
00
0C
81
Ho
dg
kin
's d
ise
as
e5
3.2
0.6
53
.80
.83
2.1
0.4
10
.70
.1C
82
-C8
5;C
96
No
n-H
od
gk
in l
ymp
ho
ma
17
11
3.9
11
8.3
1.9
17
12
.13
.31
28
.32
.3C
88
;C9
0M
ult
iple
my
elo
ma
00
02
1.5
0.4
32
.10
.70
00
C9
1L
ymp
ho
id l
eu
ka
em
ia9
5.8
1.3
96
.81
.39
6.4
1.3
85
.51
.6C
92
My
elo
id l
eu
ka
em
ia5
3.2
0.9
53
.81
53
.50
.98
5.5
1.5
C9
3M
on
oc
ytic
le
uk
ae
mia
00
00
00
00
00
00
C9
4O
the
r le
uk
ae
mia
10
.60
.10
00
10
.70
.10
00
C9
5L
eu
ka
em
ia u
ns
pe
c.
10
.60
.20
00
00
00
00
Oth
er
& u
ns
pe
cif
ied
74
.51
.38
6.1
2.3
21
.40
.47
4.8
1.8
All
sit
es
15
51
00
30
.21
32
10
02
7.7
14
11
00
29
.51
45
10
03
0
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-
2-13
Age
Sta
ndar
ized
Rat
es a
nd R
elat
ive
Freq
uenc
ies f
or A
ll C
ance
r C
ases
am
ong
Saud
is b
y Si
te a
nd S
ex, J
ouf R
egio
n, 1
999-
2000
107
ICD
(10
)A
LL
SIT
ES
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
To
t.%
A
SR
C0
0L
ip0
00
00
00
00
00
0C
01
-C0
2T
on
gu
e0
00
00
00
00
00
0C
07
-C0
8S
aliv
ary
gla
nd
12
.61
.11
3.0
1.7
00
00
00
C0
3-C
06
Mo
uth
00
01
3.0
2.3
14
.21
.71
40
.5C
09
-C1
0O
rop
ha
ryn
x0
00
00
00
00
00
0C
11
Na
so
ph
ary
nx
41
0.5
7.5
26
.14
.40
00
00
0C
12
-C1
3H
ypo
ph
ary
nx
00
00
00
00
00
00
C1
4P
ha
ryn
x u
ns
pe
c.
00
00
00
00
00
00
C1
5O
es
op
ha
gu
s2
5.3
1.9
00
00
00
00
0C
16
Sto
ma
ch
00
00
00
14
.22
.10
00
C1
7S
ma
ll in
tes
tin
e0
00
13
.01
.70
00
00
0C
18
Co
lon
12
.61
.80
00
00
00
00
C1
9-C
21
Re
ctu
m0
00
13
.01
.60
00
00
0C
22
Liv
er
12
.60
.81
3.0
1.2
00
02
83
.8C
23
-C2
4G
allb
lad
de
r e
tc.
00
.00
13
.02
.10
00
00
0C
25
Pa
nc
rea
s0
00
13
.02
.30
00
14
2.5
C3
0-C
31
No
se
, s
inu
se
s e
tc.
00
00
00
00
00
00
C3
2L
ary
nx
12
.61
.10
00
28
.33
.60
00
C3
3-C
34
Bro
nc
hu
s,
lun
g5
13
.27
.92
6.1
3.4
00
00
00
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s0
00
00
00
00
00
0C
40
-C4
1B
on
e0
00
13
.00
.61
4.2
0.4
28
1.3
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
12
.62
.41
3.0
0.4
28
.33
.72
80
.9C
45
Me
so
the
liom
a0
00
00
00
00
00
0C
46
Ka
po
si's
sa
rco
ma
00
00
00
00
00
00
C4
3M
ela
no
ma
of
sk
in0
00
00
00
00
00
0C
44
Oth
er
sk
in0
00
00
00
00
00
0C
50
Bre
as
t0
00
00
0-
--
--
-C
61
Pro
sta
te3
7.9
3.1
26
.13
.8-
--
--
-C
62
Te
sti
s0
00
26
.11
.8-
--
--
-C
60
Pe
nis
00
00
00
--
--
--
C6
3O
the
r m
ale
ge
nit
al
00
00
00
--
--
--
C5
0B
rea
st
--
--
--
31
2.5
3.8
41
67
.8C
55
Ute
rus
un
sp
ec
.-
--
--
-0
00
00
0C
53
Ce
rvix
ute
ri-
--
--
-2
8.3
6.2
14
1.3
C5
8P
lac
en
ta-
--
--
-0
00
00
0C
54
Co
rpu
s u
teri
--
--
--
00
01
40
.8C
56
Ov
ary
etc
.-
--
--
-2
8.3
60
00
C5
1-C
52
;C5
7O
the
r fe
ma
le g
en
ita
l-
--
--
-0
00
14
1.3
C6
7B
lad
de
r3
7.9
4.2
13
.01
.70
00
00
0C
64
-C6
6;C
68
Kid
ne
y e
tc.
00
00
00
28
.30
.90
00
C6
9E
ye
00
00
00
00
02
80
.8C
70
-C7
2B
rain
, n
erv
ou
s s
ys
tem
37
.92
.35
15
.24
.60
00
00
0C
73
Th
yro
id2
5.3
1.5
26
.13
.31
4.2
0.8
14
2.5
C7
4-C
75
Oth
er
en
do
cri
ne
00
00
00
00
00
00
C8
1H
od
gk
in's
dis
ea
se
12
.60
.42
6.1
11
4.2
0.7
28
1.7
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a6
15
.81
1.1
41
2.1
4.6
14
.22
28
1C
88
;C9
0M
ult
iple
my
elo
ma
12
.62
.51
3.0
1.7
14
.22
.80
00
C9
1L
ymp
ho
id l
eu
ka
em
ia1
2.6
0.4
00
03
12
.51
.21
40
.4C
92
My
elo
id l
eu
ka
em
ia1
2.6
0.7
00
01
4.2
0.7
00
0C
93
Mo
no
cyt
ic l
eu
ka
em
ia0
00
00
00
00
00
0C
94
Oth
er
leu
ka
em
ia0
00
00
00
00
00
0C
95
Le
uk
ae
mia
un
sp
ec
.0
00
00
00
00
00
0O
the
r &
un
sp
ec
ifie
d1
2.6
2.5
13
.00
.80
00
28
4.1
All
sit
es
38
10
05
3.3
33
10
04
52
41
00
36
.62
51
00
30
.6
Ma
leF
em
ale
19
99
20
00
19
99
20
00
Tabl
e 5-
3-1
Age
Dis
trib
utio
n of
Can
cer
Cas
es a
mon
g no
n-Sa
udi M
ales
, 199
9
108
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
-5
-1
0-
15
-2
0-
25
-3
0-
35
-4
0-
45
-5
0-
55
-6
0-
65
-7
0-
75
+%
C
00
Lip
2-
--
--
--
1-
1-
--
--
--
0.2
C0
1-C
02
To
ng
ue
7-
--
--
-1
--
14
-1
--
--
0.7
C0
7-C
08
Sa
liva
ry g
lan
d5
--
--
--
-1
3-
--
--
1-
-0
.5C
03
-C0
6M
ou
th7
--
--
--
-1
11
1-
-2
--
10
.7C
09
-C1
0O
rop
ha
ryn
x1
--
--
--
-1
--
--
--
--
-0
.1C
11
Na
so
ph
ary
nx
32
--
--
-2
12
32
10
43
12
-2
3.4
C1
2-C
13
Hyp
op
ha
ryn
x6
--
--
--
1-
12
--
--
--
20
.6C
14
Ph
ary
nx
un
spe
c.
2-
--
--
-1
1-
--
--
--
--
0.2
C1
5O
eso
ph
ag
us
16
--
--
--
-2
4-
12
1-
2-
41
.7C
16
Sto
ma
ch
43
--
--
1-
12
37
68
46
13
14
.6C
17
Sm
all
inte
stin
e4
--
--
--
--
-1
--
2-
-1
-0
.4C
18
Co
lon
47
--
--
--
24
61
05
64
15
13
5C
19
-C2
1R
ec
tum
49
--
--
-1
54
49
26
64
15
25
.2C
22
Liv
er
49
--
1-
--
-1
26
61
29
26
22
5.2
C2
3-C
24
Ga
llbla
dd
er
etc
.1
1-
--
--
--
11
-1
2-
31
11
1.2
C2
5P
an
cre
as
15
--
--
--
1-
22
13
21
2-
11
.6C
30
-C3
1N
os
e,
sin
use
s e
tc.
5-
--
--
--
--
-1
11
1-
1-
0.5
C3
2L
ary
nx
21
--
--
--
--
12
41
34
14
12
.2C
33
-C3
4B
ron
chu
s, l
un
g3
7-
--
--
--
13
74
62
71
33
3.9
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s3
--
--
-1
--
11
--
--
--
-0
.3C
40
-C4
1B
on
e2
7-
11
25
25
41
32
--
1-
--
2.9
C4
7;C
49
Co
nn
ect
ive
tis
su
e2
2-
-1
11
11
-4
43
11
22
--
2.3
C4
5M
eso
the
liom
a6
--
--
--
-1
--
11
21
--
-0
.6C
46
Ka
po
si's
sa
rco
ma
1-
--
-1
--
--
--
--
--
--
0.1
C4
3M
ela
no
ma
of
skin
4-
--
--
--
-1
-2
--
-1
--
0.4
C4
4O
the
r s
kin
51
--
-1
1-
-1
26
61
11
15
11
55
.4C
50
Bre
ast
5-
--
--
--
--
-1
-1
2-
1-
0.5
C6
1P
ros
tate
37
--
--
--
--
--
26
63
64
10
3.9
C6
2T
est
is2
0-
--
-1
35
24
32
--
--
--
2.1
C6
0P
en
is2
--
--
--
11
--
--
--
--
-0
.2C
63
Oth
er
ma
le g
en
ita
l0
--
--
--
--
--
--
--
--
-0
C6
7B
lad
de
r6
2-
--
--
-1
-3
76
14
78
66
46
.6C
64
-C6
6;C
68
Kid
ne
y e
tc.
19
-1
-1
--
-1
12
16
21
11
12
C6
9E
ye3
-2
--
--
--
--
--
-1
--
-0
.3C
70
-C7
2B
rain
, n
erv
ou
s s
yste
m4
6-
27
91
-3
-3
11
32
21
-1
14
.9C
73
Th
yro
id2
3-
--
11
1-
25
26
21
-1
1-
2.4
C7
4-C
75
Oth
er
en
do
cri
ne
4-
11
--
--
--
--
--
1-
-1
0.4
C8
1H
od
gk
in's
dis
ea
se
27
--
-3
11
21
63
41
32
--
-2
.9C
82
-C8
5;C
96
No
n-H
od
gk
in l
ymp
ho
ma
83
-4
23
25
59
71
17
11
64
31
38
.8C
88
;C9
0M
ulti
ple
mye
lom
a1
6-
--
--
1-
--
14
62
2-
--
1.7
C9
1L
ymp
ho
id le
uk
ae
mia
28
-4
15
22
11
31
-2
42
--
-3
C9
2M
yelo
id le
uk
ae
mia
45
-1
23
23
44
76
38
1-
--
14
.8C
93
Mo
no
cyt
ic le
uk
ae
mia
2-
-1
--
--
--
--
--
1-
--
0.2
C9
4O
the
r le
uk
ae
mia
0-
--
--
--
--
--
--
--
--
0C
95
Le
uk
ae
mia
un
sp
ec
.2
--
--
--
--
1-
--
-1
--
-0
.2O
the
r &
un
sp
ec
ifie
d4
7-
--
1-
-1
48
51
08
-5
21
25
All
site
s9
44
01
61
73
01
92
34
25
39
11
17
10
91
30
87
75
46
38
51
10
0
Tabl
e 5-
3-2
Age
Dis
trib
utio
n of
Can
cer
Cas
es a
mon
g no
n-Sa
udi F
emal
es, 1
999
109
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
-5
-1
0-
15
-2
0-
25
-3
0-
35
-4
0-
45
-5
0-
55
-6
0-
65
-7
0-
75
+%
C
00
Lip
0-
--
--
--
--
--
--
--
--
0C
01
-C0
2T
on
gu
e2
--
--
--
--
--
1-
--
1-
-0
.3C
07
-C0
8S
aliv
ary
gla
nd
0-
--
--
--
--
--
--
--
--
0C
03
-C0
6M
ou
th2
--
--
--
--
-1
--
1-
--
-0
.3C
09
-C1
0O
rop
ha
ryn
x0
--
--
--
--
--
--
--
--
-0
C1
1N
as
op
ha
ryn
x5
--
--
--
--
-1
1-
1-
2-
-0
.7C
12
-C1
3H
ypo
ph
ary
nx
4-
--
--
-1
1-
1-
1-
--
--
0.5
C1
4P
ha
ryn
x u
ns
pe
c.
0-
--
--
--
--
--
--
--
--
0C
15
Oe
so
ph
ag
us
10
--
--
--
-1
--
3-
-2
21
11
.4C
16
Sto
ma
ch
14
--
--
--
-2
11
11
24
1-
11
.9C
17
Sm
all
inte
sti
ne
2-
--
--
--
--
-2
--
--
--
0.3
C1
8C
olo
n1
9-
--
--
1-
-2
12
16
22
11
2.6
C1
9-C
21
Re
ctu
m1
5-
--
--
--
1-
23
1-
4-
22
2.1
C2
2L
ive
r1
2-
--
--
11
1-
22
21
-1
-1
1.6
C2
3-C
24
Ga
llbla
dd
er
etc
.6
--
--
--
-1
--
2-
21
--
-0
.8C
25
Pa
nc
rea
s3
--
--
1-
-2
--
--
--
--
-0
.4C
30
-C3
1N
os
e,
sin
us
es
etc
.1
--
--
--
1-
--
--
--
--
-0
.1C
32
La
ryn
x3
--
--
--
--
1-
--
1-
1-
-0
.4C
33
-C3
4B
ron
ch
us
, lu
ng
19
-1
1-
--
--
2-
43
23
21
-2
.6C
37
-C3
8O
the
r T
ho
rac
ic o
rga
ns
2-
--
--
1-
--
-1
--
--
--
0.3
C4
0-C
41
Bo
ne
6-
-1
-2
--
--
1-
1-
-1
--
0.8
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
7-
2-
--
11
-1
2-
--
--
--
1C
45
Me
so
the
liom
a1
--
--
--
--
--
1-
--
--
-0
.1C
46
Ka
po
si's
sa
rco
ma
0-
--
--
--
--
--
--
--
--
0C
43
Me
lan
om
a o
f s
kin
5-
--
--
--
--
21
1-
-1
--
0.7
C4
4O
the
r s
kin
19
--
--
--
--
11
62
21
12
32
.6C
50
Bre
as
t2
74
--
--
-2
83
05
25
44
93
41
11
88
53
37
.5C
55
Ute
rus
un
sp
ec
.7
--
--
--
-2
11
--
-2
--
11
C5
3C
erv
ix u
teri
51
--
--
-1
-5
81
35
64
62
1-
7C
58
Pla
ce
nta
0-
--
--
--
--
--
--
--
--
0C
54
Co
rpu
s u
teri
21
--
--
--
-1
15
13
23
32
-2
.9C
56
Ov
ary
etc
.2
8-
--
-1
--
33
4-
43
12
25
3.8
C5
1-C
52
;C5
7O
the
r fe
ma
le g
en
ita
l5
--
--
--
--
--
21
1-
-1
-0
.7C
67
Bla
dd
er
11
--
--
--
1-
-1
11
22
11
11
.5C
64
-C6
6;C
68
Kid
ne
y e
tc.
9-
21
--
--
-1
-1
11
1-
1-
1.2
C6
9E
ye2
-2
--
--
--
--
--
--
--
-0
.3C
70
-C7
2B
rain
, n
erv
ou
s s
yste
m1
6-
18
2-
-1
1-
--
1-
1-
1-
2.2
C7
3T
hyr
oid
35
--
--
-3
15
87
5-
14
-1
-4
.8C
74
-C7
5O
the
r e
nd
oc
rin
e2
-1
--
--
--
--
-1
--
--
-0
.3C
81
Ho
dg
kin
's d
ise
as
e1
9-
-1
22
33
-1
22
--
2-
-1
2.6
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a2
2-
-2
-3
22
41
--
-2
31
2-
3C
88
;C9
0M
ult
iple
mye
lom
a1
2-
--
--
--
--
-1
-4
4-
-3
1.6
C9
1L
ymp
ho
id l
eu
ka
em
ia1
4-
33
-2
1-
22
-1
--
--
--
1.9
C9
2M
yelo
id l
eu
ka
em
ia1
4-
1-
--
-1
23
21
22
--
--
1.9
C9
3M
on
oc
ytic
le
uk
ae
mia
1-
--
--
--
1-
--
--
--
--
0.1
C9
4O
the
r le
uk
ae
mia
0-
--
--
--
--
--
--
--
--
0C
95
Le
uk
ae
mia
un
sp
ec
.2
--
--
--
-1
--
-1
--
--
-0
.3O
the
r &
un
sp
ec
ifie
d2
9-
1-
--
11
42
33
4-
25
12
4
All
sit
es
73
10
14
17
41
11
72
27
09
11
07
10
27
25
16
63
72
52
51
00
Tabl
e 5-
3-3
Inci
denc
e R
ates
for
Can
cer
Cas
es a
mon
g no
n-Sa
udi M
ales
by
Age
Gro
up (p
er 1
00,0
00),
1999
110
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
5-
10
-1
5-
20
-2
5-
30
-3
5-
40
-4
5-
50
-5
5-
60
-6
5-
70
-7
5+
CIR
AS
RC
00
Lip
2-
--
--
--
0.2
-0
.3-
--
--
--
0.1
0C
01
-C0
2T
on
gu
e7
--
--
--
0.2
--
0.3
2.3
-2
.3-
--
-0
.20
.3C
07
-C0
8S
aliv
ary
gla
nd
5-
--
--
--
0.2
0.6
--
--
-8
.7-
-0
.10
.3C
03
-C0
6M
ou
th7
--
--
--
-0
.20
.20
.30
.6-
-8
.6-
-2
0.8
0.2
0.8
C0
9-C
10
Oro
ph
ary
nx
1-
--
--
--
0.2
--
--
--
--
--
0C
11
Na
sop
ha
ryn
x3
2-
--
--
0.8
0.2
0.3
0.6
0.6
5.7
4.2
74
.31
7.4
-4
1.5
12
.5C
12
-C1
3H
ypo
ph
ary
nx
6-
--
--
-0
.2-
0.2
0.6
--
--
--
41
.50
.20
.9C
14
Ph
ary
nx
un
spe
c.2
--
--
--
0.2
0.2
--
--
--
--
-0
.10
C1
5O
eso
ph
ag
us
16
--
--
--
-0
.30
.8-
0.6
2.1
2.3
-1
7.4
-8
30
.52
.5C
16
Sto
ma
ch4
3-
--
-1
.1-
0.2
0.3
0.6
2.2
3.4
8.3
9.4
25
.98
.76
3.2
20
.81
.34
.3C
17
Sm
all
inte
stin
e4
--
--
--
--
-0
.3-
-4
.7-
-2
1.1
-0
.10
.6C
18
Co
lon
47
--
--
--
0.3
0.6
1.2
3.1
2.9
6.2
9.4
4.3
43
.62
1.1
62
.31
.44
.3C
19
-C2
1R
ect
um
49
--
--
-0
.40
.80
.60
.82
.81
.16
.21
41
7.2
8.7
10
54
1.5
1.5
5.2
C2
2L
ive
r4
9-
-0
.5-
--
-0
.20
.41
.93
.41
2.5
21
.18
.65
2.3
42
.14
1.5
1.5
5.5
C2
3-C
24
Ga
llbla
dd
er
etc
.1
1-
--
--
--
0.2
0.2
-0
.62
.1-
12
.98
.72
1.1
20
.80
.31
.8C
25
Pa
ncr
ea
s1
5-
--
--
-0
.2-
0.4
0.6
0.6
3.1
4.7
4.3
17
.4-
20
.80
.41
.6C
30
-C3
1N
ose
, si
nu
ses
etc
.5
--
--
--
--
--
0.6
12
.34
.3-
21
.1-
0.1
0.8
C3
2L
ary
nx
21
--
--
--
--
0.2
0.6
2.3
17
17
.28
.78
4.3
20
.80
.63
.6C
33
-C3
4B
ron
chu
s, lu
ng
37
--
--
--
-0
.20
.62
.22
.36
.24
.73
0.2
8.7
63
.26
2.3
1.1
4.8
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s3
--
--
-0
.4-
-0
.20
.3-
--
--
--
0.1
0.1
C4
0-C
41
Bo
ne
27
-0
.40
.51
.35
.40
.80
.80
.60
.20
.91
.1-
-4
.3-
--
0.8
1.2
C4
7;C
49
Co
nn
ect
ive
tis
sue
22
--
0.5
0.7
1.1
0.4
0.2
-0
.81
.21
.71
2.3
8.6
17
.4-
-0
.71
.5C
45
Me
soth
elio
ma
6-
--
--
--
0.2
--
0.6
14
.74
.3-
--
0.2
0.5
C4
6K
ap
osi
's s
arc
om
a1
--
--
1.1
--
--
--
--
--
--
-0
.1C
43
Me
lan
om
a o
f sk
in4
--
--
--
--
0.2
-1
.1-
--
8.7
--
0.1
0.3
C4
4O
the
r sk
in5
1-
--
0.7
1.1
--
0.2
0.4
1.9
3.4
11
.42
5.8
21
.68
.72
1.1
10
41
.55
.7C
50
Bre
ast
5-
--
--
--
--
-0
.6-
2.3
8.6
-2
1.1
-0
.10
.9C
61
Pro
sta
te3
7-
--
--
--
--
-1
.16
.21
41
2.9
52
.38
4.3
20
81
.18
.9C
62
Te
stis
20
--
--
1.1
1.2
0.8
0.3
0.8
0.9
1.1
--
--
--
0.6
0.5
C6
0P
en
is2
--
--
--
0.2
0.2
--
--
--
--
-0
.10
C6
3O
the
r m
ale
ge
nita
l0
--
--
--
--
--
--
--
--
--
0C
67
Bla
dd
er
62
--
--
--
0.2
-0
.62
.23
.41
4.6
16
.43
4.5
52
.31
26
83
1.9
8.9
C6
4-C
66
;C6
8K
idn
ey
etc
.1
9-
0.4
-0
.7-
--
0.2
0.2
0.6
0.6
6.2
4.7
4.3
8.7
21
.12
0.8
0.6
2C
69
Eye
3-
0.8
--
--
--
--
--
-4
.3-
--
0.1
0.3
C7
0-C
72
Bra
in,
ne
rvo
us
syst
em
46
-0
.83
.25
.91
.1-
0.5
-0
.63
.41
.72
.14
.74
.3-
21
.12
0.8
1.4
2.7
C7
3T
hyr
oid
23
--
-0
.71
.10
.4-
0.3
10
.63
.42
.12
.3-
8.7
21
.1-
0.7
1.4
C7
4-C
75
Oth
er
en
do
crin
e4
-0
.40
.5-
--
--
--
--
-4
.3-
-2
0.8
0.1
0.7
C8
1H
od
gki
n's
dis
ea
se2
7-
--
21
.10
.40
.30
.21
.20
.92
.31
78
.6-
--
0.8
1.3
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a8
3-
1.7
0.9
22
.22
0.8
1.5
1.4
3.4
41
1.4
14
17
.22
6.1
21
.16
2.3
2.5
5.8
C8
8;C
90
Mu
ltip
le m
yelo
ma
16
--
--
-0
.4-
--
0.3
2.3
6.2
4.7
8.6
--
-0
.51
C9
1L
ymp
ho
id le
uk
ae
mia
28
-1
.70
.53
.32
.20
.80
.20
.20
.60
.3-
2.1
9.4
8.6
--
-0
.81
.7C
92
Mye
loid
leu
ka
em
ia4
5-
0.4
0.9
22
.21
.20
.70
.61
.41
.91
.78
.32
.3-
--
20
.81
.31
.9C
93
Mo
no
cytic
leu
kae
mia
2-
-0
.5-
--
--
--
--
-4
.3-
--
0.1
0.2
C9
4O
the
r le
uka
em
ia0
--
--
--
--
--
--
--
--
--
0C
95
Le
uka
em
ia u
nsp
ec.
2-
--
--
--
-0
.2-
--
-4
.3-
--
0.1
0.2
Oth
er
& u
nsp
eci
fied
47
--
-0
.7-
-0
.20
.61
.61
.55
.78
.3-
21
.61
7.4
21
.14
1.5
1.4
3.7
All
site
s9
44
07
82
02
19
79
18
36
62
13
52
04
32
34
01
80
01
05
92
8.2
91
.1
Tabl
e 5-
3-4
Inci
denc
e R
ates
for
Can
cer
Cas
es a
mon
g no
n-Sa
udi F
emal
es b
y A
ge G
roup
(per
100
,000
), 19
99
111
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
5-
10
-1
5-
20
-2
5-
30
-3
5-
40
-4
5-
50
-5
5-
60
-6
5-
70
-7
5+
CIR
AS
RC
00
Lip
0-
--
--
--
--
--
--
--
--
--
C0
1-C
02
To
ng
ue
2-
--
--
--
--
-2
.3-
--
12
.5-
-0
.10
.5C
07
-C0
8S
aliv
ary
gla
nd
0-
--
--
--
--
--
--
--
--
--
C0
3-C
06
Mo
uth
2-
--
--
--
--
1.2
--
8.1
--
--
0.1
0.4
C0
9-C
10
Oro
ph
ary
nx
0-
--
--
--
--
--
--
--
--
--
C1
1N
aso
ph
ary
nx
5-
--
--
--
--
1.2
2.3
-8
.1-
25
.1-
-0
.31
.3C
12
-C1
3H
ypo
ph
ary
nx
4-
--
--
-0
.50
.4-
1.2
-3
.6-
--
--
0.2
0.3
C1
4P
ha
ryn
x u
nsp
ec.
0-
--
--
--
--
--
--
--
--
--
C1
5O
eso
ph
ag
us
10
--
--
--
-0
.4-
-6
.8-
-1
7.5
25
.12
6.4
20
0.6
2.8
C1
6S
tom
ach
14
--
--
--
-0
.70
.61
.22
.33
.61
6.1
35
12
.5-
20
0.8
3.3
C1
7S
ma
ll in
test
ine
2-
--
--
--
--
-4
.5-
--
--
-0
.10
.3C
18
Co
lon
19
--
--
-0
.8-
-1
.21
.24
.53
.64
8.4
17
.52
5.1
26
.42
01
.15
C1
9-C
21
Re
ctu
m1
5-
--
--
--
0.4
-2
.36
.83
.6-
35
-5
2.8
40
0.9
4C
22
Liv
er
12
--
--
-0
.80
.50
.4-
2.3
4.5
7.2
8.1
-1
2.5
-2
00
.72
C2
3-C
24
Ga
llbla
dd
er
etc
.6
--
--
--
-0
.4-
-4
.5-
16
.18
.7-
--
0.4
1.3
C2
5P
an
cre
as
3-
--
-1
--
0.7
--
--
--
--
-0
.20
.1C
30
-C3
1N
ose
, si
nu
ses
etc
.1
--
--
--
0.5
--
--
--
--
--
0.1
-C
32
La
ryn
x3
--
--
--
--
0.6
--
-8
.1-
12
.5-
-0
.20
.7C
33
-C3
4B
ron
chu
s, lu
ng
19
-0
.40
.4-
--
--
1.2
-9
.11
0.8
16
.12
6.2
25
.12
6.4
-1
.14
.2C
37
-C3
8O
the
r T
ho
raci
c o
rga
ns
2-
--
--
0.8
--
--
2.3
--
--
--
0.1
0.2
C4
0-C
41
Bo
ne
6-
-0
.4-
2-
--
-1
.2-
3.6
--
12
.5-
-0
.40
.9C
47
;C4
9C
on
ne
ctiv
e t
issu
e7
-0
.8-
--
0.8
0.5
-0
.62
.3-
--
--
--
0.4
0.4
C4
5M
eso
the
liom
a1
--
--
--
--
--
2.3
--
--
--
0.1
0.1
C4
6K
ap
osi
's s
arc
om
a0
--
--
--
--
--
--
--
--
--
-C
43
Me
lan
om
a o
f sk
in5
--
--
--
--
-2
.32
.33
.6-
-1
2.5
--
0.3
0.8
C4
4O
the
r sk
in1
9-
--
--
--
-0
.61
.21
3.6
7.2
16
.18
.71
2.5
52
.86
0.1
1.1
4.9
C5
0B
rea
st2
74
--
--
-1
.64
.31
13
0.4
62
.41
12
12
38
8.8
15
81
00
13
26
0.1
16
.43
6.2
C5
5U
teru
s u
nsp
ec.
7-
--
--
--
0.7
0.6
1.2
--
-1
7.5
--
20
0.4
1.2
C5
3C
erv
ix u
teri
51
--
--
-0
.8-
1.8
4.7
15
11
.42
1.7
32
.35
2.5
25
.12
6.4
-3
7.8
C5
8P
lace
nta
0-
--
--
--
--
--
--
--
--
--
C5
4C
orp
us
ute
ri2
1-
--
--
--
0.4
0.6
5.8
2.3
10
.81
6.1
26
.23
7.6
52
.8-
1.3
5C
56
Ova
ry e
tc.
28
--
--
1-
-1
.11
.84
.6-
14
.52
4.2
8.7
25
.15
2.8
10
01
.76
.4C
51
-C5
2;C
57
Oth
er
fem
ale
ge
nita
l5
--
--
--
--
--
4.5
3.6
8.1
--
26
.4-
0.3
1.3
C6
7B
lad
de
r1
1-
--
--
-0
.5-
-1
.22
.33
.61
6.1
17
.51
2.5
26
.42
00
.73
.1C
64
-C6
6;C
68
Kid
ne
y e
tc.
9-
0.8
0.4
--
--
-0
.6-
2.3
3.6
8.1
8.7
-2
6.4
-0
.51
.7C
69
Eye
2-
0.8
--
--
--
--
--
--
--
-0
.10
.1C
70
-C7
2B
rain
, n
erv
ou
s sy
ste
m1
6-
0.4
3.6
1.3
--
0.5
0.4
--
-3
.6-
8.7
-2
6.4
-1
1.6
C7
3T
hyr
oid
35
--
--
-2
.40
.51
.84
.78
.11
1.4
-8
.13
5-
26
.4-
2.1
4C
74
-C7
5O
the
r e
nd
ocr
ine
2-
0.4
--
--
--
--
-3
.6-
--
--
0.1
0.2
C8
1H
od
gk
in's
dis
ea
se1
9-
-0
.41
.32
2.4
1.6
-0
.62
.34
.5-
-1
7.5
--
20
1.1
2.2
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a2
2-
-0
.9-
31
.61
.11
.50
.6-
--
16
.12
6.2
12
.55
2.8
-1
.33
.8C
88
;C9
0M
ulti
ple
mye
lom
a1
2-
--
--
--
--
-2
.3-
32
.33
5-
-6
0.1
0.7
4C
91
Lym
ph
oid
leu
ka
em
ia1
4-
1.2
1.3
-2
0.8
-0
.71
.2-
2.3
--
--
--
0.8
0.8
C9
2M
yelo
id le
uk
ae
mia
14
-0
.4-
--
-0
.50
.71
.82
.32
.37
.21
6.1
--
--
0.8
1.5
C9
3M
on
ocy
tic le
uk
ae
mia
1-
--
--
--
0.4
--
--
--
--
-0
.1-
C9
4O
the
r le
uk
ae
mia
0-
--
--
--
--
--
--
--
--
--
C9
5L
eu
ka
em
ia u
nsp
ec.
2-
--
--
--
0.4
--
-3
.6-
--
--
0.1
0.2
Oth
er
& u
nsp
eci
fied
29
-0
.4-
--
0.8
0.5
1.5
1.2
3.5
6.8
14
.5-
17
.56
2.7
26
.44
01
.75
.6
All
site
s7
31
06
83
11
14
12
26
53
12
42
32
26
04
12
57
74
64
66
05
00
43
.71
20
.5
Tabl
e 5-
3-5
Age
Dis
trib
utio
n of
Can
cer
Cas
es a
mon
g no
n-Sa
udi M
ales
, 200
0
112
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
-5
-1
0-
15
-2
0-
25
-3
0-
35
-4
0-
45
-5
0-
55
-6
0-
65
-7
0-
75
+%
C
00
Lip
2-
--
--
--
--
-1
--
--
-1
0.2
C0
1-C
02
To
ng
ue
8-
--
--
--
-1
1-
-4
-1
-1
1C
07
-C0
8S
aliv
ary
gla
nd
5-
--
--
--
11
21
--
--
--
0.6
C0
3-C
06
Mo
uth
8-
--
--
--
--
-2
12
-2
-1
1C
09
-C1
0O
rop
ha
ryn
x2
--
--
--
-1
--
--
-1
--
-0
.2C
11
Na
so
ph
ary
nx
19
--
--
1-
-1
15
61
31
--
-2
.3C
12
-C1
3H
ypo
ph
ary
nx
7-
--
--
-1
-2
-1
11
--
1-
0.9
C1
4P
ha
ryn
x u
nsp
ec
.1
--
--
--
--
--
-1
--
--
-0
.1C
15
Oe
sop
ha
gu
s1
8-
--
--
-1
--
35
21
3-
-3
2.2
C1
6S
tom
ac
h3
7-
--
--
-5
12
34
36
43
33
4.5
C1
7S
ma
ll in
test
ine
2-
--
--
--
--
--
2-
--
--
0.2
C1
8C
olo
n4
3-
--
--
-1
44
82
68
71
11
5.2
C1
9-C
21
Re
ctu
m4
7-
--
--
22
36
71
14
45
3-
-5
.7C
22
Liv
er
40
--
1-
--
--
22
45
11
38
13
4.9
C2
3-C
24
Ga
llbla
dd
er
etc
.4
--
--
-1
--
-1
11
--
--
-0
.5C
25
Pa
ncr
ea
s8
--
--
--
--
--
11
21
11
11
C3
0-C
31
No
se
, s
inu
ses
etc
.1
--
--
--
--
--
1-
--
--
-0
.1C
32
La
ryn
x1
2-
--
--
--
-1
11
12
42
--
1.5
C3
3-C
34
Bro
nch
us,
lu
ng
48
--
--
--
41
36
49
44
65
25
.8C
37
-C3
8O
the
r T
ho
rac
ic o
rga
ns
5-
--
--
--
--
2-
--
2-
-1
0.6
C4
0-C
41
Bo
ne
15
-1
21
-1
31
21
1-
11
--
-1
.8C
47
;C4
9C
on
ne
ctiv
e t
iss
ue
9-
--
11
11
--
11
--
11
-1
1.1
C4
5M
eso
the
liom
a0
--
--
--
--
--
--
--
--
-0
C4
6K
ap
osi
's s
arc
om
a3
--
--
--
-1
-1
--
-1
--
-0
.4C
43
Me
lan
om
a o
f sk
in2
--
--
--
--
-2
--
--
--
-0
.2C
44
Oth
er
sk
in5
1-
--
--
-1
13
58
91
36
23
-6
.2C
50
Bre
ast
3-
--
--
--
--
--
12
--
--
0.4
C6
1P
ros
tate
28
--
--
--
--
--
14
65
53
43
.4C
62
Te
stis
15
-1
--
1-
41
12
41
--
--
-1
.8C
60
Pe
nis
1-
--
--
--
--
1-
--
--
--
0.1
C6
3O
the
r m
ale
ge
nit
al
1-
--
--
--
--
--
--
1-
--
0.1
C6
7B
lad
de
r4
8-
1-
--
11
26
74
55
34
45
5.8
C6
4-C
66
;C6
8K
idn
ey
etc
.2
9-
21
-1
-1
1-
53
55
13
1-
3.5
C6
9E
ye7
-4
--
--
-1
--
1-
-1
--
-0
.9C
70
-C7
2B
rain
, n
erv
ou
s s
yste
m3
5-
-1
-3
-2
36
35
43
22
-1
4.3
C7
3T
hyr
oid
16
--
-1
23
1-
21
51
--
--
-1
.9C
74
-C7
5O
the
r e
nd
oc
rin
e6
-5
--
--
-1
--
--
--
--
-0
.7C
81
Ho
dg
kin
's d
ise
as
e2
4-
-6
21
21
41
5-
2-
--
--
2.9
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a7
6-
2-
51
34
45
13
91
56
51
3-
9.3
C8
8;C
90
Mu
ltip
le m
yelo
ma
15
--
--
--
-1
41
43
1-
1-
-1
.8C
91
Lym
ph
oid
leu
ka
em
ia3
1-
66
2-
11
22
33
2-
-2
-1
3.8
C9
2M
yelo
id le
uk
ae
mia
46
-1
12
42
39
48
44
2-
-2
-5
.6C
93
Mo
no
cyt
ic le
uk
ae
mia
1-
--
--
--
--
--
--
1-
--
0.1
C9
4O
the
r le
uk
ae
mia
0-
--
--
--
--
--
--
--
--
0C
95
Le
uk
ae
mia
un
sp
ec
.4
--
--
--
--
12
--
1-
--
-0
.5O
the
r &
un
sp
ec
ifie
d3
8-
--
--
14
22
95
55
31
1-
4.6
All
site
s8
21
02
31
81
41
51
84
14
66
21
11
10
39
99
86
64
92
92
91
00
Tabl
e 5-
3-6
Age
Dis
trib
utio
n of
Can
cer
Cas
es a
mon
g no
n-Sa
udi F
emal
es, 2
000
113
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
-5
-1
0-
15
-2
0-
25
-3
0-
35
-4
0-
45
-5
0-
55
-6
0-
65
-7
0-
75
+%
C
00
Lip
2-
--
--
--
-1
--
--
--
-1
0.3
C0
1-C
02
To
ng
ue
8-
--
-1
--
--
2-
1-
3-
1-
1.1
C0
7-C
08
Sa
liva
ry g
lan
d5
--
--
--
-1
2-
2-
--
--
-0
.7C
03
-C0
6M
ou
th6
--
--
--
-1
-1
2-
11
--
-0
.8C
09
-C1
0O
rop
ha
ryn
x1
--
--
--
--
--
--
-1
--
-0
.1C
11
Na
so
ph
ary
nx
7-
-1
--
-1
--
22
1-
--
--
1C
12
-C1
3H
ypo
ph
ary
nx
8-
--
--
-1
-1
1-
11
12
--
1.1
C1
4P
ha
ryn
x u
ns
pe
c.
0-
--
--
--
--
--
--
--
--
0C
15
Oe
so
ph
ag
us
7-
--
--
--
-1
-1
--
3-
11
1C
16
Sto
ma
ch
13
--
--
--
--
22
--
14
-4
-1
.8C
17
Sm
all
inte
sti
ne
4-
--
--
--
--
-1
2-
--
1-
0.5
C1
8C
olo
n1
7-
--
--
-1
11
52
33
1-
--
2.3
C1
9-C
21
Re
ctu
m1
8-
--
--
2-
3-
52
2-
11
11
2.5
C2
2L
ive
r1
0-
--
--
--
12
11
-1
1-
12
1.4
C2
3-C
24
Ga
llbla
dd
er
etc
.9
--
--
--
-3
--
-2
11
2-
-1
.2C
25
Pa
nc
rea
s8
--
--
-1
--
21
--
12
-1
-1
.1C
30
-C3
1N
os
e,
sin
us
es
etc
.0
--
--
--
--
--
--
--
--
-0
C3
2L
ary
nx
0-
--
--
--
--
--
--
--
--
0C
33
-C3
4B
ron
ch
us
, lu
ng
6-
--
--
--
-1
-1
-3
1-
--
0.8
C3
7-C
38
Oth
er
Th
ora
cic
org
an
s3
-1
--
--
-1
--
--
--
1-
-0
.4C
40
-C4
1B
on
e1
2-
13
23
--
1-
--
--
11
--
1.6
C4
7;C
49
Co
nn
ec
tiv
e t
iss
ue
7-
1-
1-
-2
--
-1
-1
1-
--
1C
45
Me
so
the
liom
a1
--
--
--
--
--
--
1-
--
-0
.1C
46
Ka
po
si's
sa
rco
ma
2-
--
--
--
--
--
1-
1-
--
0.3
C4
3M
ela
no
ma
of
sk
in7
--
--
-1
--
2-
22
--
--
-1
C4
4O
the
r s
kin
28
--
--
--
-2
-5
75
24
11
13
.8C
50
Bre
as
t2
31
--
--
--
42
53
45
44
52
41
51
66
53
31
.6C
55
Ute
rus
un
sp
ec
.4
--
--
--
--
3-
--
1-
--
-0
.5C
53
Ce
rvix
ute
ri5
5-
--
--
--
58
10
88
27
52
-7
.5C
58
Pla
ce
nta
1-
--
--
-1
--
--
--
--
--
0.1
C5
4C
orp
us
ute
ri1
9-
--
--
-1
-1
-1
52
34
-2
2.6
C5
6O
va
ry e
tc.
29
--
-1
2-
-1
39
51
21
21
14
C5
1-C
52
;C5
7O
the
r fe
ma
le g
en
ita
l1
-1
--
--
--
--
--
--
--
-0
.1C
67
Bla
dd
er
13
--
--
-1
-1
-1
3-
31
12
-1
.8C
64
-C6
6;C
68
Kid
ne
y e
tc.
17
-1
3-
--
-1
3-
41
3-
1-
-2
.3C
69
Eye
5-
5-
--
--
--
--
--
--
--
0.7
C7
0-C
72
Bra
in,
ne
rvo
us
sys
tem
13
-2
--
1-
-3
4-
-1
2-
--
-1
.8C
73
Th
yro
id3
0-
--
12
34
24
54
31
1-
--
4.1
C7
4-C
75
Oth
er
en
do
cri
ne
5-
11
-2
--
--
--
1-
--
--
0.7
C8
1H
od
gk
in's
dis
ea
se
12
--
-4
-1
1-
22
--
-1
1-
-1
.6C
82
-C8
5;C
96
No
n-H
od
gk
in l
ymp
ho
ma
27
-1
1-
-1
32
14
11
23
23
23
.7C
88
;C9
0M
ult
iple
mye
lom
a7
--
--
-1
--
--
21
1-
-2
-1
C9
1L
ymp
ho
id l
eu
ka
em
ia1
8-
52
--
-3
11
12
-1
11
--
2.5
C9
2M
yelo
id l
eu
ka
em
ia2
1-
--
1-
23
33
42
21
--
--
2.9
C9
3M
on
oc
ytic
le
uk
ae
mia
0-
--
--
--
--
--
--
--
--
0C
94
Oth
er
leu
ka
em
ia0
--
--
--
--
--
--
--
--
-0
C9
5L
eu
ka
em
ia u
ns
pe
c.
0-
--
--
--
--
--
--
--
--
0O
the
r &
un
sp
ec
ifie
d3
4-
2-
--
11
14
57
2-
33
23
4.7
All
sit
es
73
10
21
11
10
11
14
26
59
86
12
01
08
70
52
64
34
28
17
10
0
Tabl
e 5-
3-7
Inci
denc
e R
ates
for
Can
cer
Cas
es a
mon
g no
n-Sa
udi M
ales
by
Age
Gro
up (p
er 1
00,0
00),
2000
114
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
5-
10
-1
5-
20-
25-
30
-3
5-
40
-4
5-
50
-5
5-
60-
65
-7
0-
75+
CIR
AS
RC
00
Lip
2-
--
--
--
--
-0
.5-
--
--
12
.20
.10
.3C
01
-C0
2T
on
gu
e8
--
--
--
--
0.2
0.3
--
6.6
-8
.1-
12
.20
.20
.8C
07
-C0
8S
aliv
ary
gla
nd
5-
--
--
--
0.2
0.2
0.5
0.5
--
--
--
0.1
0.1
C0
3-C
06
Mo
uth
8-
--
--
--
--
-0
.90
.93
.3-
16
.2-
12
.20
.21
C0
9-C
10
Oro
ph
ary
nx
2-
--
--
--
0.2
--
--
-3
.5-
--
0.1
0.1
C1
1N
aso
ph
ary
nx
19
--
--
0.8
--
0.2
0.2
1.4
2.8
0.9
53
.5-
--
0.5
0.7
C1
2-C
13
Hyp
op
ha
ryn
x7
--
--
--
0.2
-0
.4-
0.5
0.9
1.7
--
14
.2-
0.2
0.5
C1
4P
ha
ryn
x u
nsp
ec.
1-
--
--
--
--
--
0.9
--
--
--
-C
15
Oe
sop
ha
gu
s1
8-
--
--
-0
.2-
-0
.82
.31
.71
.71
0.5
--
36
.60
.51
.5C
16
Sto
ma
ch3
7-
--
--
-1
0.2
0.4
0.8
1.9
2.6
10
13
.92
4.2
42
.63
6.6
1.1
3.7
C1
7S
ma
ll in
test
ine
2-
--
--
--
--
--
1.7
--
--
-0
.10
.1C
18
Co
lon
43
--
--
--
0.2
0.6
0.7
2.2
0.9
5.2
13
.32
4.4
8.1
14
.21
2.2
1.2
2.8
C1
9-C
21
Re
ctu
m4
7-
--
--
10
.40
.51
.11
.95
.13
.56
.61
7.4
24
.2-
-1
.32
.5C
22
Liv
er
40
--
0.4
--
--
-0
.40
.51
.94
.31
8.3
10
.56
4.6
14
.23
6.6
1.1
4.5
C2
3-C
24
Ga
llbla
dd
er
etc
.4
--
--
-0
.5-
--
0.3
0.5
0.9
--
--
-0
.10
.1C
25
Pa
ncr
ea
s8
--
--
--
--
--
0.5
0.9
3.3
3.5
8.1
14
.21
2.2
0.2
1.1
C3
0-C
31
No
se,
sin
use
s e
tc.
1-
--
--
--
--
-0
.5-
--
--
--
0C
32
La
ryn
x1
2-
--
--
--
-0
.20
.30
.50
.93
.31
3.9
16
.2-
-0
.31
.3C
33
-C3
4B
ron
chu
s, lu
ng
48
--
--
--
0.8
0.2
0.5
1.6
1.9
7.8
6.6
13
.94
8.5
71
24
.41
.44
.9C
37
-C3
8O
the
r T
ho
raci
c o
rga
ns
5-
--
--
--
--
0.5
--
-7
--
12
.20
.10
.6C
40
-C4
1B
on
e1
5-
0.4
0.8
0.5
-0
.50
.60
.20
.40
.30
.5-
1.7
3.5
--
-0
.40
.5C
47
;C4
9C
on
ne
ctiv
e t
issu
e9
--
-0
.50
.80
.50
.2-
-0
.30
.5-
-3
.58
.1-
12
.20
.30
.8C
45
Me
soth
elio
ma
0-
--
--
--
--
--
--
--
--
--
C4
6K
ap
osi
's s
arc
om
a3
--
--
--
-0
.2-
0.3
--
-3
.5-
--
0.1
0.2
C4
3M
ela
no
ma
of
skin
2-
--
--
--
--
0.5
--
--
--
-0
.1-
C4
4O
the
r sk
in5
1-
--
--
-0
.20
.20
.51
.43
.77
.82
1.6
20
.91
6.2
42
.6-
1.4
3.8
C5
0B
rea
st3
--
--
--
--
--
-0
.93
.3-
--
-0
.10
.2C
61
Pro
sta
te2
8-
--
--
--
--
-0
.53
.51
01
7.4
40
.44
2.6
48
.80
.84
.3C
62
Te
stis
15
-0
.4-
-0
.8-
0.8
0.2
0.2
0.5
1.9
0.9
--
--
-0
.40
.4C
60
Pe
nis
1-
--
--
--
--
0.3
--
--
--
--
-C
63
Oth
er
ma
le g
en
ital
1-
--
--
--
--
--
--
3.5
--
--
0.1
C6
7B
lad
de
r4
8-
0.4
--
-0
.50
.20
.31
.11
.91
.94
.38
.31
0.5
32
.35
6.8
61
.11
.44
.7C
64
-C6
6;C
68
Kid
ne
y e
tc.
29
-0
.80
.4-
0.8
-0
.20
.2-
1.4
1.4
4.3
8.3
3.5
24
.21
4.2
-0
.82
.1C
69
Eye
7-
1.7
--
--
-0
.2-
-0
.5-
-3
.5-
--
0.2
0.4
C7
0-C
72
Bra
in,
ne
rvo
us
syst
em
35
--
0.4
-2
.5-
0.4
0.5
1.1
0.8
2.3
3.5
57
16
.2-
12
.21
2C
73
Th
yro
id1
6-
--
0.5
1.7
1.5
0.2
-0
.40
.32
.30
.9-
--
--
0.5
0.6
C7
4-C
75
Oth
er
en
do
crin
e6
-2
.1-
--
--
0.2
--
--
--
--
-0
.20
.3C
81
Ho
dg
kin
's d
ise
ase
24
--
2.5
10
.81
0.2
0.6
0.2
1.4
-1
.7-
--
--
0.7
0.7
C8
2-C
85
;C9
6N
on
-Ho
dg
kin
lym
ph
om
a7
6-
0.8
-2
.60
.81
.50
.80
.60
.93
.54
.21
31
01
7.4
8.1
42
.6-
2.2
4C
88
;C9
0M
ulti
ple
mye
lom
a1
5-
--
--
--
0.2
0.7
0.3
1.9
2.6
1.7
-8
.1-
-0
.40
.6C
91
Lym
ph
oid
leu
kae
mia
31
-2
.52
.51
-0
.50
.20
.30
.40
.81
.41
.7-
-1
6.2
-1
2.2
0.9
1.7
C9
2M
yelo
id le
uka
em
ia4
6-
0.4
0.4
13
.31
0.6
1.4
0.7
2.2
1.9
3.5
3.3
--
28
.4-
1.3
1.9
C9
3M
on
ocy
tic le
uka
em
ia1
--
--
--
--
--
--
-3
.5-
--
-0
.1C
94
Oth
er
leu
kae
mia
0-
--
--
--
--
--
--
--
--
--
C9
5L
eu
kae
mia
un
spe
c.4
--
--
--
--
0.2
0.5
--
1.7
--
--
0.1
0.1
Oth
er
& u
nsp
eci
fied
38
--
--
-0
.50
.80
.30
.42
.42
.34
.38
.31
0.5
8.1
14
.2-
1.1
1.9
All
site
s8
21
01
07
71
29
87
11
30
48
86
16
32
30
39
64
12
35
42
3.3
58
Tabl
e 5-
3-8
Inci
denc
e R
ates
for
Can
cer
Cas
es a
mon
g no
n-Sa
udi F
emal
es b
y A
ge G
roup
(per
100
,000
), 20
00
115
ICD
(10
)A
LL
SIT
ES
To
t.U
NK
.0
5-
10
-1
5-
20
-2
5-
30
-3
5-
40
-4
5-
50
-5
5-
60
-6
5-
70
-7
5+
CIR
AS
RC
00
Lip
2-
--
--
--
-0
.5-
--
--
--
17
.10
.10
.4C
01
-C0
2T
on
gu
e8
--
--
0.8
--
--
1.8
-3
.4-
27
.7-
11
.9-
0.5
1.7
C0
7-C
08
Sa
liva
ry g
lan
d5
--
--
--
-0
.41
-3
.7-
--
--
-0
.30
.3C
03
-C0
6M
ou
th6
--
--
--
-0
.4-
0.9
3.7
-5
.69
.2-
--
0.3
0.9
C0
9-C
10
Oro
ph
ary
nx
1-
--
--
--
--
--
--
9.2
--
-0
.10
.4C
11
Na
sop
ha
ryn
x7
--
0.4
--
-0
.6-
-1
.83
.73
.4-
--
--
0.4
0.6
C1
2-C
13
Hyp
op
ha
ryn
x8
--
--
--
0.6
-0
.50
.9-
3.4
5.6
9.2
33
.1-
-0
.51
.9C
14
Ph
ary
nx
un
spe
c.0
--
--
--
--
--
--
--
--
--
-C
15
Oe
sop
ha
gu
s7
--
--
--
--
0.5
-1
.9-
-2
7.7
-1
1.9
17
.10
.41
.8C
16
Sto
ma
ch1
3-
--
--
--
-1
1.8
--
5.6
37
-4
7.8
-0
.72
.8C
17
Sm
all
inte
stin
e4
--
--
--
--
--
1.9
6.7
--
-1
1.9
-0
.20
.7C
18
Co
lon
17
--
--
--
0.6
0.4
0.5
4.6
3.7
10
.11
6.9
9.2
--
-1
2.2
C1
9-C
21
Re
ctu
m1
8-
--
--
1.7
-1
.3-
4.6
3.7
6.7
-9
.21
6.5
11
.91
7.1
12
.5C
22
Liv
er
10
--
--
--
-0
.41
0.9
1.9
-5
.69
.2-
11
.93
4.3
0.6
1.8
C2
3-C
24
Ga
llbla
dd
er
etc
.9
--
--
--
-1
.3-
--
6.7
5.6
9.2
33
.1-
-0
.52
C2
5P
an
cre
as
8-
--
--
0.9
--
10
.9-
-5
.61
8.5
-1
1.9
-0
.51
.4C
30
-C3
1N
ose
, si
nu
ses
etc
.0
--
--
--
--
--
--
--
--
--
-C
32
La
ryn
x0
--
--
--
--
--
--
--
--
--
-C
33
-C3
4B
ron
chu
s, lu
ng
6-
--
--
--
-0
.5-
1.9
-1
6.9
9.2
--
-0
.31
.2C
37
-C3
8O
the
r T
ho
raci
c o
rga
ns
3-
0.4
--
--
-0
.4-
--
--
-1
6.5
--
0.2
0.6
C4
0-C
41
Bo
ne
12
-0
.41
.21
2.5
--
0.4
--
--
-9
.21
6.5
--
0.7
1.4
C4
7;C
49
Co
nn
ect
ive
tis
sue
7-
0.4
-0
.5-
-1
.3-
--
1.9
-5
.69
.2-
--
0.4
0.9
C4
5M
eso
the
liom
a1
--
--
--
--
--
--
5.6
--
--
0.1
0.2
C4
6K
ap
osi
's s
arc
om
a2
--
--
--
--
--
-3
.4-
9.2
--
-0
.10
.5C
43
Me
lan
om
a o
f sk
in7
--
--
-0
.9-
-1
-3
.76
.7-
--
--
0.4
0.7
C4
4O
the
r sk
in2
8-
--
--
--
0.9
-4
.61
31
6.8
11
.23
71
6.5
11
.91
7.1
1.6
5C
50
Bre
ast
23
1-
--
--
-2
.51
0.8
6.6
49
.68
3.5
80
.68
4.4
14
89
9.3
59
.75
1.4
13
.22
8.4
C5
5U
teru
s u
nsp
ec.
4-
--
--
--
-1
.5-
--
5.6
--
--
0.2
0.3
C5
3C
erv
ix u
teri
55
--
--
--
-2
.23
.99
.21
4.9
26
.91
1.2
64
.78
2.7
23
.9-
3.1
9.1
C5
8P
lace
nta
1-
--
--
-0
.6-
--
--
--
--
-0
.10
.1C
54
Co
rpu
s u
teri
19
--
--
--
0.6
-0
.5-
1.9
16
.81
1.2
27
.76
6.2
-3
4.3
1.1
5.3
C5
6O
vary
etc
.2
9-
--
0.5
1.7
--
0.4
1.5
8.3
9.3
3.4
11
.29
.23
3.1
11
.91
7.1
1.7
3.9
C5
1-C
52
;C5
7O
the
r fe
ma
le g
en
ital
1-
0.4
--
--
--
--
--
--
--
-0
.10
.1C
67
Bla
dd
er
13
--
--
-0
.9-
0.4
-0
.95
.6-
16
.99
.21
6.5
23
.9-
0.7
2.5
C6
4-C
66
;C6
8K
idn
ey
etc
.1
7-
0.4
1.2
--
--
0.4
1.5
-7
.43
.41
6.9
-1
6.5
--
12
.1C
69
Eye
5-
2.2
--
--
--
--
--
--
--
-0
.30
.3C
70
-C7
2B
rain
, n
erv
ou
s sy
ste
m1
3-
0.9
--
0.8
--
1.3
1.9
--
3.4
11
.2-
--
-0
.71
C7
3T
hyr
oid
30
--
-0
.51
.72
.62
.50
.91
.94
.67
.41
0.1
5.6
9.2
--
-1
.72
.6C
74
-C7
5O
the
r e
nd
ocr
ine
5-
0.4
0.4
-1
.7-
--
--
-3
.4-
--
--
0.3
0.4
C8
1H
od
gk
in's
dis
ea
se1
2-
--
2.1
-0
.90
.6-
11
.8-
--
9.2
16
.5-
-0
.71
.3C
82
-C8
5;C
96
No
n-H
od
gk
in ly
mp
ho
ma
27
-0
.40
.4-
-0
.91
.90
.90
.53
.71
.93
.41
1.2
27
.73
3.1
35
.83
4.3
1.5
4.8
C8
8;C
90
Mu
ltip
le m
yelo
ma
7-
--
--
0.9
--
--
3.7
3.4
5.6
--
23
.9-
0.4
1.2
C9
1L
ymp
ho
id le
uk
ae
mia
18
-2
.20
.8-
--
1.9
0.4
0.5
0.9
3.7
-5
.69
.21
6.5
--
11
.9C
92
Mye
loid
leu
ka
em
ia2
1-
--
0.5
-1
.71
.91
.31
.53
.73
.76
.75
.6-
--
-1
.21
.5C
93
Mo
no
cytic
leu
ka
em
ia0
--
--
--
--
--
--
--
--
--
-C
94
Oth
er
leu
ka
em
ia0
--
--
--
--
--
--
--
--
--
-C
95
Le
uk
ae
mia
un
spe
c.0
--
--
--
--
--
--
--
--
--
-O
the
r &
un
spe
cifie
d3
4-
0.9
--
-0
.90
.60
.41
.94
.61
36
.7-
27
.74
9.6
23
.95
1.4
1.9
5.9
All
site
s7
31
09
45
91
21
62
54
21
10
20
02
35
29
25
92
56
33
34
29
14
1.8
10
4.3
PART VIAPPENDICES
Reporting HospitalsRiyadh region Western regionKing Khaled University Hospital King Abdul Aziz University HospitalKing Faisal Specialist Hospital King Khaled National Guard HospitalSecurity Forces Hospital King Abdul Aziz Hospital & Oncology CenterKing Fahad National Guard Hospital King Fahad Armed Forces HospitalAFH Millitary (RKH Programe) King Fahad General HospitalKing Abdul Aziz University Hospital King Abdul Aziz, Al Zaher HospitalKing Khaled Eye Specialist Hospital King Faisal Hospital (Taif)Riyadh Medical Complex Al Jedaani HospitalPrince Salman Bin Abdul Aziz Hospital Al Salamah HospitalKing Khaled General Hospital (Kharj) United Doctors HospitalKing Khaled General Hospital (Majmaa) Bugshan General HospitalAl Hammadi Hospital Al Dhagastani HospitalAl Mobarak Hospital Bakhsh HospitalAl Yamamah Hospital Dr Erfan & Bagedo HospitalSocial Insurance Hospital (GOSI) Dr Soliman Fakeeh HospitalDallah Hospital New Jeddah Clinic HospitalDr Abdlrhmn Al Mishari Hospital Children & Maternity Hospital (Jeddah)Watani Hospital Aziziyah for Children & Maternity Hospital
Saudi German HospitalEastern region Saudi Medical ServicesDhahran Health Center (ARAMCO) Al Noor Specialist HospitalKing Fahad Hospital of the University Hera General HospitalDammam Central Hospital Maternity & Children Hospital (Taif)Hofuf Hospital Al Qunfudah General HospitalAl Qatif Central Hospital Royal Commission Medical (Janboa)Al Mana General Hospital (Khobar)Almana General Hospital (Dammam) Madinah regionKing Khalid General Hospital Al Hanakyah HospitalAl Mouwasat Hospital Al Miqat HospitalPrince Saud Bin Jalawi Hospital Badr HospitalDr Fakhry Hospital Chest Diseases HospitalMaternity & Children’s Hospital Heatstroke HospitalAl Jubail Hospital King Fahad HospitalAl Salama Hospital Maternity & Children’s HospitalAl-Dossary Hospital Madina National HospitalAl Thomairy Hospital Ohoud HospitalChest Disease Hospital Al Ula General HospitalArabian Oil Comp Hospital Khaybar General HospitalAbqaiq Health Centre Al Mahd HospitalAl Qatif General HospitalKing Fahad Hospital (Hofuf)
117
APPENDIX A
Qassim region Tabuk regionKing Fahd Specialist Hospital King Fahad HospitalKing Saud University Hospital King Khalid General HospitalOnaizah General Hospital Maternity & Children’s HospitalBuraidah Central Hospital Umm Lujj General HospitalAl Midhnab General Hospital Al Wajh General HospitalAr Rass General HospitalBukairiya General Hospital Asir region
Asir Central HospitalHail region Al Zafer HospitalHail General Hospital Chest & Fever HospitalKing Khaled General Prince Abdullah Bin Abdul Aziz HospitalAl Rashid HospitalBaqa Hospital Baha region
King Fahd HospitalJazan region Al Mandaq HospitalKing Fahad Central HospitalJazan General Hospital Najran regionJazan Millitary Hospital King Khaled General HospitalFarasan General Hospital
118
APPENDIX B
National Cancer Registry Offices
119
APPENDIX C
Armed Forces Hospital P.O. Box 7897, Riyadh 11159Tel.: 01-477-7714 x6747Fax: 01-477-7714 x6743
Central Region P.O. Box 2925, Riyadh 11461Tel.: 01-467-9488 / 467-2398Fax: 01-467-9487
Eastern Region P.O. Box 4004, Al Khobar 31952Tel.: 03-896-6741Fax: 03-896-6741
Madinah & Northern Region King Fahd Hospital, Madinah Al MonawarahTel.: 04-846-1500 x3134/3146Fax: 04-846-0951
Main Office P.O. Box 3354 MBC 64, Riyadh 11211Tel.: 01-442-3938Fax: 01-442-3941
National Guard Hospitals P.O. Box 6615, Jeddah 21452Tel.: 02-624-0000 x4085/4086Fax: 02-624-7242
Security Forces Hospital P.O. Box 3643, Riyadh 11481Tel.: 01-477-4480 x1193Fax: 01-467-4757
Southern Region P.O. Box 641, AbhaTel.: 07-226-0711/224-7800 x118Fax: 07-224-0964/224-7570
Western Region P.O. Box 31467, Jeddah 21497Tel.: 02-637-5555 x2283/2200Fax: 02-637-9811/637-9830
APPENDIX D
NATIONAL CANCER REGISTRYBOARD OF DIRECTORS
CHAIRMAN:Dr. Shouki Bazarbashi, King Faisal Specialist Hospital & Research Centre
DEPUTY CHAIRMAN:Dr. Nasser Al Hamdan, Ministry of Health
BOARD MEMBERS:Dr. Dahish Ajarim, King Saud University, RiyadhDr. Edward De Vol, Director, King Faisal Specialist Hospital & Research CenterProf. Hassan Al Idrissi, King Faisal University, DammamDr. Hadir Meir, King Abdulaziz Hospital and Cancer Center, JeddahDr. Hassan Trabulsi, King Khalid University, AbhaDr. Mohamoud Shaheen Al Ahwal, King Abdulaziz University, JeddahDr. Rizq Allah Assiri, Armed Forces Hospital, RiyadhDr. Abdulwahab Andejani, National Guard Hospitals, JeddahDr. Abdulaziz Saleh Aba Hussein, Security Forces Hospital, RiyadhDr. Hisham Ali Yousef, King Fahad Hospital, Madinah
NCR ADMINISTRATIVE STAFF:Susan Young, CCHRA(C), CTR, Administrative Director (2003-present)Mohammed Haydar, CTR, Tumor RegistrarHaya Al Eid, BDS, DFE, Epidemiologist, CTRSuad O. Arteh, MA, Data Manager
ADDRESS:NATIONAL CANCER REGISTRYP.O. BOX 3354, MBC 64Riyadh 11211, Saudi Arabia
Website:www.kfshrc.edu.sa/NCR/
E-mail:bazarbashi@kfshrc.edu.sasyoung@kfshrc.edu.sa
PHONE: 966-1-442- 3938FAX: 966-1-442-3941
120
APPENDIX E
121
NATIONAL CANCER REGISTRY MINISTRY OF HEALTH KINGDOM OF SAUDI ARABIA
Request for data from the National Cancer Registry All requests should be submitted to the attention of the Chairman, Board of Directors, National Cancer Registry, MBC 64, P.O. Box 3354, Riyadh, 11211,
Saudi Arabia, Fax: 966 1 442 3941
Name: ______________________ Date Submitted: _________ Department: __________________ Hospital: _____________________ Telephone number: _____________ Information Requested: (Specify patient population, Time period, Year/s, Anatomic site/Histology, Staging information, region, etc.) Purpose of Request: (Specify presentation at conference/meeting/publication, clinical/epidemiological study, personal information, etc.) Collaborators and Co-authors: Requesters affirmation statement: I hereby, the requester of the above data affirm that the data given to me by the NCR will be treated with utmost confidentiality in relation to patient’s identity. I also affirm that the data given to me will not be presented or published by me or any of my collaborators as an original work but rather can be cited in my presentations and / or publication with acknowledgment to the NCR. Requester signature:_______________________ Date: _________________ ************************************************************************************ For Official use only: Request: Approved____________ Denied____________ Chairman NCR Board of Directors Signature: _______________________________________ Dr. Nasser Al Hamdan Date: _____________
APPENDIX F
122
KINGDOM OF SAUDI ARABIA MINISTRY OF HEALTH
NATIONAL CANCER REGISTRY
CANCER REGISTRATION REPORT
1. ACCESSION NUMBER
2. ACCESSION DATE / /
d d m m y y y y
NAME
7. SAUDI ID Number
8. MARITAL STATUS 9. SEX 10. DATE OF BIRTH / / d d m m y y y y
11. AGE 1-Single 2-Married 3-Divorced 4-Widowed 9-Unknown
1-Male 2-Female 9-Unkown
12. NATIONALITY code text
13. ADDRESS code text
14. 15. TEL. NO.
16. DATE OF DIAGNOSIS / / d d m m y y y y
17. TOPOGRAPHY C code text
18. MORPHOLOGY code text
19. BEHAVIOR 0-Benign 1-Uncertain 2-Insitu 3-Malignant
20. GRADE 1-Well diff 2-Moderately diff 3-Poorly diff 4-Undifferentiated
5-T.cell 6-B.cell 7-Null cell 8-Natural killer cell
9-Unknown
21. EXTENT 1-Insitu 2-Localized 3-Regional by direct extension 4-Regional by lymph nodes
5-Regional (both 2 and 3) 6-Regional NOS 7-Distant metastases/systemic Disease 9-Unknown
22. T= 23. N= 24. M=
25. BASIS OF DIAGNOSIS 0-DCO
1-Clinical
2-Radiology
3-Surg/Autopsy
4-LAB test
5-Cyto/Hematology
6-Histology of Metastasis
7-Histology of Primary
8-Histology/Autopsy
9-Unknown
26. LATERALITY 0-Not paired, unknown, ill – defined 1-Right 2-Left 3-One side, But unknown
4-Bilateral involvement 9-Paired site, Laterality unknown
27. REPORTING HOSPITAL code text
28. PATIENT M.R. No. 29. PATHOLOGY No.
30. SURGERY 1-Yes 2-No 3-Unknown
31. CHEMOTHERAPY 1-Yes 2-No 3-Unknown
32. HORMONE 1-Yes 2-No 3-Unknown
33. RADIATION 1-Yes 2-No 3-Unknown
34. IMMUNOTHERAPY 1-Yes 2-No 3-Unknown
35. LAST CONTACT / / d d m m y y y y
38. CANREG No.
36. STATUS 1-Dead 2-Alive
9-Unknown
37. CAUSE OF DEATH 1-Cancer 2-Other 9-Unknown
39. SIGNATURE
3. FIRST 4. FATHER 5. GRAND FATHER 6. FAMILY
top related